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1 Introduction and Summary  
The PhD work described in this thesis was developed in the context of a 
cooperation between the Laboratory of Peptide & Protein Chemistry & 
Biology of the University of Florence (Prof. Anna Maria Papini) and the 
Laboratory for Translational Research of Harvard Medical School (Prof. 
Michael Chorev).  
The present thesis describes some applications of modified peptides to the 
study of diabetes and cancer disease forms with a special attention to the 
development of diagnostic/prognostic assays based on molecular tools. To this 
aim, we developed non proteinogenic modified amino acids, orthogonally 
protected for Solid Phase Peptide Synthesis peptide sequences bearing post-
translational modifications and possible stabilized conformation to be used in 
various biochemical applications. 
The goal of the diabetic project has been the development of a 
diagnostic/prognostic tool for type I and type II diabetes. A convergent 
approach of multiple different strategies proceeding in parallel has been 
adopted (section 1). 
To this aim, a panel of new Fmoc-Lysine derivates bearing a glycation 
modification has been developed for SPPS of glycated peptides and proteins 
(section 1.1). 
A systematic approach to the synthesis of a glycated hCD59(37-50) peptide 
antigen has been carried out (section 2.2.3). 
The glycated antigen has been used to produce specific anti-glycated hCD59 
antibodies that efficiently recognize the glycated protein (hCD59) in vivo 
(section 2.2.5). 
A panel of glycated antigenic peptide probes has been generated and tested 
with un-competitive ELISA experiments against type I diabetic patients’ sera 
(section 2.3.5). Preliminary results show the presence of specific 
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autoantibodies anti-glycated-hCD59 in a subfamily of diabetic patients 
(section 2.4.2). 
The strategy for total synthesis by Native Chemical Ligation of glycated and 
un-glycated hCD59 protein has been set up (section 2.5.1). 
Future developments will be the optimization of the biochemical assays base 
on the synthetic peptide probes and antibodies generated as well as the 
completion of the NCL synthesis of hCD59; it will also be undertaken an 
analytical study of the glycated metabolites in diabetic patients’ sera; and 
finally, the synthetic peptide probes will be tested in uncompetitive ELISA 
assays against type II diabetic patients’ sera (section 2.6.2). 
The goal of the cancer project has been the development of new eIF4E 
Binding Protein (4E-BP) peptide inhibitors with stabilized conformation to be 
used as suppressors of Translation Initiation in a context of cancer therapy 
(section 3.3). 
A collection of Nα-Fmoc protected unnatural amino acids bearing on the side 
chain azido or alkynyl functions was synthesized and introduced by SPPS in 
the fluoresceinated-4E-BP (621-636) peptide sequence to afford by Cu(I) 
catalyzed Huisgen reaction, a new collection of cyclopeptides containing the 
triazolyl moiety (section 3.5). The side-chain-to-side chain cyclization of 
linear peptides generated via click chemistry lead to cyclopeptides containing 
the triazolyl moiety linked to the α-carbon of the amino acids by alkyl chains 
of different lengths. 
The collection of linear and cyclic peptides has been tested with Fluorescence 
Polarization Assay to measure the affinity for the eIF4E protein. The position 
and length of the triazole-bridge appears to play a critical role in enhancing 
and decreasing the affinity of the binding protein peptide analogs (4E-BP) for 
the target protein (eIF4E) (section 3.6.1). 
A NMR/CD conformational study has been carried out on the cyclopeptides 
analogs containing triazolyl moiety. From preliminary data the triazole bridge 
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seems, as expected, to stabilize the α-helical structure of the peptides (section 
3.7.1). 
The completion of the synthesis and characterization of the 4E-BP 
cyclopeptides collection is in progress. The peptides presenting the best 
affinity with eIF4E will be selected for experiments of templated click 
cyclization free from metal catalyst and in presence of the protein (eIF4E) 
(section 3.5.2.4). The cell membrane permeability of the fluoresceinated 
peptides will also be assessed with a confocal microscope. 
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2 PART A: Glycation in diabetes; a post-translational 
modification useful for the development of biomarkers. A 
convergent approach aimed to diagnostic tools. 
 
We have undertaken a convergent development of a 
diagnostic/prognostic tool for type I and type II diabetes. The 
designation of “convergent” points out that, different approaches have 
been forsaken in parallel in order to maximize the possibility of success 
(Scheme 2-1). 
Our proof-of-concept is that aberrant post-translational modifications 
(PTMs) affecting specific proteins can trigger an autoimmune response. 
This process could be one of the factors contributing to autoimmune 
diseases development or being just a side effect of the autoimmune 
condition. In either case we concentrated our efforts in taking advantage 
of the biunivocal correlation between pathology and aberrant 
modifications in order to develop efficient diagnostic/prognostic tools. 
The second step is the selection of a panel of potential biomarkers of a 
given disease on the base of previously identified PTMs, synthetically 
reproduced. 
The definition of a biological marker (biomarker) is the following:  
a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention1. 
                                                 
1 Biomarkers Definitions Working Group (2001) Clinical Pharmacology and Therapeutics, 
Bethesda, Md, 3. 
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Scheme 2-1 Convergent development of a diagnostic/prognostic tool 
 
The third stage is to set up a biochemical experiment that allows 
identifying and quantifying the selected biomarker in a statistical 
significant number of biological samples (i.e., urines or sera). The most 
promising and successful of those biochemical assays will be optimized 
to deliver a prototype to be transferred for technical industrialization 
and becoming a fully reliable diagnostic/prognostic tools for final 
marketing. 
We have focused our work on the subject of glycation in diabetes and 
we have selected four different types of biomarkers versus which we 
have directed our experiments as shown in Table 2–1. 
 
Selection of a panel of biomarkers
Identification of Post-Translational Modifications and 
minimal epitopes  
Strategies to monitor the biomarkers  
in biological samples 
From the study of a given  
autoimmune disease 
Development of bio-chemical assays 
in vitro synthetic reproduction 
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Strategy Biomarker Molecular tool Application 
 
Experiment 
 
 
Glycated hCD59 
 
Glycated hCD59(37-50) peptide antigen Rise of mono and polyclonal anti glycated hCD59 antibodies 
Identification of glycated CD59 rich 
tissues in diabetic patients biopsies Direct approach 
(synthetic antibodies)  
Glycated hCD59 
 
Glycated hCD59 protein 
(complete sequence, total synthesis by 
NCL) 
Rise of mono and polyclonal anti 
glycated hCD59 antibodies with high 
specificity 
Identification of glycated CD59 rich 
tissues in diabetic patients biopsies 
 
Anti-glycated hCD59 
auto-antibodies 
 
Glycated hCD59(37-50) peptide antigen Recognition of anti-glycated hCD59 autoantibodies in diabetic patient sera 
Uncompetitive ELISA screening of 
patient sera 
Reverse approach 
(synthetic antigenic probes)  
Unspecific anti-glycated 
auto-antibodies 
 
Glycated antigenic probe 
(CSF114) 
Recognition of anti-glycation 
autoantibodies in diabetic patient sera 
Uncompetitive ELISA screening of 
patients sera 
 
Free glycated Lysine metabolites 
 
Synthetic glycated Lysine 
Synthetic glycated Lysine is used as a 
standard for metabolic free glycated 
Lysine in patient sera 
UPLC-MS/HPLC analysis of patient 
sera 
Amino acid analysis 
Glycated Lysine residues 
(from hydrolysis of the proteins 
of patient sera) 
Synthetic glycated Lysine 
Synthetic glycated Lysine is used as a 
standard for metabolic free glycated 
Lysine in patient sera hydrolyzate 
UPLC-MS/HPLC analysis of patient 
sera hydrolyzate 
Table 2-1 Strategies for the development of a diagnostic-prognostic tool for diabetes based on the glycation process. 
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2.1 Glycation  
Glycation of proteins through non-enzymatic reactions between glucose or 
other reducing sugars and reactive amino groups represents one of the most 
abundant processes involved in post-translational modification of proteins2. 
Spontaneous and reversible condensation of a reducing sugar and a free amino 
group of a protein forms an aldimine also known as the “Schiff base” that 
undergoes a rearrangement into the more stable ketoamine known also as the 
Amadori product3 (Scheme 2.1-1). In the case of glucose, the initially formed 
Schiff base rearranges into the more stable 1-deoxyfructosyl moiety. 
Subsequent dehydration, condensation, fragmentation, oxidation, and 
cyclization reactions lead to the irreversible formation of Advanced Glycation 
End Products (AGEs). This process leads to inactivation of proteins and is 
involved in pathologies such as senile cataract4, arteriosclerosis5, vascular 
complications of diabetes6, dysfunction of skin collagen7, and 
neurodegenerative diseases such as Alzheimer’s disease8,9 and Parkinson 
disease10.  
 
 
 
 
 
 
                                                 
2 Doyle, H.A. and Mamula, M.J. (2001) Trends Immunol., 22, 443.  
3 Ulrich, P. and Cerami, A. (2001) Recent Prog. Horm. Res., 56, 1. 
4 Lyons, T.J., Silvestri, G., Dunn, J.A., and Dyer, D.G. (1991) Diabetes, 40, 1010. 
5 Price, C.L. and Knight, S.C. (2007) Curr. Pharm. Des., 13, 3681. 
6 Gugliucci, A.J. (2000) Am. Osteopath. Assoc., 100, 621. 
7 Avery, N.C. and Bailey, A.J. (2006) Pathol. Biol. (Paris), 54, 387.  
8 Yan, S.D., Chen, X., Schmidt, A.M., Brett, J., Godman, G., Zou, Y.S., Scott, C.W., Caputo, 
C., Frappier, T., and Smith, M.A. (1994) Proc.Natl. Acad. Sci. U.S.A., 91, 7787. 
9 Takeuchi, M. and Yamagishi, S. (2008) Curr. Pharm. Des., 14, 973. 
10 Munch, G., Gerlach, M., Sian, J., Wong, A., and Riederer, P. (1998) Ann. Neurol., 44, 85. 
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Scheme 2.1-1 The glycation reaction. 
 
The function of a glycated protein may be impaired if an amino group affected 
by glycation is in, or close to, its active site. For example, glycation of the b 
chains of hemoglobin gives rise to the glycated hemoglobins (HbA1), in which 
responsiveness to 2,3-diphosphoglycerate is decreased and oxygen affinity 
increased11. Also, glycation of the major thrombin inhibitor of the coagulation 
system, antithrombin III, decreases its affinity for heparin, possibly 
contributing to the hypercoagulable state associated with diabetes12. Even 
though proteins contain many surface amino groups, only a few are 
preferentially glycated. This intriguing observation was explained when the  
identification of glycated amino groups in proteins with known three-
dimensional structure revealed that glycation preferably occurs at amino 
groups that are either close to an imidazole moiety or part of a Lysine doublet. 
Proximity ('5 Å) of an amino group to an imidazole moiety is the strongest 
                                                 
11 McDonald, M.J., Bleichman, M., and Bunn, H.F. (1979) J. Biol. Chem., 254, 702. 
12 Ceriello, A., Giugliano, D., Quatraro, A., Stante, A., Consoli, G., Dello Russo, P., and 
D’Onofrio, F. (1987) Diabete Metab., 13, 16. 
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predictor of susceptibility to glycation13. This site specificity of protein 
glycation is the consequence of localized acid–base catalysis of the 
aldimineyketoamine tautomerization14,15. In conclusion the glycation 
phenomenon, thought non enzymatic, is sequence dependent 
                                                 
13 Fluckiger, R. and Strang, C.J. (1995) Protein Sci. 4, 186. 
14 Iberg, N. and Fluckiger, R. (1986) J. Biol. Chem. 261, 13542. 
15 Watkins, N.G., Neglia-Fisher, C.I., Dyer, D.G., Thorpe, S.R., and Baynes, J.W. (1987) J. 
Biol. Chem., 262, 7207. 
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2.1.1 Diabetes 
Changes in human behavior and lifestyle over the last century have resulted in 
a dramatic increase in the incidence of diabetes worldwide. The number of 
adults with diabetes in the world will rise from 135 million in 1995 to 300 
million in the year 202516 (Figure 2.1-1). Most cases will be of type II 
diabetes, which is strongly associated with a sedentary lifestyle and obesity17. 
This trend of increasing prevalence of diabetes and obesity has already 
imposed a huge burden on health-care systems and this will continue to 
increase in the future. Although type II diabetes is numerically more prevalent 
in the general population, type I diabetes is the most common chronic disease 
of children. But with the increasing prevalence of type II diabetes in children 
and adolescents, the order may be reversed within one to two decades18.  
 
 
Figure 2.1-1 Number of people with diabetes (in millions) for 2000 and 2010 (top and 
middle values, respectively), and the percentage of increase. 
 
                                                 
16 King, H., Aubert, R.E., and Herman, W.H. (1998) Diab. Care., 21,1414. 
17 Kahn, B.B. and Flier, J.S. (2000) J. Clin. Invest.,106, 171.  
18 Fagot-Gampagna, A. (2000) J. Pediatr,. 136, 664. 
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Current estimates from different countries in Europe and the United States 
have shown that diabetes and its complications account for 8–16% of the total 
health costs for society and these will increase dramatically unless major 
efforts are made to prevent the ongoing epidemic19. 
 
 
 
 
 
 
 
 
                                                 
19 Torben, H. (2002) CURRENT SCIENCE, 83, 25. 
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2.1.1.1 Type I diabetes 
 
Type I diabetes encompass several diabetic forms characterized by 
immunologically-mediated β-cell destruction, usually leading to absolute 
insulin deficiency and represent the 10% of all diabetic cases. Around the 
world there is a great variation in the type I diabetes incidence which is raising 
3-5% per year due to environmental causes (Figure 2.1–2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1-2 Type I diabetes incidence in caldron aged 0-14 other 100.000individuals. 
 
The most common of this disease forms is known as Insulin-Dependent 
Diabetes Mellitus (IDDM) or juvenile-onset diabetes, results from 
autoimmune mediated destruction of the insulin-producing beta cells of the 
pancreas20.The rate of destruction is quite variable, being rapid in some 
individuals and slow in others21. The rapidly progressive form is commonly 
                                                 
20 K.G., Alberti, and Zimmet, P.Z. (1998) Diabetic Med., 15, 539. 
21 Zimmet, P.Z., Tuomi, T., Mackay, R., Rowley, M.J., Knowles, W., and Cohen, M. (1994) 
Diabetic Med., 11, 299. 
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observed in children, but also may occur in adults22. The slowly progressive 
form generally occurs in adults and is sometimes referred to as Latent 
Autoimmune Diabetes in Adults (LADA). Some patients, particularly children 
and adolescents, may present with ketoacidosis as the first manifestation of the 
disease23.Others have modest fasting hyperglycemia that can rapidly change to 
severe hyperglycemia and/or ketoacidosis in the presence of infection or other 
stress. Still others, particularly adults, may retain residual beta cell function, 
sufficient to prevent ketoacidosis, for many years24.  
Type I diabetes is characterized by severe complicances such as macro and 
microangiopathy, arteriosclerosis, retinopathy, nefropathy and neuropathy 
(Figure 2.1–3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1-3 Type I diabetes complications. 
 
                                                 
22 Humphrey, A.R., McCarty, D.J., Mackay, I.R., Rowley, M.J., Dwyer, T., and Zimmet, P. 
(1998) Diabetic Med., 15, 113. 
23 Japan and Pittsburgh Childhood Diabetes Research Groups (1985) Diabetes, 34, 1241. 
24 Zimmet, P.Z. (1995) Diabetes Care, 18, 1050. 
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Markers of immune destruction, including islet cell autoantibodies, and/or 
autoantibodies to insulin, and autoantibodies to Glutamic Acid Decarboxylase 
(GAD65) are present in 85–90 % of individuals with type I diabetes mellitus 
when fasting diabetic hyperglycemia is initially detected25. The peak incidence 
of this form of type 1 diabetes occurs in childhood and adolescence, but the 
onset may occur at any age, ranging from childhood to the ninth decade of 
life26. There is a genetic predisposition to autoimmune destruction of beta 
cells, and it is also related to environmental factors that are still poorly defined. 
Although patients are rarely obese when they present with this type of 
diabetes, the presence of obesity is not incompatible with the diagnosis. These 
patients may also have other autoimmune disorders such as Graves’ disease, 
Hashimoto’s thyroiditis, and Addison’s disease27. 
There are some forms of type 1 diabetes, called Idiopathic, which have no 
known etiology. Some of these patients have permanent insulinopenia and are 
prone to ketoacidosis, but have no evidence of autoimmunity28. This form of 
diabetes is more common among individuals of African and Asian origin. In 
another form found in Africans an absolute requirement for insulin 
replacement therapy in affected patients may come and go, and patients 
periodically develop ketoacidosis29. 
Studies measuring the expression of diabetes related autoantibodies in young 
children from birth suggest that the appearance of these markers is a major risk 
for the future development of type I diabetes,30. However, the role of 
                                                 
25 Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., and Jackson, R.A., Diabetes 
(1996), 45, 926. 
26 Mølbak, A.G., Christau, B., Marner, B., Borch-Johnsen, K., and Nerup, (1994) J. Diabetic 
Med, 11, 650. 
27 Betterle, C., Zanette, F., Pedini, B., Presotto, F., Rapp, L.B., and Monsciotti, C.M. (1983) 
Diabetologia, 26, 431. 
28 McLarty, D.G., Athaide, I., Bottazzo, G.F., Swai, A.B., and Alberti, K.G. (1990) Diabetes, 
Res Clin Pract, 9, 219. 
29 Ahre´n, B. and Corrigan, C.B. (1984) Diabetic Med, 2, 262. 
30 Yu, L., Robles, D.T., Abiru, N., Kaur, P., Rewers, M., and Kelemen, K., (2000) Proc Natl 
Acad Sci USA, 97, 1701. 
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autoantibodies in the actual pathogenesis of type I diabetes has not been 
established in humans. In fact, a recent case report showed the development of 
type 1 diabetes in a patient with X linked agammaglobulinaemia, suggesting 
that autoantibodies are not needed for either the initiation or the progression of 
type I diabetes31. In general, type I diabetes is considered primarily a T cell 
mediated disease, and extensive evidence exists in both man and mouse to 
support this. Examination of islet tissue obtained from pancreatic biopsy from 
patients with recent onset type I diabetes confirms insulitis, with the presence 
of an infiltrate composed of CD4 and CD8 T lymphocytes, B lymphocytes, 
and macrophages, suggesting that these cells have a role in destruction of the _ 
cells32. Early studies in mice showed that anti-CD3 treatment prevented 
diabetes, and a trial using humanized anti-CD3 antibody in patients with new 
onset type I diabetes is under way33. Figure 2.1–4 describes a general model of 
β-cell destruction leading to type I diabetes. The initial interaction of genes 
and environmental factors seem to trigger an immune mediated response, with 
the appearance of autoantibodies as the first sign of β-cell destruction, 
followed eventually by the loss of the first phase insulin response. The 
progression to overt diabetes resulting in significant β-cell destruction is 
triggered by the development of a more aggressive T cell phenotype and a 
change in the Th1 to Th2 balance towards a more proinflammatory milieu. The 
expression of FasLigand on cytotoxic T cells also marks the progression to 
overt diabetes. Examination of islets during insulitis suggests that Fas 
mediated apoptosis occurs and therefore provides one possible mechanism of 
β-cell destruction34. 
                                                 
31 Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W.A., Kolb, H., and Noordzij, 
J.G. (2001) N. Engl. J. Med., 345, 1036. 
32 Imagawa, A., Hanafusa, T., Itoh, N., Waguri, M., Yamamoto, K. and Miyagawa, J. (1999) 
Diabetologia, 42, 574. 
33 Herold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor, L., and Donaldson, D. 
(2002) N. Engl. J. Med., 346, 1692. 
34 Foulis, A.K., Liddle, C.N., Farquharson, M.A., Richmond, J.A., and Weir, R.S (1986) 
Diabetologia, 29, 267. 
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Figure 2.1-4 Model of phatogenesis and natural history of type I diabetes 
 
Individuals with underlying islet autoimmunity who are at risk for type I 
diabetes can be identified years before symptomatic presentation by the 
presence of circulating autoantibodies to specific islet antigens: (pro)insulin, 
the molecular weight 65,000 isoform of glutamic acid decarboxylase 
(GAD65), tyrosine phosphatase-like insulinoma antigen 2 (IA2) and beta cell-
specific zinc transporter 8. As can be seen in Figure 2.1-4 the preclinical 
factors mentioned above lay on the second half of the secondary prevention 
window. The environmental promoters (mostly un-known) lay upstream. Thus 
the decision to focus on glycation that can be considered as a factor 
characteristic of the early onset of the disease and that could be the core of a 
biochemical assay for type I diabetes early diagnosis. 
  21 
2.1.1.2 Type II diabetes 
 
Type II diabetes is not a single entity but a group of metabolic disorders 
characterized by the clinical feature of hyperglycemia which is due to insulin 
resistance or elative insulin deficiency, either of which may be present at the 
time that diabetes becomes clinically manifest35 (Figure 2.1-5). 
  
 
Figure 2.1-5 Pathway of the raising of glucose blood level in type II diabetes 
 
There is continuing debate as to the primary aetiological factor for the 
syndrome. Genetic factors, visceral obesity, insulin resistance and endothelial 
dysfunction may all contribute either solely or jointly36. 
Type II diabetes complicances are very similar to those given by type I 
diabetes, namely the macro and microangiopathy, arteriosclerosis, retinopathy, 
nephropathy and neuropathy (Figure 2.1–4). This is due to the fact that such 
                                                 
35 Narayan, K.M. (2003) JAMA, 290, 1884. 
36 Reaven, G. (1988) Diabetes, 37, 1595. 
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complications are primary generated by an excess of glucose37 in the blood 
which is a common feature of all diabetic types. Glucose is responsible for 
glycation of the plasma soluble proteins and generation of the Advanced 
Glycation End Products, which play a key role in the complicances. 
Type II diabetes is increasingly common, indeed epidemic, primarily because 
of increases in the prevalence of a sedentary lifestyle and obesity. Prevention 
of complications is a key issue because of the huge premature morbidity and 
mortality associated with the disease. The possibility of preventing the disease 
by interventions that affect the lifestyles of subjects at high risk for the disease 
is now the subject of numerous studies These have focused on people with 
Impaired Glucose Tolerance (IGT) commonly referred as “pre-diabetics”38. 
IGT is defined as hyperglycemia (with glucose values intermediate between 
normal and diabetes) following a glucose load39, and affects at least 200 
million people worldwide. It represents a key stage in the natural history of 
type II diabetes as these people are at much higher future risk than the general 
population for developing diabetes40. 
The type II diabetes diagnosis is established when it is observed a raise of the 
blood glucose level which is kept within a very narrow range of 7-12 mmol/L 
under normal physiological conditions41 (Table 2.1-1). 
 
                                                 
37 Stitt, A.W., Jenkins, A.J., and Cooper, M.E. (2002) Expert Opin. Investig. Drugs., 11, 1205. 
38 Eastman, R., Javitt, J., Herman, W., Dasbach, E. and Harris, M. (1996) In Diabetes Mellitus: 
A Fundamental and Clinical Text, eds Le-Roith, D., Taylor, S. and Olefsky, J. (Lippincott-
Raven, New York) 621. 
39 World Health Organization. Definition, Diagnosis and Classification of Diabetes mellitus 
and itsComplications, (1999) Department of Noncommunicable Disease Surveillance, 
Geneva,12. 
40 Shaw, J., Hodge, A., de Courten, M., Chitson, P., and Zimmet, P. (1999) Diabetologia, 42, 
1050. 
41 Zimmet, P., Alberti, K.G., and Shaw, J. (2001) NATURE, 414, 782. 
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Table 2.1-1 Values for diagnosis of diabetes and other types of hyperglycemia 
 
Interestingly the measurement of glycated hemoglobulin (HbA1c) is no more 
recommended as a diagnostic test for diabetes because of lack of standardized 
methodology resulting in varying nondiabetic reference ranges among 
laboratories42. 
The latter consideration adds value to our commitment of developing a new 
diagnostic/prognostic tool for diabetes based on the recognition of specific 
glycated sequences, amino acids and metabolites. 
 
                                                 
42 The Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus (2003) 
Biabetes Care, 26, 15. 
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2.1.2 Correlation between glycation of hCD59 and complement-
mediated diabetes complicances 
 
Humans are particularly prone to develop proliferative micro and 
macrovascular disease that mediating some of the most common long-term 
complicances of diabetes mellitus43. These vascular complicances of diabetes 
are caused by elevated blood glucose levels over long periods of time44. 
Understanding the molecular mechanisms that link hyperglycemia and the 
vascular proliferative disease in humans is essential for designing adequate 
animal models and therapeutic strategies for a condition that represents a 
leading cause of morbidity and mortality in the adult population. Glycation is 
considered a major pathophysiological mechanism causing tissue damage in 
diabetic subjects45. Reports of increased deposition of the membrane attack 
complex of complement (MAC) in blood vessels and kidneys of diabetic 
patients46,47 suggest that there may be a link between complement activation 
and the development of chronic proliferative diabetic complications.  
The complement system consists of a group of >12 soluble proteins that 
interact with one another in three distinct enzymatic activation cascades 
known as the classical, alternative, and lectin pathways. All activation 
pathways converge to form the membrane attack complex (MAC). The MAC 
is a circular polymer of 12–18 monomers of the C9 complement protein with 
the capacity to insert into cell membranes and form a transmembrane pore of 
an effective internal radius of 5–7 nm. Influx of salt and water through the 
MAC pore induces colloidosmotic swelling and lysis of MAC-targeted cells 
such as gram-negative bacteria or heterologous erythrocytes. We have 
                                                 
43 Duhault, J., and Koenig-Berard, E. (1997) Therapie, 52, 375. 
44 Nathan, D.M. (1996) Ann. Intern. Med. 124, 86. 
45 Brownlee, M., Vlassara, H., and Cerami, A. (1984) Ann. Intern. Med., 101, 527. 
46 Weiss, J.S., Sang, D.N., and Albert, D.M. (1990) Cornea, 9, 131. 
47 Falk, R.J., Sisson, S.P., Dalmasso, A.P., Kim, Y., Michael, A.F., and Vernier, R.L. (1987) 
Am. J. Kidney Dis., 9, 121. 
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demonstrated that during the assembly of the MAC pore, there is a phase when 
the MAC pore is transient and reversible, permitting opening and 
closing/resealing of the plasma membrane48,49,50. These transient MAC pores 
can generate significant changes in the membrane permeability of autologous 
cells without compromising their viability and thereby mediate physiological 
and/or pathological responses51. 
Indeed, the MAC stimulates proliferation of fibroblasts and smooth muscle, 
mesangial, and other cells52,53, in part by releasing growth factors such as basic 
fibroblast growth factor and platelet-derived growth factor from MAC-targeted 
endothelium54. The MAC also induces increased synthesis of extracellular 
matrix proteins by mesangial cells55. Thus, increased MAC deposition in 
diabetic tissues may induce the release of growth factors that would stimulate 
cell proliferation in the vascular wall and contribute to the development of 
vascular proliferative disease. In the kidneys, MAC-induced vascular 
proliferation and expansion of the extracellular matrix may contribute to the 
characteristic glomerulosclerosis of diabetic nephropathy56. Increased MAC 
deposition in diabetes is well documented but the underlying mechanism is 
poorly understood. Autologous MAC deposition is normally restricted because 
cells express complement regulatory membrane proteins such as DAF and 
CD59, which limit complement activation and MAC formation. In particular, 
CD59, a glycan phosphatidylinositol-linked membrane protein that is 
universally expressed in cells, restricts MAC assembly by interacting with the 
                                                 
48 Halperin, J.A., Nicholson-Weller, A., Brugnara, C., and Tosteson, D.C. (1988) J. Clin. 
Invest., 82, 594. 
49 Halperin, J.A., Taratuska, A., Rynkiewicz, M., Nicholson-Weller, A. (1993) Blood, 81, 200. 
50 Acosta, J.A., Benzzaquen, L.R., Goldstein, D.J., Tosteson, M.T., and Halperin, J. (1996) 
Mol. Med., 2, 755. 
51 Nicholson-Weller, A. and Halperin, J. (1993) Immunol Res., 12, 244. 
52 Halperin, J.A., Taratuska, A. and Nicholson-Weller, A. (1993) J. Clin. Invest. 91,1974. 
53 Torzewski, J., Oldroyd, R., Lachmann, P., Fitzsimmons, C., Proudfoot, D., and 
Bowyer, D. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 673. 
54 Benzaquen, L.R., Nicholson-Weller, A., and Halperin, J.A. (1994) J. Exp. Med., 179, 985. 
55 Wagner, C., Beer, M., Rother, K., and Hansch, G.M. (1994) Exp.Nephrol. 2, 51. 
56 Ziyadeh, F.N. (1993) Am. J. Kidney Dis., 22, 736. 
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terminal complement proteins C8 and C9, thus preventing C9 polymerization57 
(Figure 2.1-6). 
 
 
 
 
 
 
 
 
Figure 2.1-6 Complement/MAC regulation by CD59. 
 
It has been demonstrated that hCD59 is prone to glycation at a specific Lysine 
site thanks to a glycation motif or consensus sequence58. The NMR structure 
of human CD5959 reveals that Lysine-41 (K41) should be susceptible to 
glycation because of its critical proximity to the unique Histidine, Histidine-44 
(H44), in the protein Figure 2.1-7. Furthermore, the fact that K41 is adjacent to 
tryptophan-40 (W40), a conserved amino acid that is essential for CD59 
function60,61 (18, 19), suggests that glycation of K41 may hinder the activity of 
CD59.  
 
                                                 
57 Ninomiya, H. and Sims, P.J. (1992) J. Biol. Chem. 267, 13675. 
58 Acosta, J., Hettinga, J., Fluckiger, R., Krumrei, N., Goldfine, A., Angarita, L., Halperin, J. 
(2000) PNAS, 97, 5450. 
59 Fletcher, C.M., Harrison, R.A., Lachmann, P.J., and Neuhaus, D. (1994) Structure, 2, 185. 
60 Bodian, D.L., Davis, J.S., Morgan, B.P., and Rushmere, N.K. (1997) J. Exp. Med., 185, 507. 
61 Yu, J., Abagyan, R., Dong, S., Gilbert, A., Nussenzweig, V. and Tomlinson, S. (1997) J. 
Exp. Med., 185, 745. 
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Figure 2.1-7 NMR structure of the protein backbone of human CD59. The figure 
shows the 20 lowest energy structures of human CD59 with all Lysine side chains and 
H44. The structures were superimposed for the backbone of the β-turn 41–44. The 
square highlights the K41–H44 glycation motif. The K41 is within 5.91 ± 1.44 Å of 
the D1 imidazolic nitrogen of H44. 
 
Haplerin et al. extensively demonstrated that selective Lys 41 glycation 
deactivated hCD59 and destabilize MAC homeostasis: 
(i) in vitro glycation of human CD59 inhibits its homologous restriction 
activity, (ii) replacement by site-directed mutagenesis of either K41 or H44 
abolishes the sensitivity of human CD59 to glycation–inactivation, (iii) 
glycation of CD59 in human RBC (hRBC) increases their sensitivity to MAC-
mediated lysis, (iv) glycation of human umbilical vein endothelial cells 
(HUVEC) renders them more sensitive to MAC-mediated growth factor 
release, and (v) glycated CD59 is present in human urine, indicating that CD59 
is glycated in vivo 
Thus glycation inhibiting the principal MAC inhibitor destabilize MAC 
regulation and promote diabetic complication. Glycation as a an aberrant-post-
translational modification it is the key molecular factor that links complement 
to diabetic complications  
Importantly, the H44 residue of human CD59 is not present in any other 
species in which CD59 has been sequenced (Table 2.1-2).  
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Table 2.1-2 Alignment of CD59 amino acid sequences from different species 
around residue W40 
 
It has been propose that the presence of the glycation motif K41–H44 in 
human CD59 provides a possible molecular explanation for the propensity of 
humans to develop the combination of vascular complications that characterize 
human diabetes. Indeed most of the existing diabetic animal models do 
develop diabetes, for example iperglycemia, but don’t show any or little trace 
of diabetic complication. 
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2.2 Building blocks for the synthesis of post-translationally 
modified glycated peptides and proteins. 
 
Glycation of proteins through non-enzymatic reactions between glucose or 
other reducing sugars and reactive amino groups represent one of the more 
abundant processes involved in post-translational modification of proteins2. 
Spontaneous and reversible condensation of a reducing sugar and a free amino 
group of a protein forms an aldimine also known as the Schiff base that 
undergoes a rearrangement into the more stable ketoamine known also as the 
Amadori product3 In the case of glucose, the initially formed Schiff base 
rearranges into the more stable 1-deoxyfructosyl moiety. 
Growing evidence suggests that glycation occurs preferentially at specific 
glycation motifs characterized by acidic amino acids, mainly glutamate and 
Lysine residues that catalyze the glycation of nearby Lysines62,63. Proximity to 
histidine either in the primary or secondary structure was also suggested to 
promote glycation of adjacent Lysines64,65. Recent interest to fully characterize 
the glycation products and to use them as biomarkers and antigens for 
diagnosis and prognosis of disease, monitoring its progress and evaluation of 
the efficiency of therapy generated the need for glycated peptides representing 
the glycation motifs specifically modified by the 1-deoxyfructosyl. Today, 
syntheses of site-specific Amadori modified peptides are carried out on 
partially protected synthetic peptides in which only the lysyl residues 
designated for glycation are exposed while the rest are protected66,67,68,69 . This 
                                                 
62 Johansen, M.B., Kiemer, L., and Brunak, S. (2006) Glycobiology, 16, 844. 
63Venkatraman, J., Aggarwal, K., and Balaram, P. (2001) Chem. Biol., 8, 611. 
64 Baynes, J.W., Watkins, N.G., Fisher, C.I., Hull, C.J., Patrick, J.S., Ahmed, M.U.; Dunn, and 
J.A.; Thorpe, S.R. (1989) Clin. Biol. Res., 304, 43. 
65 Acosta, J., Hettinga, J., Fluckiger, R., Krumrei, N., Goldfine, A., Angarita, L., and Halperin, 
J., (2000) Proc. Natl. Acad. Sci. U.S.A., 97, 5450. 
66 Frolov, A., Singer, D., and Hoffmann, R. (2006) J. Pept. Sci., 12, 389. 
67 Frolov, A., Singer, D., and Hoffmann, R. (2007) J. Pept. Sci., 13, 862. 
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approach involves orthogonal protection strategies and suffers from low yields 
and elaborated purification schemes. 
Stepwise assembly of site-specific Amadori modified peptides requires Nα-
protected-Nε-glycated-Lys s and represents a fully controlled and effective 
synthetic strategy. Herein, we report the synthesis, purification, and 
characterization of Nα-Fmoc, Nε-Boc, Nε-(1-deoxyfructosyl)Lysine s needed 
for Fmoc-based solid phase synthesis of Amadori modified peptides. 
This study offers a controlled side-specific introduction of Nε-Amadori-
modified Lys residue into synthetic peptides during a stepwise assembly either 
in solution or solid phase methodologies. This strategy will overcome tow 
major problems associated with the modification of already assembled 
peptides: 1) lack of site-specificity in the introduction of the modification. 2) 
elaborate orthogonal protection scheme in an effort to achieve site-specificity. 
And 3) extremely low yields and complicated reaction mixtures due to side 
reactions following the direct thermal glycation. Adapting the conditions for 
generating Amadori peptides by direct thermal glycation in the presence of 
excess D-glucose66 to the direct glycation of Nα-Fmoc-Lysine led to the 
synthesis of Nα-Fmoc-Lys[Nε-1-deoxyfructosyl)]-OH (1a) in 67% yield 
(Scheme 2.2–1, pathway A). Preliminary attempt to use 1a as a in stepwise 
assembly of peptides suggested that further protection of the ε-amino by the 
orthogonal Boc group may eliminate some of the observed side products. To 
this end Boc protection of 1a yielded the pure Nα-Fmoc-Lys[Nε-1-
deoxyfructosyl, Nε-Boc)]-OH (1) in 45% yield.  
                                                                                                                     
68 Stefanowicz, P., Kapczynska, K., Kluczyk, A., and Szewczuk, Z. (2007) Tetrahedron Lett., 
48, 967. 
69 Jakas, A., Vinkovic, M., Smrecki, V., Sporec, M., and Horvat, S. (2008) J. Pept. Sci., 14, 
936. 
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Scheme 2.2-1.Synthesis of Nα-Fmoc-Lys[Nε-1-deoxyfructosyl, Nε-Boc)]-OH (1) and 
Nα-Fmoc-Lys[Nε-(2,3;4,5-di-O-isopropylidene-1-deoxyfructosyl, Nε-Boc)]-OH (2). 
 
Anticipating that quantitative incorporation of 1 may require highly activated 
Nε-Amadori modified building block and extended reaction times we sought 
the synthesis of an exhaustively protected product in which in addition to the 
primary and secondary amino function we also protected the hydroxyls on the 
carbohydrate moiety. To this end, reductive alkylation of the Nα-Fmoc-Lys-
OH by 2,3:4,5-di-O-isopropylidene-aldehydo-β-D-arabino-hexos-2-ulo-2,6-
pyranose70,71,72 in the presence of NaCNBH3 led to the formation of 2a in 22% 
(Scheme 2.2–1, pathway B). The pure fully protected Nα-Fmoc-Lys[Nε-
(2,3;4,5-di-O-isopropylidene-1-deoxyfructosyl, Nε-Boc)]-OH (2) was obtained 
in 67% yield. Figure 1 depicts the analytical RP-HPLC tracings obtained for 
the purified s 1 and 2, and their precursors 1a and 2a. 
In conclusion, we have developed Nα-Amadori-containing Nα-Fmoc-Lys-OH 
derivatives as new s for the synthesis of site specific Amadori-modified 
peptides. Contrary to previously published post-synthetically Amadori-
                                                 
70 Brady, R.F. Jr. (1970) Carbohydr. Res., 15, 35. 
71 Cubero, I., and Lopez-Espinosa, M. (1990) Carbohydr. Res., 205, 293. 
72 Yuasa, Y., Ando, J., and Shibuya, S. (1996) J. Chem. Soc., Perkin Trans. 1, 343, 793. 
 
  32 
modified peptides, these building blocks will enable efficient and site specific 
incorporation of a major post-translational modification into bioactive and 
antigenic peptides by stepwise assembly.  
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2.2.1 Peculiarities of the Nε-1-deoxyfructosyl sugar moiety 
 
We have observed for those bulding block products carrying the unprotected 
sugar moiety, 1 and 1a, a curious behavior on LC-MS. The mass 
chromatogram appears as a collection of peaks placed at precise intervals 
(Figure 2.2–1). We have realized that such peaks reproduce the fragmentation 
pattern of 1-deoxyfructosyl derivates reported in literature for ESI-MS-MS73 
(Scheme 2.2–2). Basely the 1-deoxyfructosyl residue looses water and 
formaldehyde units generating the oxonium, bis-dehydrated, pyrylium, 
furylium and immonium ions. However in our measures we have use the 
standard conditions of mild ionization of LC-ESI-MS which don’t fragment 
most organic molecules.  
 
 
Figure 2.2-1 ESI-MS chromatogram of Nα-Fmoc-Lys(Nε-1-deoxyfructosyl)-OH, 
product 1a, with the labeled peaks of the fragmentation ions [531=Amadori(I), 513= 
oxonium (II), 495=-2H2O (III), 477= pyrylium (IV), 447=furylium (V) and 
immonium (VI)]; in the small box is reported the analytical HPLC chromatogram      
of 1a. 
                                                 
73 Frolov, A., Hoffmann, P., and Hoffmann, R. (2006) J. Mass Spectrom., 41, 1459. 
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From this consideration we speculate that the sugar moiety is particularly 
sensitive to ionization.  
O O O
O O
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NHR
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OH
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Scheme 2.2-2 Mass Fragmentation pattern of the Amadori forms(531=Amadori, 513= 
oxonium, 495=-2H2O, 477= pyrylium, 447=furylium and immonium). 
 
Another interesting feature has been displayed by glycated building block 1, 
with the free glucose moiety and the Boc protection on the ε-amino. The LC 
chromatograms show a characteristic pattern of four peaks with exactly the 
same mass (Figure 2.2–2). Despite numerous attempts it has been impossible 
to isolate the different isomers because each fraction collected generated the 
same pattern regardless of the solvent and/or pH conditions applied. We 
speculate, in accordance from what was previously reported for short post-
synthetically glycated peptides74,75, that the incorporated sugar moiety 
presents, in solution, several tautomeric forms in equilibrium similarly to what 
free sugar do in solution (Scheme 2.2-3). In fact, the saccaridic unit of 
reducing sugars is in equilibrium between an open form (thermodynamically 
un-favored, less than 1%) and several closed forms, notably α-pyranose, β-
                                                 
74 Horvat, S. and Jakas, A. (2004) J. Pept. Sci., 10, 119. 
75 Jakas, A., Katic, A., Bionda, N., and Horvat, S. (2008) Carbohydr. Res., 343, 2475. 
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pyranose, α-furanose and β-furanose forms (with the pyranose adducts 
generally being the most favoured, especially the β form).  
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Figure 2.2-2 Above is reported the analytical HPLC chromatogram of product 1 with 
the zoom of the peak region from LC-MS. Below is reported the mass spectrum of the 
four peaks. 
 
Interestingly among the four glycated Lysine derivate we have generated, only 
product 1 displayed such putative tautomerization. Our explanation is that in 
the case of products 2 and 2a the equilibrium of isomeric forms is suppressed 
by the isopropylide protection that doesn’t allow the sugar moiety to assume 
the open form and sub sequentially to tautomerize. However, in the case of  
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Scheme 2.2-3 In solution tautomeric equilibrium of the glycated adducts. 
 
analog 1a we have seen none of the tautomerization regardless of the sugar 
being free from protection. We speculate that the chemical environment 
influences the tautomerization allowing it to be a thermodynamically driven 
process or a kinetically driven one. With a simple glycated Lysine we are in 
the first case, thermodynamic control meaning that the sugar moiety is almost 
exclusively in the β-pyranose form and the LC chromatogram shows only one 
peak. With hindered, semi-protected glycated Lysines and with glycated 
peptides we are in the second case, kinetical control that makes the closed 
forms over than β-pyranose less un-favored and thus detectable as separate 
peaks in LC. In this theoric frame, the peaks are not actually the isomeric 
forms but an effect of the different distribution isomers and each peak area 
should be proportional to an isomer relative probability of forming. 
Finally regarding the purification of Amadori building block, reverse phase 
flash chromatography (RPFC) proved to be more efficient than direct phase 
which may be used only with the fully-protected building block (product 2) 
with is the less polar one (Figure 2.2–3). Products 1 and 1a, both with free 
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hydroxyls, were not separated by RPFC without the presence of acid in the 
solvents and appear as a single peak However when acid (TFA 0.1-0.05 %) is 
added the two peaks separates accordingly to the analytical HPLC behavior. 
Probably without acid the products are in form of corresponding TEA salts 
while after the TFA addition the free acids are formed and polarity is more 
relevant in the chromatographic separation. 
 
 
 
Figure 2.2-3 Above is reported the RP flash chromatogram of a mixture of product 1 
and 1a without acid in the solvents (A) and with acid (B). 
B 
A 
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2.2.2 Nα-Fmoc-Lys[Nε-(2,3:4,5-Di-O-Isopropylidene-1-
Deoxyfructopyranosyl),Nε-Boc]-OH 
 
As expected, the fully protected building block, bearing a Boc protection on 
the ε-amino and two isopropilidene protections on the vicinal hoxydryls of the 
sugar moiety, proved to be completely stable to the condition of solid phase 
peptide elongation by Fmoc/tBu strategy. 
The sugar moiety is unaffected by the concentrated TFA treatment required for 
cleavage of the peptide from the resin and side chain deprotection. The 
isopropilidene protection however are only partially removed by 2-3 hours 
TFA exposure and the resulting crude peptide (Figure 2.2–4 A) is a mixture of 
fully deprotected sugar product, mono-protected isopropylidene form and di-
protected form. The latter two adducts at progressively longer retention time 
compare to the unprotected one.  
 
 
Figure 2.2-4 LC-MS chromatogram of a glycated peptide cleavage after 30 min (A), 
2h (B) and second TFA treatment (overall 4h) (C). 
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An additional TFA treatment is required to completely remove the 
isopropylidene protection (Figure 2.2–4 B and C). Scavenger must be added to 
the deprotecting mixture to prevent undesired alkylation due to the presence of 
carbocations generated in the previous cleavage. 
In conclusion the glycated building block represents a highly relabile tool for 
introducing glycation modifications in specific positions of a peptide sequence 
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2.2.3 Systematic approach to the synthesis of a glycated hCD59 
peptide antigen 
 
The ultimate goal of this project was the generation of specific glycated-CD59 
antibodies to be used as diagnostic/prognostic tool for diabetes. In order to 
produce the desired glycated CD59 antigen, to be use for mice and rabbit 
immunization, five different convergent strategies were carried out (Scheme 
2.2–4): (A) in solution direct glycation, (B) on resin direct glycation, (C) on 
resin reductive amination, (D) in solution reductive amination and stepwise 
synthesis (E).  
 
 
 
 
 
 
 
 
Scheme 2.2-4 Convergent strategies for the synthesis of glycated hCD59(37-50) 
 
A first problem that we had to address was the requirement of selectivity for 
glycation of hCD59(37-50) Lysine41 since the sequence contains the close by 
Lysine38. Post-synthetic approaches (A,B,C and D) are not selective and 
require orthogonal protection schemes to achieve a selective glycation on a 
given position otherwise all the accessible amino groups will react in similar 
way. On-resin post-synthetic modification (B and C) was achieved by 
protecting Lysine 41 orthogonally to  
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Scheme 2.2-5 Synthetic routs of the five convergent strategies attempted. 
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only there the glycation could take place (Scheme 2.2-5). This was achieved 
using the 1-(4,4’-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl (ivDde)76 
protection, cleavable with 2% hydrazine in DMF. The hCD59(37-50) sequence 
was synthesized by SPPS using Fmoc/tBu strategy obtaining intermediate 
peptide I. After selective deprotection of Lys41 was obtained intermediate 
peptide Ia on which was performed on resin direct glycation and on resin 
reductive amination. 
For the in-solution approaches (A and D) we synthesized the intermediate 
peptide II, a hCD59(37-50) sequence with Lysine38 and Lysine41 
respectively protected with ivDde and Boc groups. The product was obtained 
after concentrated TFA cleavage (with all positions unprotected but Lysine38)  
Direct glycation is the oldest among post-synthetic glycation strategies and is 
normally performed by incubating peptides and proteins in presence of a high 
excess (50to100 fold) of aldose sugars, glucose usually. In spite of the excess 
of reactants the glycation is slow and usually the reaction is held for 30 days. 
We have adopted a recently described method which describes glycation with 
glucose incubation at 110° in DMF for 30 min77. This strategy represents an 
improvement of the former method because it is faster and the yield of 
glycation product III is good (ca. 70%) but there is a serious problem with 
undesired byproducts. Such undesired reactions caused probably by oxidation, 
degradation and polymerization reactions, that gave side products almost 
impossible to separate from the desired product. The on-resin approach was 
superior in terms of yield to the in-solution one due to the protection of side 
chain residues. 
The other post-synthetic strategy attempted was reductive amination of the 
Lysine residue with a specific D-ribose aldehyde derivate, the 2,3:4,5-di-O-
isopropylidene-aldehydo-β-D-arabino-hexos-2-ulo-2,6-pyranose, which after 
                                                 
76 Chhabra, S.R., Hothi, B., Evans, D.J., White, P.D., Bycroft, B.W., and Chan, W.C. (1998) 
Tetrahedron Lett., 39, 1603. 
77 Frolov, A, Singer, D., and Hoffmann, R. (2006) J. Pept. Sci., 12, 389. 
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the formation of the corresponding Schiff base can be reduced to the 1-
deoxyfructosyl form that is indistinguishable from the derivate form of D-
glucose glycation occurring in Nature78 This strategy proved to be more 
successful in-solution than on resin where the rate of reaction was slow and 
remained a substantial amount of un-glycated form. On the contrary in 
solution, reductive amination was fast and proceeded almost to completion. 
The draw back of the latter strategy was the necessity of many purification 
steps which influenced the final yield. 
On the other hand, step wise synthesis using our building block 2, the specific 
glycated Fmoc-Lysine derivate, Nα-Fmoc-Lys[Nε-1-deoxyfructosyl, Nε-
Boc)]-OH79, proved to be completely reliable with no side effects or 
shortcomings.  
                                                 
78 Brady, R.F. Jr. (1970) Carbohydr. Res., 15, 35. 
79 Carganico, S., Rovero, P., Halperin, J.A., Papini, A.M., and Chorev, M. (2009) J. Pept. Sci., 
15, 67. 
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2.2.4 Post-synthetic strategies versus building-block approach 
 
One important feature common to all the preparations was the realization that 
the glycated, 1-deoxyfructosyl-form, of a the peptide had the retention times in 
C18, C8 and C4 very close to the corresponding un-glycated form. Under a 
very shallow, almost isocratic gradient, the glycated and un-glycated forms of 
our antigen barely starts to separate (Figure 2.2-5).  
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Figure 2.2-5 LC-MS method 15 to 17 % acetonitrile in water in 15 min, 
chromatogram of a mixture of un-glycated peptide ( at 11.31 min, [M+2H]2+=883.12) 
and glycated peptide ( at 12.05 min, [M+2H]2+=964.00) and glycated peptide. 
 
Further purification by semi-preparative reverse phase HPLC using very 
shallow and isocratic gradients was unsatisfactory in terms of yield due to the 
poor separation of the two forms (glycated and un-glycated ones).  
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In conclusion semi-preparative C18 purification of glycated peptide 
preparations were found to be strongly dependent on the presence of the un-
glycated form of the peptide antigen.  
This purification shortcoming undermined the success of the post synthetic 
strategies (A), (C), and (D), due to the fact that a complete conversion of the 
starting material into the glycated product was not achieved regardless of the 
different synthetic conditions attempted. Longer reaction times, higher 
temperatures or higher excess of reactants lead to formation of di-glycation, 
that again displayed overlapping retention time with the glycated and un-
glycated form suggesting some kind of compensation between the increased 
polar nature of a glycated form versus the increased steric hindrance. Taking 
into account the fact that even free Lys and glycated Lysine have very similar 
retention times, we believe that the introduction of a glycation modification 
into a peptide sequence generates no significant net change in reverse phase 
chromatography reaction time. 
Method (B) was the only post-synthetic strategy that afforded selectively the 
desired glycated product however the yield is lowered by the necessity of 
several purification steps (after peptide synthesis, reductive amination and 
ivDde deprotection). 
Finally, the step-wise pathway using a specific glycated building block proved 
to be by far the most successful pathway, affording the desired product in high 
yield, with no trace of the un-glycated form, requiring just one purification 
step. 
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2.2.5 Generation and characterization of monoclonal anti glycated 
hCD59 antibodies. 
 
The glycated peptide antigen of hCD59(37-50) was used to immunize rabbits 
with the aim to generate specific anti-glycated-hCD59 antibodies to be used 
for identification of the glycated protein in biological samples. 
The combined efforts of a specialized private company (Epitomics) and the 
Laboratory for Translationa Research susseccfully isolate rabbit spleen cells 
producing a monoclonal antibody that efficiently recognizes glycated hCD59 
from urine (Figure 2.2-6). From the comparison of Figure 2.2-6 with Figure 
2.2-7 it is possible to conclude that the headlight band corresponds to the same 
molecular entity and this corresponds to glycated hCD59 because the N-20 
antibody only binds to the C-terminus sequence of hCD59. It can be argued 
that exists the possibility that the protein recognized it is un-glycated hCD59 
and not the glycated hCD59. However upon treatment of the samples with 
NaCNBH3 the monoclonal supernatants are not able any more to recognize the 
protein (the reducing agent transforms the glycated protein into the 
correspondent glucitoLysine-derivate). At the same time N-20 still recognized 
the protein as does a specific anti-glucitoLysine antibody that has been 
previously developed80 in the Laboratory for Translational Research.   
 
                                                 
80 Sonya Chantel et al. (2009) JACS, in press. 
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60-5       60-4      60-3 60-1     56-10 56-4  
56-5     62-9      62-8 62-6 62-2      62-1
 
Figure 2.2-6 Western blot to detect β-ME treated human CD59 with different 
supernatants of rabbit clones (risen with glycated hCD59(37-50) peptide antigen). In 
red is headlined the glycated CD59 band. Prominent signal is seen for monoclonal 60-
3, 56-10, and 62-6 antibodies. 
 
 
 
Figure 2.2-7 Blot 60-3 is reprobed with N-20 (anti-C-terminus-hCD59 commercial 
antibody) which only binds to β-ME treated CD59. 
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2.3 Synthesis of glycated antigenic probes for auto-antibodies 
recognition in diabetes 
2.3.1 Antigen-Antibody interactions 
The antigen (Ag) is a substance eliciting an immune response (e.g., the 
production of specific antibody molecules) when into the tissues of a 
susceptible animal. It is able to combine antibodies molecules or a receptor for 
T lymphocytes.81 Antigens are simple compounds like metabolic ones (i.e. 
sugars, lipids, and hormones), as well as macromolecules (as complex 
carbohydrates, phospholipids, nucleic acids, and proteins). 
Antigens are generally of high molecular weight and commonly are proteins or 
polysaccharides, despite of antibodies that are proteins and secreted by B cells 
after triggering an immune response. 
Antibodies (Abs, also known as immunoglobulins) are proteins, found in 
blood or other body fluids of vertebrates, and used by the immune system to 
identify and neutralize foreign objects, such as bacteria and viruses. 
Polypeptides, lipids, nucleic acids and many other molecules can be 
recognized as antigenic compounds by an antibody, while T lymphocytes can 
only recognize peptides and proteins, as well as hapten proteins and peptides.  
The question of T cell recognition of glycopeptides may be important in the 
immune defense against microorganisms, because many microbial antigens are 
glycosylated. Bäcklund et al. 82 provide evidence that T cell recognition of 
protein glycans may be crucial also for T cell responses to autoantigens in the 
course of autoimmune diseases. Glycopeptides with simple sugars have been 
suitable for studies of the antigen fine specificity of glycopeptide-specific T 
cells. 
                                                 
81 Davies D.R., and Cohen, G.H. (1996) Proc. Natl. Acad. Sci. USA, 93, 7. 
82 Bäcklund, J., Carlsen, S., Hoger, T., Holm, B., Fugger, L., Kihlberg, J., Burkhardt, H. and 
Holmdahl, R. ( 2002) Proc. Natl. Acad. Sci. USA, 99, 9960. 
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However, immune responses may also be generated against little molecules, 
termed haptens, if these are chemically coupled to a larger carrier protein, such 
as bovine serum albumin, or other synthetic matrices. Moreover, this specific 
immune response is highly variable and depends also on size, structure and 
composition of antigens.  
Only the small site on an antigen to which a complementary antibody may 
specifically bind is called an epitope. This is usually one to six 
monosaccharides or 5–8 amino acid residues on the surface of the antigen. 
Because antigen molecules are spatially oriented, the epitope recognized by an 
antibody may be dependent upon the presence of a specific three-dimensional 
antigenic conformation (a unique site formed by the interaction of two native 
protein loops or subunits). Moreover, an epitope may correspond to a simple 
primary sequence region. Such epitopes are described as conformational and 
linear, respectively. In conformational epitopes, the antibody interacts with 
amino acids not sequentially linked but spatially closed one to each other, 
because of the protein folding. The range of possible binding sites is 
enormous, with each potential binding site having its own structural properties 
derived by covalent bonds, ionic bonds and hydrophilic and hydrophobic 
interactions (Figure 2.3–1). 
 
 
Figure 2.3-1 MHC-I bound epitope is scanned by T-cell receptor. 
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Proteins can undergo post-translational modifications or proteolysis altering 
their covalent structure and generating new epitopes. These modified regions 
are termed neo-antigenic epitopes and can be recognized by other specific 
antibodies. 
The specific association of antigens and antibodies is dependent on hydrogen 
bonds, hydrophobic interactions, electrostatic forces, and Van der Waals 
forces. All antigen-antibody binding is reversible, but follows the basic 
thermodynamic principles of any reversible bimolecular interaction. 
 
2.3.2 Autoimmunity 
The immune system can occasionally attack self-antigens triggering an 
autoimmune response, with damages to the tissues on which these antigens are 
expressed. An autoimmune response can be triggered by several factors. In 
some cases infections are the starting triggering cause. 
Molecular mimicry is the process by which a viral or bacterial infection 
activates an immune response cross-reacting with self-antigens. Mimicry 
cannot be simply explained by the structural similarity of two peptides, as 
elucidated by the original model of autoimmune mimicry,83 in which a foreign 
antigen is sufficiently similar to a self-antigen to trigger an autoimmune 
response (Figure 2.3–2). 
 
Figure 2.3–2 Molecular mimicry. 
                                                 
83 Oldstone, M.B. A. Cell 1987, 50, 819-820. 
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Thus, pathogen epitopes very similar to molecules of the organism may trigger 
an autoreactive reaction. By this model, autoimmunity can be explained by a 
response of the immune system towards self-antigens no more tolerated and 
thus recognized as non-self (Figure 2.3–3). 
 
 
Figure 2.3–3 Autoimmune response. 
 
Autoimmune diseases are generally triggered by T lymphocytes further 
inducing an autoantibody response. An autoimmune response can cause 
inflammation and damages to the hit tissue (Figure 2.3–4). Localization of the 
autoimmune response and damages depends on the disease. In some 
autoimmune diseases the damages are localized to single organs, while others 
are systemic. 
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Figure 2.3–4 Mechanism of autoimmune response. 
 
2.3.3 Chemical Reverse Approach to characterize autoantibodies as 
autoimmune disease biomarkers 
Autoimmune diseases are due to an "error of evaluation" of the immune 
system, which no more recognizes self-antigens.84 It is well-known that 
autoimmune diseases have a multifactor origin, which includes: genetic 
predisposition, endogenous, and exogenous elements. Different hypotheses 
can be made to explain autoimmune processes because of the intricate 
pathogeneses of such diseases and of the natural complexity of the 
biochemical mechanisms. Autoimmune diseases are very frequent (they affect 
at least 5% of the whole population) and have a high social impact, because 
patients have a long expectation of life during which are subordinated to the 
follow up of the disease by means of very expensive techniques such as 
Magnetic Resonance Imaging (MRI) that are not suitable for routine use.  
Sera from patients suffering from autoimmune disorders often contain multiple 
types of autoantibodies. Some autoantibodies can be exclusive of a disease and 
                                                 
84 Rose, N., and Mackay, I. (2006) In The Autoimmune Diseases, Elsevier Academic Press, 4th 
edition, 55. 
  53 
thus used as biomarkers for diagnosis; others fluctuate with disease 
exacerbations or remissions and are extremely valuable in the follow-up of 
patients.85 Therefore, the antibodies present in patients’ serum can be used as 
disease biomarkers. 
A biomarker is an anatomical, physiological, biochemical parameter, which 
can be easily determined and used as pointer of normal physiological or 
pathogenic processes. Molecules present in biological fluids can be identified 
as biomarkers and used to set up diagnostic/prognostic tools and for 
monitoring the effects of a therapeutic treatment. 
The identification of synthetic peptides as antigenic probes for the 
characterization of autoantibodies as biomarkers can be achieved by a 
“Chemical Reverse Approach”. This approach is defined “Reverse” because 
the screening of the antigenic probes is guided by autoantibodies circulating in 
autoimmune disease patients’ biological fluids. The autoantibody recognition  
drives the selection and optimization of the “Chemical” structure of defined 
focused peptide libraries. Thus, autoantibodies circulating in patients’ 
biological fluids allow the definition of synthetic post-translationally modified 
peptides mimicking the neo-antigenic epitopes. Peptides identified by this 
approach, selectively and specifically recognizing autoantibodies, can be used 
as antigenic probes in immunoenzymatic assays to detect disease biomarkers.86 
Summarizing, in the Direct Approach antigenic peptides are used to immunize 
animals in order to generate antibodies that recognize those specific proteins 
that the antigens mimic (Scheme 2.3-1). In the Reverse Approach antigenic 
peptides are used as synthetic probes to recognize autoantibodies in patients’ 
sera. In the first case the native proteins are the biomarkers of the disease, in 
the second the biomarkers are represented by the autoantibodies.  
 
                                                 
85 Leslie, D., Lipsky, P., and Notkins, A.L. (2001) J Clin Invest, 108, 1417. 
86 Alcaro, M.C., Lolli, F., Migliorini, P., Chelli, M., Rovero, P., and Papini, A.M. (2007)  
Chemestry Today, 25, 14. 
  54 
Glycated hCD59 synthetic antigen
Mice and rabbit
Immunization
Anti glycated hCD59 antibodies
Direct Approach
Detection of glycated hCD59
in patient sera
Reverse Approach
Synthetic Antigenic Probes
ELISA
Detection of 
anti glycated hCD59 auto-antibodies
in patient sera
 
Scheme 2.3-1 The Direct and Reverse Appoarch for the development of 
diagnostic/prognostic tools of autoimmune disease. 
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2.3.4 CSF114: universal scaffold for synthetic antigenic probes 
 
In previous studies, performed at the Laboratory of Peptide & Protein 
Chemistry & Biology, it was demonstrated that the glycopeptide 
[Asn31(Glc)hMOG(30-50)], containing a β-D-glucopyranosyl residue linked to 
the Asn31 residue by an N-glucosydic bond, is able to detect autoantibodies in 
Multiple Sclerosis patients’ sera by ELISA experiments.87 
Conformational studies performed on hMOG(30-50) and its glucosylated 
analogue established the fundamental role of the glucosyl moiety in 
autoantibody recognition (Figure 2.3–5). It was observed that the active 
glucosylated peptide [Asn31(Glc)hMOG(30-50)] and the inactive 
unglucosylated peptide hMOG(30-50) adopted similar conformations in 
solution.88 Therefore, it was hypothesized that the ability of the glucosylated 
peptide to detect autoantibodies in Multiple Sclerosis was linked to 
characteristics other than conformation and that the specific autoantibody 
binding site on MOG glycopeptide was related to the N-linked glucosyl 
moiety. This result, together with the observation that the N-glucosylated 
asparagine alone was able to bind Multiple Sclerosis autoantibodies in a 
solution-phase competitive ELISA experiment, allowed to define that the 
minimal epitope is the Asn(Glc) moiety. 
                                                 
87 Mazzucco, S., Mata, S., Vergelli, M., Fioresi, R., Nardi, E., Mazzanti, B., Chelli, M., Lolli, 
F., Ginanneschi, M., Pinto, F., Massacesi, L., and Papini, A.M. (1999) Bioorg. Med. Chem. 
Lett., 9, 167. 
88 Carotenuto, A.; D'Ursi, A. M.; Nardi, E.; Papini, A. M., and Rovero, P. (2001) J. Med. 
Chem., 44, 2378. 
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Figure 2.3–5 Conformational analysis of peptides hMOG(30-50) (in red) and 
[Asn31(Glc)hMOG(30-50)] (in blue).88 
 
Hence, the recognition properties of the molecule were optimized through the 
design and screening of focused libraries of glycopeptides. A specific 
antigenic probe, CSF114(Glc), was developed to identify a family of 
autoantibodies, as biomarkers of Multiple Sclerosis correlating with disease 
activity.  
The CSF114(Glc) structure was obtained after a structure-based design 
confirming that antigen conformation is fundamental for the correct exposition 
of the minimal epitope Asn(Glc) recognizing specific antibodies. CSF114(Glc) 
is characterized by a β-hairpin structure in which the Asn(Glc) epitope is on 
the tip of type I’ β-turn.89 CSF114(Glc) showed a high specificity for Multiple 
Sclerosis autoantibodies, because no antibody reactivity was detected in other 
autoimmune diseases or other infective neurological diseases.90 Therefore, 
CSF114(Glc) is the first MSAP for detecting specific autoantibodies that can 
be used as relabile biomarkers for the practical evaluation of the disease 
activity in a subpopulation of MS patients. CSF114(Glc) was selected by an 
                                                 
89 Carotenuto, A., D’Ursi, A.M., Mulinacci, B., Paolini, I., Lolli, F., Papini, A.M., Novellino, 
E., and Rovero, P. (2006) J. Med. Chem., 49, 5072. 
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innovative “Chemical Reverse Approach” that starting from synthetic peptides 
univocally characterized, can screen autoantibody populations present in sera 
of patients (Figure 2.3–6).  
It was demonstrated that specific probes characterised by β-hairpin structures 
are able to follow up disease activity in a statistically significant number of 
Multiple Sclerosis patients. It was hypothesized that CSF114(Glc) β-hairpin 
structures could be mimetic of aberrantly glucosylated native antigens. 
Moreover a specific immunoaffinity column based on CSF114(Glc) allowed 
isolation of disease specific autoantibodies recognising only myelin and 
olygodentriocytes. 91 
 
Figure 2.3–6 Calculated structures of CSF114(Glc). Ribbon diagram of the lowest 
energy conformer of 200 calculated structures of CSF114(Glc) derived from NMR 
data. 
 
                                                 
90 Lolli, F., Mazzanti, B., Pazzagli, M., Peroni, E., Alcaro, M.C., Sabatino, G., Lanzillo, R., 
Brescia, M., Santoro, V., Gasperini, L., Galgani, C., D’Elios, S., Zipoli, M.M.; Sotgiu, V., 
Pugliatti, S., Rovero, P., Chelli, M. and Papini, A.M. (2005) J. Neuroimmunol, 167, 131. 
91 “Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of 
Multiple Sclerosis”. Inventors: Papini, A.M., Rovero, P., Chelli, M. and Lolli, F. Applicant: 
University of Florence, Italy. PCT International application (2003) WO 03000733 A2. Italian 
Patent n. 0001327122 (27/04/2005). 
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Up to now, glucosylation, a post-translational modification not common in 
eucariotic proteins, has been detected only in bacterial glycoproteins.92 
Putative glucosylation of myelin proteins, by still unknown mechanisms, could 
transform self-antigens in non-self ones and trigger an autoimmune response. 
More than one protein could be aberrantly glucosylated creating neo 
autoantigens. 
To further investigate the role of sugars and linkage between sugar and the 
amino acid, in autoantibody recognition, a collection based on glycoamino 
acids diversity is fundamental to understand this special molecular mechanism 
of an antibody mediated Multiple Sclerosis. 
                                                 
92 Wieland, F., Heitzer, R., and Schaefer, W. (1983) Proc. Natl. Acad. Sci. U.S.A., 80, 5470. 
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2.3.5 Generation of a panel of Synthetic Antigenic Probes for the 
diagnosis of type I and type II diabetes 
 
Three different peptides bearing posttranslational modifications and 
corresponding unmodified analogs (without the PTMs, Table 2.3-1) were 
synthesize to be used as synthetic antigenic probes for the identification of 
anti-glycated-epitopes autoantibodies in type I and II diabetes patient sera. 
The peptide scaffold CSF114 was selected for it is capacity to expose in best 
way to the solvent a residue in position 7 which is the top of a β-turn. On that 
specific position was introduced a glycated Lysine using the glycated Fmoc-
Lysine derivate 2 obtaining peptide IV. On CSF114 position 7 was also 
introduced a residue of N-glycosylated Asparagine (using a specific developed 
for this purpose in PeptLab) affording peptide V. 
Product VII was obtained introducing building block 2 into position 41 of 
hCD59(37-50). 
 
(8Lys(1-deoxyfructosyl) CSF114 TPRVERuGHSVFLAPYGWMVK IV 
[(8Asn(Glc)] CSF114 TPRVERvGHSVFLAPYGWMVK V 
CSF114 TPRVERNGHSVFLAPYGWMVK VI 
[41Lys(1-deoxyfructosyl)]hCD59(37-50) NKAWuEHANFNDC VII 
hCD59(37-50) NKAWKEHANFNDC VIII 
Table 2.3-1 Sequences of the synthesized antigenic probes u= glycated Lysine,          
v= glycosylated Asparagine. 
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2.4 Screening of diabetic patient sera by non-competitive ELISA 
The following section describes the work originated by the collaboration with 
Dr. Francesco Dotta of the Diabetic Department of the University of Siena 
who provided the sera of type I and type II diabetic patients.  
 
2.4.1 Enzyme-Linked Immunosorbent Assay  
This technique can exploit the capability of antibodies to detect biomolecules 
with a high sensibility. Immunoassays are based on an antigen/antibody 
interaction to identify a target compound or a class of compounds. 
Concentrations of analytes are identified through the use of a sensitive 
colorimetric reaction. The concentration of the analyte depends on the 
Lambert-Beer equation and is thus determined by the intensity of color in the 
sample. The concentration can be determined accurately with a photometer or 
a spectrophotometer. 
Immunoassays take advantage of the ability of antibodies to bind selectively to 
a target antigen present in a sample matrix and characterized by a specific 
chemical structure.  
One of the most used immunoassay technique is the Enzyme Linked 
ImmunoSorbent Assay (ELISA) (Scheme 2.4-1), a technique introduced by 
Engvall and Perlmann,93 and used for the detection of antigens and antibodies. 
The sensitivity of this technique is comparable to that of a radioimmunoassay.  
The two components involved in ELISA are: a solid phase, to which a specific 
antigen or antibody is coated, and an enzyme-labeled anti-antibody conjugated 
to the corresponding antibody or antigen. The enzyme acts on an appropriate 
substrate, releasing a coloured compound that can be easily detected by a 
spectrophotometer. 
                                                 
93 Egall, E., and Perlmann, P. (1972) J. Immunol., , 109, 129. 
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Scheme 2.4-1 A sandwich ELISA. (1) Plate is coated with a capture antibody; (2) 
sample is added, and any antigen present binds to capture antibody; (3) detecting 
antibody is added, and binds to antigen; (4) enzyme-linked secondary antibody is 
added, and binds to detecting antibody; (5) substrate is added, and is converted by 
enzyme to detectable form. 
 
2.4.1.1 Types of ELISA 
Direct ELISA is used to detect an antigen after it has been coated to the solid 
phase. An antibody, conjugated with a label, is then incubated with the 
captured antigen. After washing off excess of the conjugate and incubating 
with a substrate and a chromogen, the presence of an expected color indicates 
a specific antibody-antigen interaction. 
Indirect ELISA is useful for the detection of antibodies using specific antigens. 
Once again an antigen is adsorbed onto a solid phase. The first, or primary 
antibody, is incubated with the antigen, then the excess is washed off. The 
bound antibody is detected after incubation with an enzyme labeled with 
specific anti-immunoglobulin (secondary antibody) followed by the enzyme 
substrate. 
Competitive ELISA is useful for identification and quantitation of either 
antigens or antibodies. In antigen determination, the antigen present in the 
sample competes for sites on the antibody with labeled antigen added to the 
medium. The color change will be inversely proportional to the amount of 
antigen in the sample. Competition principle can be exploited in different 
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ways. In a competitive ELISA, a patient’s serum and an antigen-specific 
conjugate are co-incubated with a captured antigen. The amount of color 
developed is inversely proportional to the amount of antigen-specific patient Ig 
present. 
Inhibition ELISA works similarly to competitive. One antigen is coated on the 
plate and the other is added at various concentrations in the presence of the 
antibody. The antibody binds to the free antigen in solution rather than to the 
coated antigen. In this case, the free antigen inhibits the antibody binding to 
the coated antigen. This is particularly useful in determining the identity of 
specific antigens or antibodies. 
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2.4.1.2 Immunological assays using CSF114 analogues as antigens 
 
The autoantibody recognition by CSF114 analogues as antigens was evaluated 
by competitive ELISA on Multiple Sclerosis patients’ sera. The inhibition 
curves (Figure 2.4-1) showed that the glycopeptides Asn7RibCSF114 does not 
present activity, in fact it was not able to inhibit anti-CSF114(Glc) 
autoantibodies in Multiple Sclerosis patients. On the other hand, glycopeptide 
Phe7GlcCSF114 displayed inhibitory activity only at higher concentration. 
CSF114(Glc) is the glycopeptide with the lower IC50 value (concentration 
required for 50% inhibition).  
In conclusion, the glycopeptide containing the Asn(Glc) residue showed the 
higher affinity to autoantibodies in Multiple Sclerosis patients’ sera. These 
results demonstrate again the crucial importance of the N-glycosydic bond 
between the sugar and the amino acid and the role of the sugar moiety for 
autoantibody recognition in Multiple Sclerosis patients’ sera. 
0
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Figure 2.4-1 Inhibition curves of anti-CSF114(Glc) antibodies with the three CSF114-
type glycopeptides. Results are expressed as % of a representative Multiple Sclerosis 
positive serum (y axis). Concentrations of peptides as inhibitors are reported on the x 
axis. 
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2.4.2 ELISA screening of type I diabetes patients’ sera  
 
The interaction between a given peptide and the ELISA plate depends on 
several factors including plate type, dilution buffer, pH, and temperature. 
Moreover, each peptide binds to the plate surface in a different way and this is 
mostly unpredictable. In order to find the best conditions for the assay, each 
synthetic antigen peptide was tested on a standard non-competitive ELISA 
versus a reduced number of healthy blood donors and patients’ sera. Eight 
different conditions were used for each product (four different coating 
solutions each one applied to two different blocking solutions). 
After optimization of the coating/blocking conditions the peptides IV-VIII 
(Table 2.4-1) were tested under the optimized conditions.  
 
(8Lys(1-deoxyfructosyl) CSF114 TPRVERuGHSVFLAPYGWMVK IV 
[(8Asn(Glc)] CSF114 TPRVERvGHSVFLAPYGWMVK V 
CSF114 TPRVERNGHSVFLAPYGWMVK VI 
[41Lys(1-deoxyfructosyl)]hCD59(37-50) NKAWuEHANFNDC VII 
hCD59(37-50) NKAWKEHANFNDC VIII 
Table 2.4-1 Sequences of the synthesized antigenic probes. u= glycated Lysine,         
v= glycosylated Asparagine. 
 
To each set of values we associated a cut-off of + 2 SD (the average of the 
healthy blood donors’ values plus two times the standard deviation of the 
healthy blood donors’ values). The cut-off represents the minimum value of 
absorbance that can be taken as positive during the assay. The second SD 
addition minimizes the possibility to have a false positive. 
Peptides IV-VI didn’t show any recognition for IgG but displayed significant 
signals for IgM, in particular peptide VI (bearing the glucosylated Asparagine) 
Figure 2.4-2 A and B. The data, in spite of being preliminary (not fully 
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optimize testing conditions and low number of patients’ and healthy donors), 
have been object of a standard diagnostic treatment. In fact, to each value for 
patient sera has been subtracted the blank sera values average and the healthy 
donors blank average. In addition a cut-off of ā (healthy signals average) + 2 
SD (standard deviation) and not just merely ā was used. Under a less strict 
treatment, that does not consider the standard deviation, the recognition 
increases as is shown in Table 2.4-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4-2 Non-competitive ELISA assay of peptides IV-VI against type I diabetic 
patients’ sera and cut-off from healthy blood donors values. Results for IgG (A) and 
IgM(B). TB_E 20 is an unrelated peptide. 
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IgG IV V VI IgM IV V VI 
Recognition* 6 0 0 Recognition* 17 0 0 
Recognition** 17 0 0 Recognition** 16 10 28 
Table 2.4-2 IgM and IgG autoantibodies recognition in patients’ sera (%) for peptides 
IV-VI with strict standard diagnostic treatment* and with preliminary data 
treatment**. 
 
Glycated hCD59 VII displayed a high recognition for both IgG and IgM under 
a preliminary treatment of the data (Figure 2.4-4, Figure 2.4-4, and Table 
2.4-3) and retains a significant recognition (10-15%) even upon addition of 
twice the standard deviation to the cut off.  
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Figure 2.4-3 Non-competitive ELISA test of peptides glycated hCD59 VII (A) and 
un-glycated hCD59 VIII (B) against type I diabetic patients’ sera and cut-off from 
healthy blood donors values. Results for IgG. 
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On the other hand, unglycated hCD59 VIII showed, as expected, less 
recognition compared to its glycated analog under both data treatments 
 
0
0,5
1
1,5
2
2,5
D
M
1
D
M
3
D
M
5
D
M
7
D
M
9
D
M
11
D
M
13
D
M
15
D
M
17
D
M
19
D
M
21
D
M
23
D
M
25
D
M
27
pazienti
as
so
rb
an
za
 
0
0,5
1
1,5
2
2,5
D
M
1
D
M
3
D
M
5
D
M
7
D
M
9
D
M
11
D
M
13
D
M
15
D
M
17
D
M
19
D
M
21
D
M
23
D
M
25
D
M
27
pazienti
as
so
rb
an
za
 
Figure 2.4-4 Non-competitive ELISA test of peptides glycated hCD59 VII (A) and 
un-glycated hCD59 VIII (B)against type I diabetic patients’ sera and cut-off from 
healthy blood donors values. Results for IgM. 
 
IgG VII VIII IgM VII VIII 
Recognition* 10 0 Recognition* 15 13 
Recognition** 60 33 Recognition** 45 20 
Table 2.4-3 IgM and IgG autoantibodies recognition in patients’ sera (%) for peptides 
VII and VIII with strict standard diagnostic treatment* and with preliminary data 
treatment**. 
 
A 
B 
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Figure 2.4–5 and Figure 2.4–6 report the difference between the values 
of glycated hCD59(37-50) and of unmodified hCD59(37-50) for IgG 
and IgM in type I diabetic patients’ sera (A) and healthy blood donors 
(B).  
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Figure 2.4–5 Difference between the values of glycated hCD59(37-50) and of 
unmodified hCD59(37-50) for IgG in type I diabetic patients’ sera (A) and healthy 
blood donors (B). 
 
As can be seen from Figure 2.4–6 A the, almost every single patients’ 
serum has IgG antibodies recognizing the glycated peptide with higher 
A 
B 
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affinity compared to the un-glycated one (the difference is a positive 
value). This may be explained by the presence of specific anti-glycated 
antibodies in patients’ sera. 
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Figure 2.4–6 Difference between the values of glycated hCD59(37-50) and of 
unmodified hCD59(37-50) for IgM in type I diabetic patients’ sera (A) and healthy 
blood donors (B). 
B 
A 
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2.5 Protein synthesis by Native Chemical Ligation  
 
Chemical Ligations (CL) as methods to link together two or more peptide 
fragments have long been used for the synthesis of small proteins and have 
been an alternative to the strategy of fragment condensation of fully protected 
peptides in organic solvents94. The CL strategies are based on the presence in 
each peptide fragment of a unique, mutually reactive functionality, which 
enables a chemoselective reaction between the two components. The 
advantage is that this reaction can be performed using partially protected 
peptides in aqueous or semi-aqueous solvents. One example of CL is the 
famous synthesis of human immunodeficiency virus-1 protease (HIV-1 PR)95 
whose chemical basis was a nucleophilic substitution reaction between an SH 
group of a thioacid attached to the C-terminus of a peptide sequence, and an 
alkyl bromide attached to the N-terminus of the second fragment, leading to 
the formation of a thioester bond at the ligation site (Scheme 2.5-1). However 
the drawback of CL methodologies is the generation of an unnatural, meaning 
not amide, bond at the ligation point. 
 
 
Scheme 2.5-1 Total synthesis through chemical ligation of the HIV-1 PR analogue. 
 
 
                                                 
94 Kimmerlin, T. and Seebach, D. (2005) J. Peptide Res., 65, 229. 
95 Schnolzer, M. and Kent, S.B. (1992) Science, 256, 221. 
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In recent years, there was an explosion of interest in protein assembly 
technologies such as native chemical ligation (NCL)96 and its related expressed 
protein ligation (EPL)97. NCL rely on the principle of chemoselective reaction 
between two protein fragments, one containing a C-terminal thioester and the 
other containing a free N-terminal Cysteine residue The reaction is performed 
in aqueous solution in the presence of excess of thiols with unprotected 
peptides (a protection is needed only in the presence of 2 equivalents of N-
terminal Cysteine residues. The components combine to give a peptide with an 
amide bond therefore “native” at the point of ligation differently from the bond 
formed in other types of ligation (which is not an amide one). 
 
 
 
 
 
 
 
 
 
 
Scheme 2.5-2 Mechanism of Native Chemical Ligation. 
 
The mechanism involved is a rate-determining transthioesterification between 
the thiol group of the N-terminal Cysteine and the peptide-2 and the C-
terminal thioester group of peptide-1 followed by a rapid S->N acyl shift, 
which occurs via a five-member-ring transition state ( 
                                                 
96 Dawson, P.E., Muir, T.W., Clark-Lewis, I., and Kent, S.B. (1994) Science, 266, 776. 
97 T.W., Muir, D., Sondhi, and P.A. Cole, (1998) Proc. Natl. Acad. Sci. USA, 95, 6705. 
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Scheme 2.5-2)98. The ability of NCL strategies to reproduce natural peptide 
bonds and the fact that it is possible to form it in aqueous solution and in the 
absence of protecting groups, has placed this powerful technology at the 
forefront of protein synthesis. 
Nonetheless, two limitations remain associated with NCL99: the necessity to 
have an N-terminal free Cysteine and a C-terminal thioester.  
Several approaches have been developed to overcome the prerequisite of 
having an N-terminal Cysteine residue. For example, homoCysteine can be 
used for NCL and then can be methylated after ligation to render the Met-
containing protein100. Furthermore, Cys itself can be desulfurized to give an 
Ala residue101. This strategy opens the possibility of using peptides containing 
thio-derivatives of the common amino acids, which after chemical ligation and 
desulfurization can give peptides with other proteinogenic amino acids102.  
 
 
Scheme 2.5-3 Extended applicability of NCL by using N-ethanethiol (a) and N-2-
sulfanylbenzyl (b) auxiliaries or by Staudinger ligation (c) 
                                                 
98 Macmillan, D. (2006) Angew. Chem. Int. Ed., 45, 7668. 
99 Albericio, F. (2004) Current Opinion in Chemical Biology, 8, 211. 
100 Tam, J.P. and Yu, Q. (1998) Biopolymers, 46, 319. 
101 Yan, L.Z. and Dawson, P.E. (2001) J Am Chem Soc, 123, 526. 
102 Clive, D.L., Hisaindee, S., and Coltart, D.M. (2003) J Org Chem, 68, 9247. 
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Furthermore, N-ethanethiol [Scheme 2.5-3(a)]103 and N-2-sulfanylbenzyl 
auxiliaries [Scheme 2.5-3(b)]104 have been investigated. These moieties, which 
contain the thiol required for the ligation, are removed after the protein is 
formed by treatment with Zn/AcOH and under acid conditions, respectively. 
A more general strategy involves Staudinger ligation between a C-terminal 
phosphinothioester and an N-terminal azide, which gives an amide that does 
not have residual atoms [Scheme 2.5-3(c)]105. The initial intermediate is an 
iminophosphorane and this rearranges to an amidophosphonium salt that after 
hydrolysis gives the amide. 
The second and most serious limitation of NCL is related to the preparation of 
the thioester peptide, a stage that has mainly been performed using Boc/Bzl 
chemistry106. For larger polypeptide domains and protein domains intein-based 
bacterial expression systems are used107. Unfortunately, the Boc methodology 
requires the use of HF, which is extremely toxic and not well suited for 
synthesis of phospho-108 and glycopeptides109. The Fmoc–based methodology, 
on the other hand, is an attractive alternative as it does not employ HF and 
hence provides access to the synthesis of phospho- and glycopeptides in good 
yield. However, the poor stability of the thioester functionality to strong 
nucleophiles such as piperidine, which are used for the deprotection of the Nα-
Fmoc group, seriously limits the use of this methodology110.  
In order to overcome this limitation different approaches have been described 
for C-terminal peptide thioester formation with Fmoc/tBu-SPPS usually 
involving the use of special resins that release the peptide as a C-terminal 
                                                 
103 Canne, L.E., Bark, S.J., and Kent, S.B. (1996) J Am Chem Soc, 118, 5891. 
104 Vizzavona, J., Dick, F., and Vorherr, T. (2002) Bioorg Med Chem Lett, 12, 1963. 
105 Nilsson, B.L., Hondal, R.J., Soellner, M.B., and Raines, R.T. (2003) J. Am. Chem. Soc., 
125, 5268. 
 
106 Camarero, J.A., Cotton, G.J., Adeva, A., and Muir, T.W. (1998) J.Pept. Res., 51, 303. 
107 Perler, F.B., and Adam, E. (2000) Curr. Opin. Biotechnol.,10, 377. 
108 Huse, M., Holford, M.N., Kuriyan, J., and Muir, T.W. (2000) J. Am. Chem. Soc., 122, 8337. 
109 Macmillan, D. and Bertozzi, C.R. (2004) Angew. Chem. Int. Ed.Engl., 43, 1355. 
110 Camarero, J.A. and Mitchell, A.R. (2005) Protein and Peptide Letters, 12, 723. 
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thioester under specific cleavage conditions such as the acylsulfonamide111, the 
aryl-hydrazine112, BAL113, PAM114 resins. 
We have chosen a different approach which consists on the direct 
thioesterification of the free carboxylic acid of a fully protected peptide115.. 
 
 
 
 
                                                 
111 Ingenito, R., Bianchi, E., Fattori, D., and Pessi, A. (1999) J. Am. Chem. Soc., 121, 11369. 
112 Camarero, J.A., de Yoreo, J.J., and Mitchell, A.R., (2004) J. Org. Chem., 69, 4145. 
113 Brask, J., Albericio, F., and Jensen, K.J. (2003) Org. Lett., 5, 233. 
114 Swinnen, D. and Hilvert, D. (2000) Org. Lett., 2, , 789. 
115 von Eggelkraut-Gottanka, R., Klose, A., Beck-Sickingera, A.G., and Beyermann, M. (2003) 
Tetrahedron Letters, 44, 3551. 
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2.5.1 Total synthesis of glycated hCD59 by Tandem Native Chemical 
Ligation 
 
Our working hypothesis is that hyperglycemia-driven glycation of the hCD59 
protein destabilizes the Membrane attach complex homeostasis leading to 
diabetic complication in humans50. In order to achieve a diagnostic-prognostic 
tool for diabetes and diabetes complications, we have raised anti-glycated 
hCD59 antibodies using synthetic peptide antigens. Those antibodies are able 
to evidence the presence of glycated hCD59 in diabetic patient’s biopsies116. 
Now we plan the generation of more specific monoclonal antibodies, to be 
risen from the immunization of rabbits using as an antigen the whole glycated 
hCD59. 
Since ex vivo extraction of glycated hCD59 is highly problematic due to its 
low concentration we have set up a synthetic strategy for the total synthesis of 
the protein both wild type and bearing the posttranslational modification 
(glycation).  
We proposed the total synthesis of hCD59(1-77) by tandem Native Chemical 
Ligation which allows the sequential ligation of multiple peptide fragments 
(Scheme 2.5-4). The sequence has been divided into six peptide units (Table 
2.5-1) shaped as C-terminal p-acetamidophenol thioesters and N-terminal 
thioazolidine (Thz) protected Cysteine except the C-terminal fragment which 
has been left with a free N-terminal Cysteine and free C-terminal carboxylic 
acid. The Thz protecting group allows the tandem mode by masking the N-
terminal Cysteine of the incoming peptide fragment during the ligation 
reaction.  
 
                                                 
116 Halperin, J. and Chorev, M., unpablished results. 
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Scheme 2.5-4 Strategy for the totals synthesis of Bio-PEG-hCD59(1-77) wild type (41K=H)                                
and glycated (41K =1-deoxyfructosyl). 
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and, after deprotection with methoxylamine, leaving it accessible at a later 
stage for the following coupling. 
 
IX H-45CNFNDVTTRLRENELTYYCCKKDLCNFNEQLE77N-OH 
X Thz-39CWK*FE44H-COSR 
XI Thz-39CWKFE44H-COSR 
XII Thz-26CLITKAGLQVYN38K-COSR 
XIII Thz-13CKTAVNCSSDFD25A-COSR 
XIV Thz-3CYNCPNPTA12D-COSR 
XV BioPEG3500-GGSSG-IEGRIEGR1LQ-COSR 
 
Table 2.5-1 Sequence of the six ligation fragments of glycated and unglycated 
hCD59(1-77). K* is Lysine(1-deoxyfructosyl); Bio is Byotine; PEG3500 is a 
Polyetylene-glycol chain of ca. 3500 of MW; GGSSG is a spacer; IEGRIEGR is the 
factor Xa cleavage motif. 
 
The direct thioesterification of the C-terminal carboxylic acid with p-
acetamidophenol has two advantages with respect to other strategies to obtain 
a C-terminal thioester. First of all it is relatively stable compared to benzyl and 
phenyl thioesters commonly used in NCL so that thioester group can survive 
several weeks if the peptide is maintained lyophilized at -4°C. Moreover the 
synthesis of the peptide thioester is straightforward, involving a 
thioesterification with p-acetamidothiophenol115 of the peptide fully protected 
but in the C-terminal carboxylic position as shown in Scheme 2.5-5 (the 
procedure applies for all the peptide fragments except the C-terminal one). The 
peptide is synthesized on a super-acido labile 2Cl-trityl resin. Cleavage of the 
peptide from the resin occurs with dilute acetic acid. Under this conditions all 
the side chain protection are left in place. No special resins, auxiliaries or 
cleavage protocols are needed and, in addition, p-acetamidothiophenol is a 
solid were the common thiols use for similar purposes are volatile liquids toxic 
and with a very bad smell.  
The proposed synthesis of hCD59 incorporates at the N-terminal portion a 
Biotin-polietylene-glycol residue in order to give to the final adduct additional 
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biochemical properties and a better aqueous solubility. Finally, the Bio-PEG 
portion will be separated from the protein sequence by a spacer and a protease 
Xa cleavage motif that would allow selective cleavage of the unnatural tail to 
obtain the free protein sequence for structural characterization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.5-5 Synthesis of the second ligation fragment bearing the glycation(a) Fmoc 
SPPS on 2-Cl-Trt resin; (b) acetic acid/TFE/DCM (1:1:8); (c) 3eq p-acetamidophenol, 
3q PyBOP, DIEA; (d)  TFA/H2O/TIS (95:2.5:2.5) 3h. 
 
Preliminary attempts demonstrated that the ligation is highly favored and 
proceeds with excellent yields up to the second coupling stage. The week 
points of the “Tandem” synthetic strategy are the semi-preparative HPLC 
purifications cycles needed after each ligation and Thz deprotection steps. To 
othercome this difficulty we are undertaking molecular size-mediated 
centrifuge-filtration of the products on the assumption that the big ligate 
fragment will be retained on filter with a specific pore size while the much 
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lighter incoming peptide fragments will be filtrated together with the small 
molecules as thiol catalysts, methoxylamine, detergents, salts etc. 
  80 
2.6 Monitoring glycation by amino acid analysis  
 
Recent improvements in HPLC and mass spectroscopy technologies allow to 
detected metabolites in biological fluids even at extremely low concentrations. 
This can be applied to the diagnosis-prognosis of various despises provided 
that a solid correlation is established between a specific biomarker and the 
pathology. 
We have decided to apply the concept of glycation to the analysis of 
metabolites in the urine and sera of type I and type II diabetic patients. 
 
2.6.1 Amino acids and short peptide sequences in biological fluids 
 
The presence of free amino acids in human sera has been identified since 
1912117. The concentration of a given amino acids is the result of a balance 
between its consumption during protein synthesis, its uptake from the diet and 
its formation through endogenous protein degradation Some common values 
of free amino acid concentrations in human sera are reported in Table 2.6-1. It 
must be remembered, however, that those concentration change importantly 
depending on a number of physiological conditions such as age, sex, lifestyle 
etc. Interestingly, they vary according to pathological conditions also. The 
latter consideration can be used to set up diagnostic prognostic assays working 
on the assumption that a given disease may generate a specific pattern of free 
amino acids both natural and post-translationally modified in the sera. In our 
diabetic study we assume the existence of free glycated amino acids, 
especially Lysine residues. 
 
                                                 
117 Stein, A. (1954), J.of Biological Chemistry, 7, 24 
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Amino acids  Serum concentration 
mg/mL 
Aspartic acid 0.21 
Threonine 1.73 
Serine 1.27 
Proline 2.05 
Glycine 1.65 
Alanine 2.42 
Valine 2.12 
Cysteine 1.05 
Methionine 0.24 
Isoleucine 0.58 
Leucine 1.19 
Tyrosine 0.83 
Phenylalanine 0.78 
Ornitine 0.61 
Lysine 1.51 
Histidine 1.24 
Arginine 1.49 
Table 2.6-1 Common values of free amino acid concentration in human serum. 
 
An excessive rise or decrease of the plasma-a.a. concentration often leeds to 
pathological conditions as is the case of a prolonged protein-poor diet which 
brings insufficient plasma amino acid content and problems in children 
developing. The regulatory activity of a.a. has been demonstrated for several 
cases of gene expression of specific enzymes118 The details of such 
mechanisms are however unknown. Off-balanced amino acids homeostasis is 
held responsible of several pathological conditions Table 2.6-2  
 
                                                 
118 Roger, W.J. (1998) In Biochemical Individuality The basis for genetotrophic concept, Keats 
Publishing, New Canaan, Connecticut, , 40.  
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Disease Incidence Therapy 
PKU 
(phenylketonuria) 
1:10000 diet 
MSUD 
(maple syrup urine disease) 
1:100000 Diet 
OmoCysteineuria 1:150000 Vitamin B6 Betain 
Ipertyrosinemia 1:1000000 Diet 
Citrulinemia 1:100000 
glucose,sodium 
benzoate, phenylacetate 
Ipoarginasis 1:100000 Diet 
Table 2.6-2 Disease cause by off-balanced amino acids homeostasis. 
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2.6.2 Analysis of free glycated amino acids in diabetic patients’ sera 
 
We planned to investigate wether free glycated Lysine could be present in type 
I and type II diabetic patients’ sera and if its presence could be used to set up a 
diagnostic/prognostic tool for diabetes. At the same time the presence of 
glycated Lysine could detected among the free amino acids generated from 
overall hydrolysis of the proteins of diabetic patients’ sera, provided that the 
glycation moiety survives the hydrolysis conditions (HCl 6M at 110°) which is 
something that should be investigated. In both cases we planned to use as an 
HPLC analytical standard the free glycated form of Lysine (Scheme 2.6-1) 
obtained by TFA deprotection of Nα-Boc-LysNε-(2,3;4,5-di-O-isopropylidene-
1-deoxyfructosyl)-OH. 
BocNH CO2H
NH2
O O
O
O
O
BocNH CO2H
NH
CHO
O O
O
O
O
O OH
OH
OH
OH
N2H CO2H
NHTFANaCNBH3 in THF/H2O
70o C, 5h
 
Scheme 2.6-1 Synthesis of the free form of glycated Lysine. 
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2.7 Conclusions and future developments A 
 
Final goal of this project is the development of a diagnostic/prognostic tool for 
type I and type II diabetes. A convergent approach of multiple different 
strategies proceeding in parallel has been adopted (section 1). 
To this aim, a panel of new Fmoc-Lysine derivates bearing a glycation 
modification has been developed for the SPPS of glycated peptides and 
proteins (section 1.1). 
A systematic approach to the synthesis of a glycated hCD59(37-50) peptide 
antigen has been carried out (section 2.2.3). 
The glycated antigen has been used to produce specific anti-glycated hCD59 
antibodies that efficiently recognize the glycated protein (hCD59) in vivo 
(section 2.2.5). 
A panel of glycated antigenic peptide probes has been generated and tested 
with un-competitive ELISA experiments against type I diabetic patients’ sera 
(section 2.3.5). Preliminary results showed the presence of specific 
autoantibodies anti-glycated-hCD59 in a subfamily of diabetic patients 
(section 2.4.2). 
The strategy for total synthesis by Native Chemical Ligation of glycated and 
un-glycated hCD59 protein has been set up (section 2.5.1). 
Future developments will be the optimization of the biochemical assays based 
on the synthetic peptide probes and antibodies generated as well as the 
completion of the NCL synthesis of hCD59. It will also be undertaken an 
analytical study of the glycated metabolites of diabetic patients’ sera (section 
2.6.2); and finally, the synthetic peptide probes will be tested in uncompetitive 
ELISA assays for type II diabetic patients’ sera. 
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3 PART B: Cyclic clicked peptides as anticancer drugs 
 
The following section describes the synthesis and properties of clicked 
cyclopeptides derived from the binding site of eIF4E binding protein. Such 
peptides are proposed as new anticancer drugs in the context of inhibition of 
translation initiation. The introduction of a triazole-bridge in a peptide 
sequence by click chemistry is proposed as a way to stabilize the secondary 
structure of the sequence and hence enhancing the affinity in peptide-protein 
interactions. At the same time, the presence of the bridge may improve the 
peptide bio-stability and favoring intracellular drug-delivery. 
 
3.1 Stabilization of peptides in α-helical conformation 
 
Examination of complexes of proteins with other biomolecules reveals that 
proteins tend to interact with partners via folded subdomains, in which the 
backbone possesses secondary structure. α-Helices constitute the largest class 
of protein secondary structures, and play a major role in mediating protein–
protein interactions119. Significantly, the average length of helical domains in 
proteins is rather small and spans two to three helical turns (or eight to twelve 
residues)120. These complexes suggest that it may be possible to develop short 
helices that potentially participate in selective interactions with biomolecules. 
However, peptides rarely retain their conformation once excised from the 
protein. Much of their ability to specifically bind their intended targets is lost 
because they adopt an ensemble of shapes rather than the biologically relevant 
one. This happens because a short peptide in solution does not give rise to a 
                                                 
119 Guharoy, M., and Chakrabarti, P. (2007) Bioinformatics, 23, 1909. 
120 Barlow, D.J. and Thornton, J.M. (1988) J Mol Biol, 201, 601. 
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number of weak interactions (hydrogen bond and van der Waals interactions) 
big enough to stabilize a specific conformation. The proteolytic instability of 
peptides is an additional factor that limits their utility as reagents in molecular 
biology and drug discovery. Finally, peptides have a low tendency to penetrate 
biological membranes due to their mostly hydrophylic nature that is in contrast 
with the highly hydrophobic nature of the central core of the phospholipidic 
bilayer. Figure 3.1–1 illustrates the different approaches121 that have been 
adopted either to stabilize or mimic an α-helix, with the overall aim of 
endowing peptidic and non-peptidic oligomers with conformational rigidity, 
proteolytic stability, and the desired array of protein-like functionality. These 
approaches can be divided into three general categories: helix stabilization, 
helical foldamers, and helical surface mimetics.  
Helix stabilizing methods based on side chain crosslinks and hydrogen-bond 
surrogates preorganize amino acid residues and initiate helix formation; mini-
proteins that display helical domains are also part of this category. Helical 
foldamers, such as β-peptides and peptoids, are composed of amino acid 
analogs and are capable of adopting conformations similar to those found in 
natural proteins. Helical surface mimetics utilize conformationally restricted 
scaffolds with attached functional groups that resemble the i, i + 4, i + 7 
pattern of side chain positioning along the face of an α-helix.  
Stabilization of peptides in the helical structure not only reduces their 
conformational heterogeneity but also substantially increases their resistance 
to proteases. In fact these enzymes typically bind their substrates in the 
extended conformation. In addition it has recently been reported that peptides 
with a stabilized α-helical conformation display a high membrane 
permeability. 
 
                                                 
121 Henchey, L.K., Jochim, A.L., and Arora, P.S. (2008)Current Opinion in Chemical Biology, 
12, 692. 
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Figure 3.1–1 Stabilized helices and non-natural helix mimetics: Several strategies to 
stabilize the α-helical conformation in peptides or mimic this domain with non-natural 
scaffolds have been described. Recent advances include β-peptide helices, terphenyl 
helix-mimetics, mini-proteins, peptoid helices, side chain crosslinked α-helices, and 
the hydrogen bond surrogate (HBS) derived α-helices. Green circles represent amino 
acid side chain functionality. 
 
In fact, Verdine and coworkers122 have applied the olephin methatesis reaction 
for the formation of peptide side-chain to side-chain hydrocarbon bridge, 
Figure 3.1–2 (A). The bridge constraint or “staple” stabilizes the α-helical 
conformation of a peptide that efficiently promotes apoptosis of cancer cells 
by triggering intracellular receptors. As shown in Figure 3.1–2 (B) and (C) 
such peptides almost completely enter the cells. 
                                                 
122 Kim, Y.W.and. Verdine G.L (2009)Bioorganic and Medicinal Chemistry Letters, 19, 2533. 
  88 
 
 
     
Figure 3.1–2 (A) Stapled peptides with side chain to side chain hydrocarbon bridge 
(C) and (D) Confocal microscope images of HeLa cells treated with 10 μM of 
fluoresceinated peptides S,S-SAHBa (C) and R,R-SAHBa (D). 
 
Moving from the considerations described above, we have focused our efforts 
on the synthesis of peptides with an α-helical conformation stabilized by a 
side-chain to side-chain triazole bridge generated by an intermolecular click 
reaction. 
A
B C
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3.1.1 Tridimensional active conformation 
 
In nature, protein functions including enzyme activities are often regulated 
through conformational change triggered by ligand binding or post-
translational modification at specific sites.123 For example systems that control 
protein–protein and peptide–protein interactions, have been designed by 
introducing mutations into the protein at the interface of the interaction to 
reduce the binding affinity and by addition of small compounds to restore 
binding conformation.124  
The conformational state of receptor protein determines the functional state of 
a receptor. Peptides are flexible molecules, which tend to adopt a large number 
of conformations in solution but assume well-defined conformation only when 
bound to their receptors. Peptides should have active conformation that 
requested receptor to trigger the biological response. The peptide conformation 
generated by a given amino acid sequence is fundamental to express its 
biological activity. Peptides or proteins that do not have the correct 
conformation do not display their biological role. 
Therefore, the binding alters the chemical conformations, i.e. the three 
dimensional structure. The receptor bound conformation may be poorly 
populated in solution but this structure may be promoted by incorporating 
conformational constraints into the peptide. If the conformation stabilized by 
the constraint closely resembles the structure responsible for bioactivity, this 
modification can increase potency and selectivity of the resulting peptide. 
Some flexibility should be retained in the constrained molecule so that the 
side-chain pharmacophoric groups may adopt orientations analogous to those 
in the bioactive conformation of the native peptide. The conformation of a 
peptide can be stabilized by introduction of bridges of various sizes between 
                                                 
123 Pearl, L.H., and Barford, D. (2002) Curr. Opin. Struct. Biol., 12, 761. 
124 Guo, Z., Zhou, D., and Schultz, P.G. (2000) Science, 288, 2042. 
  90 
different parts of the molecule. The bridge can either be local and occurring 
within a single amino acid residue or being global and linking distant parts of 
the sequence. In this context most combinatorial libraries have been developed 
in order to modify R-groups appended to a common core scaffold where R-
groups are typically chosen to maximize diversity, but their relative spatial 
orientations are usually fixed by the geometric constraints of the scaffold. 
Cyclic peptides offer the possibility of conveniently varying both scaffold 
geometry and R-group functionality. For example, parameters such as ring size 
can have a dramatic effect on cyclopeptides conformations, allowing access to 
structurally diverse species based on simple modifications in their linear 
sequences. Cyclization affects the degrees of freedom of all residues within the 
ring and thus a macrolyte should adopt a more defined conformation than the 
equivalent linear sequence. In fact, the active conformation in cyclic peptides 
can give superpotent analogues in matched cases.125 In addition 
conformational constraints provide the basis for receptor selectivity; often 
different receptors bind the same flexible substrate in different conformations 
(Figure 3.1–3). 
 
 
Figure 3.1–3 Differences concerning the interactions ligand-receptor between a linear 
peptide and cyclic peptide. 
                                                 
125 Kessler H. (1982)Angew. Chem. Int. Ed. Engl., 21, 512. 
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It was shown that conformational constraints of peptide structures can induce 
conformations in an often predictable way.126 If the bioactive conformation is 
unknown, the spatial orientation of pharmacophoric groups on a distinct 
backbone conformation can be systematically screened. The procedure 
involves a shift of one (or more) D-amino acid around a distinct scaffold. The 
functional groups of the side-chains and their neighborhoods are retained but 
their spatial arrangement can be adjusted. If one of these conformations 
matches the bound conformation (e.g. the conformation of its biological 
receptor) superactivity can be expected. In addition, the constraints often 
prevent binding to related receptor subtypes resulting in higher selectivity. 
This procedure is applied to design a potent lead structure for an anticancer 
drug. 
A peptide mimetic thus embodies the conformational and molecular 
characteristics thought to be important for biological activity of the native 
sequence. Mimetics may exhibit enhanced potency and can be more selective 
for various receptor sub-types than their parent sequence but several 
generations of variants may need to be prepared before a drug candidate 
emerges. 
 
                                                 
126 Matter, H., and Kessler H. (1995) J. Am. Chem. Soc., 117, 3347. 
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3.1.2 Types of cyclopeptides 
 
Characterization of possible relationship between peptide structure and 
biological activity are often aided by reduction in diversity of the possible 
conformational states that a linear peptide can adopt by generating cyclic 
analogues.127 Intramolecular side-chain-to-side-chain cyclization is an 
established approach to achieve stabilization of specific conformations, and 
has been employed to achieve rigidification that results in restricting the 
conformational freedom. Biologically active cyclic peptides designed and 
prepared specifically from a linear cyclic peptide approach, have been used to 
possess several additional attributes including: (i) increased agonist or 
antagonist potency; (ii) prolonged biological activity and extended 
pharmacokinetics; (iii) increased stability to enzymatic degradation; and (iv) 
increased specificity for a particular receptor.128  
Cyclic peptides are polypeptide chains whose amino and carboxyl termini, or 
two amino acids side chains, are themselves linked together by an amide (CO-
NH), disulfide (S-S), carbon-carbon (CH2-CH2 or CH=CH), reduced amide 
(CH2-NH), methylene thioester (CH2-S), methylene sulfoxide (CH2-SO), 
methylene ether (CH2-O), thioamide (CS-NH), keto methylene (CO-CH2), aza 
(NH-NR-CO) bond or recently 1,4-[1,2,3]triazolyl bridge (Figure 3.1–4). 
                                                 
127 Felix, A.M., Wang, C.T., Heimer, E.P., and Fournier, A. (1988) Int. J.Peptide Protein Res., 
31, 231. 
128 Hruby, V.J. (1982) Life Sci. 31: 189. 
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Figure 3.1–4 Common types of cyclopeptides. 
 
In a number of studies, side-chain-to-side-chain cyclization has been 
performed by lactam bridge formation between N- and C-termini, side-chain 
and the N- or C-terminus, or two side-chains, to generate highly helical and 
biologically active peptides.129, 130 Moreover the introduction of the amide 
isosteres also results in local and global changes dipole moments and in the 
pattern of intramolecular and peptide-receptor hydrogen-bond formation. 
Thus, incorporation of amide bond isosteres cannot only improve in vivo 
stability as the mimetic is no longer a substrate for peptidases, but can improve 
selectivity towards receptor sub-types, changing pharmacological functions 
and enhancing pharmacokinetic properties. 
On the other hand cyclization in the form of a disulfide bridge between two 
Cysteines, or other thiol-containing amino acids, is the most abundant post-
translational modification resulting in side-chain-to-side-chain cyclization. 
However, under certain redox potentials, the disulfide bridge will behave as a 
                                                 
129 Kapurniotu, A. and Taylor, J.W. (1995) J. Med. Chem., 38, 836. 
130 Chorev, M., Roubini, E., McKee, R.L., Gibbons, S.W., Goldman, M.E., Caufield, M.P., and 
Rosenblatt, M. (1991) Biochemistry, 30, 5968. 
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relatively transient modification yielding either the reduced linear form or 
generate a variety of intermolecular disulfide containing products. 
On the other hand, ruthenium complexes have been applied to the ring closing 
metathesis (RCM) reactions of a number of dienic substrates. The substrate 
scope includes rings of 6 to 20 members. In addressing macrocyclic peptides, a 
class of tetrapeptide disulfides inspired the synthesis of the carbon-carbon 
bond analogs. For example, replacement of Cysteine residues by allylglycines 
resulted in the acyclic precursors which were subjected to RCM to afford the 
corresponding macrocycles. In addition, several macrocycles, which were not 
based upon disulfide bridge-containing species found in nature , were 
prepared.131 Moreover the carba replacement (CH2-CH2) is non-polar and does 
not allow the possibility of intramolecular or peptide-receptor hydrogen 
bonding, while the reduced amide (CH2-NH) unit is conformationally different 
from the amide bond because it does not have any double-bond character. 
All of these types of cyclization require orthogonal protection of side chains to 
afford a peptide cyclization. While side-chain to side-chain cyclization of 
peptide sequences has been successful in many instances, a number of factors 
are known to significantly influence the efficiency of the cyclization reaction 
and the yield of the desired cyclic peptide product.  
Therefore cyclizations, which do not require complicated orthogonal 
protection schemes, are of great interest. The recently Cu(I)-catalyzed azide–
alkyne 1,3-dipolar Huisgen’s cycloaddition 132, 133, 134 as a prototypic “Click 
chemistry reaction”135 presents a promising opportunity to develop a new 
paradigm for intramolecular side-chain-to-side-chain cyclization in peptides. 
                                                 
131 Miller, S.J., Blackwell, H.E., Grubbs, R.H. (1996) J. Am. Chem. Soc., 118, 9606. 
132 Huisgen, R. (1984) In 1,3-Dipolar Cycloaddition Chemistry (Ed: A. Padwa), Wiley, New 
York, 1.  
133 Rostovtsev, V.V., Green, L.G., Fokin, V.V., and Sharpless, K.B. (2002) Angew. Chem. Int. 
Ed. Engl., 41, 2596. 
134 Tornoe, C.W., Christensen, C., and Meldal, M. (2002) J. Org. Chem., 67, 3057. 
135 Kolb, H.C. and Sharpless, K.B., (2001) Angew. Chem. Int. Ed. Engl., 40, 2004. 
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In fact, the 1,4-[1,2,3]triazolyl bridge offers interesting mode to generate a 
structural constraint.  
 
3.2 Click Chemistry 
 
Click chemistry is an entire reaction group in which new substances are 
generated by joining small units together with heteroatom links (C−X−C).135 A 
set of stringent criteria that a process should meet to be useful in this context 
are defined as follows: 
− simple reaction conditions (ideally, the process should be insensitive 
to oxygen and water); 
− very high yields; 
− only inoffensive by-products that can be removed without using 
chromatographic methods; 
− to be stereospecific (but not necessarily enantioselective); 
− high thermodynamic driving force, usually greater than 20 kcal.mol-1. 
One of the most interesting reactions that can enter in the “click chemistry” 
definition are the cycloaddition reactions involving heteroatoms, such as 
Diels-Alder and, especially, 1,3-dipolar cycloaddition, that provide fast access 
to a variety of five- and six-membered heterocycles. In particular, Huisgen 
dipolar cycloaddition of azides and alkynes can ideally meet all prerequisites 
for an efficient “click chemistry”.  
The chemistry of alkynyl and azido group is completely orthogonal to the 
chemistry of all endogenous functional groups in proteins; an example of their 
unique reactivity is the irreversible formation of triazole rings (Scheme 
3.2-1). 
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Scheme 3.2-1 [1,2,3]-Triazole formation by [3+2] cycloaddition of an alkyne and an 
azide. 
 
Usually the cycloaddition between azides and alkynes is carried out in 
refluxing toluene leading to mixture of the 1,4- and 1,5- regioisomers, but 
modified proteins and peptides may not survive in these strong conditions. On 
the other hand, what makes azides unique for click chemistry purposes is their 
stability toward H2O and O2. Meldal and co-workers134 and Sharpless and co-
workers133 developed a mild and efficient method to generate 1,4-disubstituted 
[1,2,3]-triazoles by metal-catalyzed reaction using Cu(I) salts as catalyst even 
in the presence of H2O. 
The catalytic cycle of the Cu(I)-catalized cycloaddiction, proposed by 
Sharpless and coworkers133 (Scheme 3.2-2), starts with the formation of a 
copper(I) acetylide I (as expected, no reaction is observed with internal 
alkynes) The reaction procedes either through a concerted [2+3] cycloaddition 
(B-direct) or with a stepwise, annealing sequence (B-1, B-2, and B-3), which 
proceeds via the a six-membered copper-containing intermediate III. 
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Scheme 3.2-2 Catalytic cycle of the Cu(I)-catalized cycloaddiction. 
 
  98 
3.2.1 Development of a new strategy based on click chemistry reaction 
to generate cyclopeptides  
 
We generated 1,4-[1,2,3]triazolyl-containing cyclopeptides by Huisgen 1,3-
dipolar cycloaddition, designing appropriate modified non-coded amino acids 
bearing on the side-chain alkynyl or azido functions, and correctly protected 
on the α-functions to be introduced in peptide sequences using Fmoc/tBu 
solid-phase strategy. This cycloaddition is a simple chemical transformation 
that improves the resistance towards proteolytic degradation in vivo, and 
allowing the selective formation of covalent adducts in order to obtain 
modified bioconjugates.136 
The 1,4-disubstituted [1,2,3]triazolyl serves as a rigid linking unit mimicking a 
trans-amide bond positioning the substituents in positions 1 and 4 at 5.1 Å 
apart, which is only slightly longer than the distance between two carbons 
separated by a trans-amide bond (3.9 Å). It has a slightly larger dipole moment 
(~5 Debye), which bisects the ring plane near atoms N3 and C5, and has the 
capacity of the N2 and N3 electron lone pairs to serve as hydrogen bond 
acceptors (Figure 3.2–1). 
 
 
Figure 3.2–1 Topological similarities between amides and 1,2,3-triazoles. 
                                                 
136 Köhn, M., and Breinbauer, R. (2004)Angew. Chem. Int. Ed., , 43, 3106. 
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3.3 Inhibition of translation initiation in anticancer therapy, role 
of eIF4E binding protein  
 
Anticancer therapy by inactivation of Translation Initiation is one of the most 
important projects developed at the Laboratory for Translational Research of 
Harvard Medical School. Principles and methodologies of peptide click 
chemistry have been applied to this subject. 
Most cancer therapies target some specific characteristic of cancer cell in order 
to suppress or hinder their proliferation. Unfortunately few approaches are 
fully selective and in most cases the strategy of action relays on the concept of 
damaging cancer cells more than normal cells. This means that most existing 
treatments target one peculiar metabolic feature that is more important for 
cancer cells than for normal ones. For example genetic instability, which is 
higher for cancer cells (and essential for tumor developing) can be enhanced 
(by radiation or mutagenic compounds) to a point that is unbearable for cancer 
cells and damaging but still acceptable for normal cells. Similarly it has been 
demonstrated that cancer cells need to overexpress a set of proteins critical for 
their proliferation. It is possible to take advantage of this need by inhibiting 
translation initiation and thus making the protein synthesis of cancer cells not 
efficient enough for their proliferation. 
Protein synthesis is regulated at multiple levels but most of the regulation 
occurs at the initiation stage of translation that is the process by which the 
genetic information transcripted into m-RNA is converted into proteins137 
(Figure 3.3–1). The 3’ and 5’ terminal portions of eukaryotic m-RNA bind a 
protein complex colle eIF4E which in turn is linked to the ribosomes.  
 
                                                 
137 Sonenberg, N.and Hinnebusch, A.G. (2009) Cell 136, 731.  
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Figure 3.3–1 Regulation of Translation Initiation in eukaryotic cells. 
 
The most important stage of translation initiation is the assembly of the eIF4F 
complex of proteins. The molecular basis of this process has being studied 
intensively and one of its key stages is considered to be the binding of the cap-
protein eIF4E to the 5’-cap extremity of m-RNA. However, if the regulatory 
protein 4E-BP (4E binding protein) binds to eIF4E the mRNA is not able any 
more to interact with eIF4E and thus Translation is suppressed. Figure 3.3–2. 
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Figure 3.3–2 Repression/activation of Translation Initiation depending on the binding 
of eIF4E-mRNA to the eIF4A/eIF4G complex and regulated by 4E-BP. 
 
Our goal is the generation of synthetic modified peptides whose sequence 
reproduces the binding site of the 4E-BP. By inhibiting Translation Initiation 
such peptides represent potential anticancer agents. We plan moreover to 
stabilize with side-chain to side-chain triazole bridges the secondary structure 
of those peptides that are known to assume an α-helical conformation.  
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3.3.1 Selection of the model system, eIF4E binding protein peptide 
 
The development and study of the new intermolecular side-chain-to-side-chain 
[1,2,3]triazole containing peptide modification was carried out in the context 
of a molecular model for those structural and biological information still 
known. In previous work a peptide bearing a fluorescein residue, 4GII-FITC, 
was synthesized in the Laboratory for Translational Research of the Harvard 
Medical School: 
KKQYDRELLDFQFK(Fluorescinyl)  
The 14 amino acid sequence of such peptide reproduces the sequence of the 
binding site of 4GII (also called 4E-BP) which is the main eIF4E binding 
protein and acts as an inhibitor (Figure 3.3–2 shows the structure, determined 
by x-ray analysis, of an eIF4E/eIF4E binding protein peptide complex149). The 
synthetic peptide has proved to possess a high affinity for the protein and 
remarkable inhibiting effects.  
 
 
Figure 3.3–3 Structure, determined by x-ray analysis, of a eIF4E/eIF4E binding 
protein peptide complex. 
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Our aim was to develop cyclic, clicked eIF4E b.p. peptide analogs modifying 
the sequence of 4GII-FITC with non-coded alkynyl and azido amino acids 
specifically synthesized for click chemistry (Scheme 3.3-1).The triazole 
bridge in i/i+4 positions, stabilizing the α-helical structure of the peptide, 
should be able to increase its affinity for eIF4E: The fuorescein residue should 
be useful for Fluorescence Polarization assays for binding affinity 
measurements. 
 
KKQYDRELLDFQFK(Fluorescinyl)
KK-NHCHCO-YDR-NHCHCO-LLDFQFK(Fluorescinyl)
N3
KK-NHCHCO-YDR-NHCHCO-LLDFQFK(Fluorescinyl)
N
NN
Q3 substituted with Norleucine and
E7 with propargyl glycine
Click Cu catalized
4GII-FITC
linear modif ied
4GII-FITC
cyclic modif ied
4GII-FITC
  
Scheme 3.3-1 Scheme of 4GII-FITC modification and cyclization of the linear eIF4E 
b.p. peptide analogs. 
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3.4 New collection of amino acids to develop clicked peptides 
 
The 1,4-disubstituted-1,2,3-triazolyl moiety as an amide bond surrogate, 
specifically assembled through biorthogonal CuI-catalyzed Huisgen 1,3-
dipolar [3 + 2] cycloaddition of an alkynyl to an azido function, generated an 
unmet need for specifically designed amino-acid-derived building blocks. To 
this end, there have been several reports in which non-coded α-amino acids 
modified by ω-azido and ω-alkynyl functionalities were used as biorthogonal 
reporter peptides and proteins.134, 138, 139, 140  In addition to intermolecular side-
chain-to-side-chain click reaction between α-amino acids modified by ω-azido 
and ω-alkynyl functions these non-coded amino acids can be used also to 
conjugate the peptide of interest through an orthogonal reaction with haptens, 
tags, and labels to generate special reagents.  
To date, diazo transfer reaction was used to generate α-azido-acids in solution 
and α-azido-peptides on solid support.141 ω-Azido α-amino acids such as β-
azidoalanine were prepared from either the salt of α-amino-β-propiolactone142 
or the protected homoserinol. On the other hand only propargylglycine (Pra) is 
commercially available. It is evident that there is an unmet need for syntheses 
that will furnish an extensive homologous series of ω-azido and ω-alkynyl-Nα-
protected amino acid as s tools to generate 1,4-disubstituted-1,2,3-triazolyl 
containing peptides or for various applications. For example, combinatorial 
libraries of peptides containing ω-azido- or ω-alkynyl-α-amino acids can be 
used to generate libraries of higher order by diversifying their structure 
through click reactions with a variety of respective alkynyl and azido-
containing reagents.  
                                                 
138 Deiters, A., Cropp, T.A., Mukherji, M., Chin, J.W., Anderson, C., and Schultz, P.G. (2003) 
J. Am. Chem. Soc., 125, 11782. 
139 Dondoni, A., Giovannini, P.P. and Massi A. (2004) Org Lett., 6, 2929.  
140 Lin, H. and Walsh, C. T. (2004) J Am Chem Soc., 126, 13998. 
141 Punna, S., Kuzelka, J., Wang, Q., and Finn, M. G. (2005) Angew. Chem., Int. Ed., 44, 2215.  
142 Arnold, L.D., May, R.G., and Vederas, J.C. (1988) J. Am. Chem. Soc., 110, 2237.  
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Therefore, we developed an efficient and convenient synthetic pathway to 
generate non-coded Nα-Fmoc-ω-azido- and Nα-Fmoc-ω-alkynyl-amino acids 
suitable for Fmoc/t-Bu SPPS (Figure 3.4–1). The structural diversity enabled 
by the small library of building blocks will allow the introduction of 1,4-
disubstituted-1,2,3-triazolyl moieties into peptides of interest as modifiers of 
physicochemical and biological properties.  
 
Fmoc
H
N
OH
O
N3
Fmoc
H
N
OH
O
m = 1-3 n = 1-3
m n
 
Figure 3.4–1 Nα-Fmoc-ω-azido- and Nα-Fmoc-ω-alkynyl-α-amino acids for Fmoc/t-
Bu SPPS. 
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3.4.1 Nα-Fmoc-ω-azido-α-amino acids 
 
An efficient and convenient methodology for generating organic azides is CuII-
catalyzed diazo transfer from amines by trifluoromethanesulfonyl azide.143 
Diazo transfer from triflic azide occurs effectively with Cu2+, Ni2+ or Zn2+ as 
catalysts. The process is amenable to scale-up, can be carried out using 
commercially available reagents and does not require anhydrous conditions. 
Since the transformation does not involve the Cα, it is accomplished with a 
complete retention of the original configuration of the α-amino acid residues. 
In this manner Nα-Boc-Lysine, Nα-Boc-Ornithine, and Nα-Boc-AminoButirric 
acid were converted in good yield to the respective Nα-Fmoc-ε-azido-
Norleucine (3), Nα-Fmoc-δ-azido-Norvaline (4) and Nα-Fmoc-γ-azido-hSerine 
(5) (Scheme 3.4-1). 
 
 
Scheme 3.4-1 General procedure for the synthesis of building blocks 3, 4 and 5. 
 
This strategy required the use of the Nα-Boc-protected amino acids as starting 
material because of their stability in these reaction conditions. 
                                                 
143 Nyffeler, P.T., Liang, C.H., Koeller, K.M. Wong, C.-H. (2002) J. Am. Chem. Soc. 124, 
10773. 
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3.4.2 Nα-Fmoc-ω-alkynyl-α-amino acids  
 
The strategy to synthesize the ω-azido-α-amino acid homologs containing 
(CH2)n (where n=2,3 and 4) on the side chain, employed elaboration of glycine 
by chiral synthesis. The NiII complex of the Schiff base [NiII-(S)BPB-Gly] (14) 
derived from glycine and (S)-2-(N-benzylprolyl)aminobenzophenone (BPB) 
(13) was used as a chirality inducer during the Cα-alkylations (Scheme 
3.4-2).144 
 
 
Scheme 3.4-2 Synthesis of the chirality inducer [NiII-(S)BPB-Gly]. 
Alkylations through the si-face of the glycine enolate are largely favored to 
lead to (S)-α-amino acids. 
 
                                                 
144 Belokon, Y.N., Bulychev, A.G., Vitt, S.V., Struchkov, Y.T., Batsanov, A.S., Timofeeva, T. 
V., Tsyryapkin, V.A., Ryzhov,M.G., Lysova, L.A., Bakhmutov, V.I. and Belikov, V.M. (1985) 
J. Am. Chem. Soc., 107, 4252.  
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Scheme 3.4-3 Chiral synthesis of L-ω-alkynyl-α-amino acids employing the chirality 
inducer [NiII-(S)BPB-Gly]. 
 
This method is based on a reaction between [NiII-(S)BPB-Gly] and alkynyl 
bromides (Scheme 3.4-3). Alkylation of glycine by alkynyl bromides in the 
presence of the chirality inducer [NiII-(S)BPB-Gly], which was carried out 
according to a procedure described in the literature144, yielded the 
corresponding ω-alkynyl-α-amino acids in good diastereoisomeric excess 
(monitored by UPLC, Table 3.4-1). The separation of the diastereoisomers was 
successfully achieved by FCC.  
 
Products of alkylation of the 
Gly-Ni-BPB complex with 
S,S-diastereoisomeric 
excess (%) 
Alkylation  
yield (%) 
6-Bromohex-1-yne (9) 88 68 
5-Bromopent-1-yne (10) 71 58 
4-Bromobut-1-yne (11) 63 41 
Table 3.4-1 Diastereoisomeric excess of the alkynylated complexes. 
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The coupling step between N-benzyl-(S)-proline (BP) (12) and 2-
aminobenzophenone was accomplished in situ by PCl5-mediated 
transformation of the carboxyl function into the acyl chloride, which was used 
to acylate the 2-aminobenzophenone at pH 8. Alkylation of [NiII-(S)BPB-Gly] 
by an excess of ω-alkynyl bromide (1.4 equiv.), in the presence of NaOH in 
anhydrous acetonitrile, proceeded for 5 hours and resulted in a good yield. The 
ω-alkynyl bromides were prepared in moderate yields from the corresponding 
alcohols by treating them with TsCl (product 6, 7, and 8) followed by LiBr 
(product 9, 10, and 11) (Table 3.4-2). 
 
 
n OTs (yield %) Br (yield %) 
3 (96) (31) 
2 (93) (28) 
1 (95) (30) 
Table 3.4-2 Synthesis of the ω-alkynyl bromides. 
 
Hydrolysis of the resultant alkylated complex in 2M HCl was complete in one 
hour. Workup afforded a pale green solid containing the free alkynylated 
amino acids in the presence of Ni0 and BPB. The chirality inducer BPB was 
recovered by washing the crude with acetone and separated from traces of Ni 
by redissolving the solid in DCM, and washing it with water. The removal of 
traces of Ni0 from the free and crude ω-alkynylated α−amino acids, which 
interfered in the following Fmoc-protection reaction, was accomplished by 
overnight solid phase extraction of its MeOH/H2O solution with Na+ Chelex 
resin.  
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Finally, the free ω-alkynylated α-amino acids were Nα-protected as Fmoc to 
yield the building blocks (18, 19, and 20) in quantities adequate for SPPS by 
Fmoc/tBu strategy (Table 3.4-3).  
 
Amino acids Yield (%) Pure compound 
Nα-Fmoc-ε-alkynyl-Norleucine (18) 32 90 mg 
Nα-Fmoc-δ-alkynyl-Norvaline (19) 39 90 mg 
Nα-Fmoc-γ-alkynyl-hSerine (20) 29 80 mg 
Table 3.4-3 Yield and scale of building blocks (18, 19, and 20). 
 
We hypothesized that the low yields of the final products are due to the 
difficulties to obtain the pure free amino acids without the presence of salts 
found after neutralization of the solution, and therefore we used an excess of 
Fmoc-succinimmide that leads to side products formation decreasing yields of 
final products. 
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3.5 Collection of eIF4E binding protein cyclopeptides analogs  
 
Aim of this study is to enhance the affinity of eIF4E binding protein peptide 
with eIF4E by stabilizing the secondary structure of the peptide. This will be 
achieved by introduction of a 1,2,3-triazole ring in positions i and i+4 at 
different levels of the sequence. Under the constraint of such bridge the 
peptide will assume an α-helical conformation which is the conformation of 
the binding site of eIF4E binding protein from which the peptide sequence is 
derived. Moreover, we synthesized a panel of new modified Fmoc-amino acids 
bearing alkynyl and azide function on the side chains (Figure 3.5–1). 
Fmoc
H
N
OH
O
N3
Fmoc
H
N
OH
O
m = 1-3 n = 1-3
m n
 
Figure 3.5–1 Nα-Fmoc-ω-azido- and Nα-Fmoc-ω-alkynyl-α-amino acids for Fmoc/t-
Bu SPPS. 
 
Regarding the position of the sequence in which introducing the triazole 
bridge, initially we decided to modified the C-terminal portion (i-
i+4=positions 3-7) and we have generated an eIF4E b.p. peptide analog 
N4+C1 type, product XVI, having an azido function on the left and an alkynyl 
one on the right (Table 3.5-1).  
This choice for the triazole position has been shown, with Fluorescence 
Polarization Assay (see section 3.6.1), to be unfavorable for improving the 
affinity of the peptide for eIF4E.  
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 Peptide sequence CH2 
ring 
XVI Ac-1Lys-Lys-Gln-Tyr-Asp-Arg-Glu-Phe-Leu-Leu-Asp-Phe-Gln-Phe-15Lys-NH - 
XVII Ac-Lys-Lys-3Nrl(ε-N3)-Tyr-Asp-Arg-7Pra-Phe-Leu-Leu-Asp-Phe-Gln-Phe-Lys-NH 5 
Table 3.5-1 Peptide sequences of eIF4E binding protein peptide analogs XV and XVI. 
Non-coded amino acids [Pra= propargyl-Glycene and Nrl(ε-N3)= ε-azidoNorleucine] 
are outlined. 
 
Therefore we chose to shift the triazole bridge position in the middle of the 
sequence (positions 7-11, Figure 3.5–2 )  
 
 
Figure 3.5–2 Triazole bridge positions 3-7 and 7-11 of the eIF4E binding protein 
peptide analogs. 
 
Moreover two sets of modified amino acids (three alkynes and three azides) in 
two given positions of a sequence (i-i+4 to stabilize an α-helix) can generate 
18 combinations’ of triazole bridges with different number of methylenes and 
different orientations of the triazole. This number comes from the 32=9, 
Nm+Cn, possible combinations having the azide on the left side (position i) 
with the alkyne on the right (position i+4) (Figure 3.5–3) plus the other 32=9 
Cn+Nm, possible combinations generated by alkyne on the left side and the 
azide on the right (Figure 3.5–4). 
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Figure 3.5–3 The 32=9 possible combinations of Nm+Cn triazole bridges having the azide on the left side        
(position i) and the alkyne on the right side (position i+4). 
Nm+Cn permutations  
m=2,3,4 n=2,3,4 
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Figure 3.5–4 The 32=9 possible combinations of Cn + Nm triazole bridges having the azide on the left side (position i) and 
the alkyne on the right side (position i+4). 
Cn+Nm permutations 
m=2,3,4 n=2,3,4 
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Based on previous experiments on cyclic, clicked peptides145 we have 
discarded those combinations generating triazole bridges either too short (4 
methylene units) or too long (7-8 methylene units). A number of methylene 
between 5 and 6 has been shown to be the most favorable for α-helix 
stabilization. Thus we have planned to focus on 10 out of 18 possible 
combinations (Table 3.5-2 ). 
 
N°CH2 XVIII XIX XX XXI 
5 N2+C3 C3+N2 N3+C2 C2+N3 
     
N°CH2 XXII XXIII XXIV XXV 
6 N2+C4 C4+N2 N4+C2 C2+N4 
     
N°CH2 XXV XXVI   
6 N3+C3 C3+N3   
Table 3.5-2 The selected 10 eIF4E binding protein click peptide with triazole length 
of 5-6 methylene units. Those products that are under characterization are outlined in 
green. 
 
Peptide analogs XVIII, XIX, and XX (Table 3.5-3) have been synthesized 
purified and characterized both with in solution NMR and with Fluorescence 
Polarization Assay. 
 
 Peptide sequence CH2 
ring 
XVIII Ac-Lys-Lys-Gln-Tyr-Asp-Arg-7hSer(γ-N3)-Phe-Leu-Leu-11Nvl(δ-yl)-Phe-Gln-Phe-Lys-NH 5 
XIX Ac-Lys-Lys-Gln-Tyr-Asp-Arg-7Nvl(δ-yl)-Phe-Leu-Leu-11hSer(γ-N3)-Phe-Gln-Phe-Lys-NH 5 
XX Ac-Lys-Lys-Gln-Tyr-Asp-Arg-7Nvl(δ-N3)-Phe-Leu-Leu-11hSer(γ-yl)-Phe-Gln-Phe-Lys-NH 5 
Table 3.5-3 Peptide sequences of eIF4E binding protein peptide analogs XVIII-XX. 
Non-coded amino acids [hSer(γ-N3)= hSerine(γ-N3), Nvl(δ-yl)= Norvaline(δ-yl), 
Nvl(δ-N3)= Norvaline(δ-N3), hSer(γ-yl)= hSerine(γ-yl)] are outlined. 
                                                 
145 Scrima, M., Le Chevalier-Isaad, A., Rovero, P.,  Papini, A.M., Chorev, M., and 
D'Ursi A.M. (2009) Eur JOC in press. 
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3.5.1 Linear peptides  
 
Peptides XVI-XX were generated as described in section 5.6 on an automatic 
synthesizer starting from Rink amide resin. The first Lysine residue in the C-
terminal position was introduced with an ivDde side chain protection for 
fluorescein coupling. The non-coded amino acids were inserted by manual 
SPPS in the peptide sequence in the positions i, i+4 as reported in Table 
3.5-4.  
 
Linear 
peptide 
Xaa Yaa 
XVI NH
OH2N
O
  
XVII 
NH
ON3
NH
O
 
XVIII 
  
XIX 
 
XX 
NH
O
N3  
NH
O
 
Table 3.5-4 Non-coded amino acids introduced in the peptide sequences in the 
i, i+4 positions. Peptide XVI does not contain any non-coded amino acid. 
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At the end of the synthesis and after N-terminal α-amino acetylation 
ivDde group was removed with 2% hydrazine in DMF from the C-
terminal Lysine and the ε-amino was coupled to a carboxy-fluorescein 
residue. The peptides were purified by semi-preparative HPLC and 
characterized by ESI-MS. Analytical data are reported in Table 3.5-5. 
 
MS+(ESI) m/z Linear peptide Rt(min) HPLC found calculated 
XVII 6.3 [M+H]
+=2354.92 
[M+H]2+=1177.96 [M+H]
+=2355.62 
XVIII 15.4 [M+H]
+=2411.28 
[M+H]2+=1206.14 [M+H]
+=2410.7 
XIX 15.5 [M+H]
+=2410.98 
[M+H]2+=1205.99 [M+H]
+= 2410.7 
XX 14.1 [M+H]
+=2411.44 
[M+H]2+=1206.53 [M+H]
+= 2410.7 
Table 3.5-5 Chemical data of linear peptides XVIII-XIX. All HPLC were performed 
with a gradient 30to70% B in A. 
 
3.5.2 Cyclopeptides  
3.5.2.1 General features on click chemistry reaction conditions 
The catalytic cycle of the Cu(I)-catalyzed alkyne-azide “click” cycloaddition 
(Scheme3.5-1) shows that a source of Cu(I) is fundamental for the 
regioselectivity. Meldal and co-workers134 described the use of Cu(I) salts in 
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the solid phase, while Shrarpless133 reported solution phase by in situ reduction 
of Cu(II) salts. It is also possible to envisage the formation of Cu(I) from the 
oxidation of metallic copper. 
Alkyne π complexation requires ligand dissociation and is endothermic in 
acetonitrile. However, in aqueous solution the formation of copper species 4 
(Scheme 3.5–1) is exothermic, a result consistent with experimental findings 
of a rate acceleration in water. 
Moreover, the copper coordination lowers the pKa of the alkyne CH, thus 
making deprotonation in aqueous systems possible without the addition of a 
base; DIPEA and 2,6-lutidine minimizes the side-product formation. 
In this context, the choice of the condition reaction (solvent, base) is crucial 
for cycloaddition.  
 
Scheme3.5-1 Proposed outline of species involved in the catalytic cycle of the CuI-
catalyzed alkyne-azide “click” cycloaddition.146 
 
                                                 
146 Bock, V.D., Hiemstra, H., and van Maarseveen, J.H. (2006)Eur. J. Org. Chem., 14, 51. 
  119 
3.5.2.2 Synthesis and characterization of cyclopeptides 
 
Copper catalyzed click cyclization was performed on peptides XVII-XX using 
an excess of copper sulfate (10eq) and ascorbic acid (20eq) in 1:1 tBuOH/H2O. 
The reaction was monitored by HPLC and LC-MS. It is important to note that 
the cyclic, clicked forms have exactly the same mass of the corresponding 
linear forms so that cannot be distinguished by conventional LC-MS. However 
the two forms has different retention times, in particular all clicked peptides 
synthesized so far have a shorter retention time with respect to their 
corresponding linear forms The cyclic peptides were purified by solid phase 
extraction (SPE) followed by semi-preparative HPLC purification and 
characterized by HPLC and ESI-MS (Table 3.5-6). 
 
MS+(ESI) m/z 
Peptide 
Linear 
Rt (min) 
HPLC 
Clicked 
Rt (min) 
HPLC found Calculated 
XVIIc 6.3 4.8 [M+H]
+=2354.72 
[M+H]2+=1177.86 [M+H]
+=2355.62 
XVIIIc 15.4 15.4 [M+H]
+=2411.35 
[M+H]2+=1206.17 [M+H]
+=2410.7 
XIXc 15.5 15.5 [M+H]
+=2410.99 
[M+H]2+=1206.00 [M+H]
+= 2410.7 
XXc 14.1 14.01 [M+H]
+=2411.21 
[M+H]2+=1206.10 [M+H]
+= 2410.7 
Table 3.5-6 Chemical data of clicked peptides XVIIc-XXc. 
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3.5.2.3 Side reactions during peptide click-mediated cyclization 
 
Previous experiments147 showed that spontaneous cyclization (in absence of 
metal catalysts) of linear peptides bearing alkyne and azide functions occur to 
a very little extent as can be seen from Figure 3.5–5. 
 
 
Figure 3.5–5 Example of a typical evolution of the HPLC chromatogram (method : 
10% to 60% of B in A for 20 minutes, A = 0.1% TFA in H2O, B = 0.1% TFA in 
CH3CN) obtained in 12 days of solution of a linear peptide developed for click 
chemistry. 
 
Moreover alkyne-azido functions of modified peptides are stable if kept in dry 
solid form under low temperature. During peptide click reaction 
intermolecular cyclization obviously competes with intermolecular oligo-
polimerizations between alkyne and azide residues of different molecules. 
Under a high dilution, of the order of 0.1 μmM, the latter intermolecular 
reactions are suppressed. However the triazole orientation, the size of the 
bridge and the position of the bridge itself in the peptide sequences seems to 
play a role. In our preliminary studies no undesired oligomerization was 
                                                 
147 Le Chevalier-Isaad A., PhD Thesis 2008. 
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detected when the triazole was closed to the N-terminal residue of the peptide 
(analog XVII). On the contrary a certain degree of oligomerization was 
present when the bridge was in the middle of the sequence, as for the case of 
peptides XVIII-XX. The reaction rate itself was slower and complete 
exhaustion of the linear precursors took longer (3-4 days) compared to XVII 
(12 h). This may imply that a more central position for the bridge could hinder 
the intermolecular cyclization making the intermolecular reaction more 
favorable. At the same time we noticed a higher degree of oligomerization for 
peptide XVIII (C3+N2) compared to peptide XIX (N2+C3) and peptide XX 
(N3+C2) suggesting that the orientation of the triazole influences the rate of 
the cyclization. Figure 3.5–6 reports the LCMS chromatogram for click 
reaction of peptide XIX. Together with the linear and cyclic peptides, two 
more peacks are present being the dimmer and trimer oligomers (the 
correspondent mass is shown in Figure 3.5–7. More systematic studies will be 
necessary to elucidate the peptide click cyclization dynamics. 
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Figure 3.5–6 UPLC-MS of the cyclization reaction of peptide XIX, method 20to60% 
B in A (215nm, 254nm, TIC). The chromatograms show the trimer adduct at 1.62 min, 
the dimer adduct at 1.77 min, the clicked peptide at 2.02 min, and the linear peptide    
at 2.16min. 
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Figure 3.5–7 Mass spectrums of the purified dimmer form (A) and trimer form (B) 
with corresponding calculated [M+H]+ values. 
A 
B 
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3.5.2.4 Peptide templated click cyclization 
 
Sharpless and co-worker148 have demonstrated that the in situ click-chemistry 
approach can be successfully applied to the formation of HIV-1-Pr inhibitors. 
HIV-1 Protease assembles its own potent inhibitor through formation of the 
triazole linkage from azide- and alkyne-containing fragments that are 
themselves poor binders. In fact the protein itself acts as a template for the 
reaction and greatly increases the rate of formation of the 1,4-triazole product. 
In this context, to study the ring size influence, we have set up the synthesis of 
a collection of linear peptides containing alkynyl- and azido-moiety on the side 
chain backbone for in situ template cyclization. The assumption is that eIF4E 
binding protein peptide analogs in presence of eIF4E will fit the protein 
binding site assuming an α-helical conformation (this is known to happen from 
x-ray crystal studies of eIF4E/eIF4E b.p. peptides)149. Under these conditions 
the alkyne and azido side chain functions will find themselves in close contact 
and will cyclise without any need of metal catalysts as has been the case of 
HIV-1-Pr inhibitors. 
Templated click cyclization studies are currently held on linear peptide 
analogs XIX and XX. 
                                                 
148 Whiting, M., Muldoon, J., Sharpless, K.B., Elder, J.H. and Fokin, V. V. Angew. Chem. Int. 
Ed. 2006, 45, 1435. 
149 Marcotrigiano, J.,  Gingras, A.D., Sonenberg, N., Burley, S.K. (1999) Molecular Cell, 3, 
707. 
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3.6 Fluorescence Polarization Assay studies 
Fluorescence anisotropy is a method for measuring the binding interaction 
between two molecules, and can be used to measure the binding constant (or 
the inverse, the disassociation constant) for the interaction.150 The basic idea is 
that a fluorophore excited by polarized light (light whose "waves" only go into 
one direction) will also emit polarized light. However, if a molecule is moving, 
it will tend to "scramble" the polarization of the light by radiating at a different 
direction from the incident light (Figure 3.6–1). The "scrambling" effect is 
greatest with fluorophores freely tumbling in solution and decreases with 
decreased rates of tumbling. Protein interactions can be detected when one of 
the interacting partners is fused to a fluorophore: upon binding of the partner 
molecule a larger, more stable complex is formed which will tumble more 
slowly (thus, increasing the polarization of the emitted light and reducing the 
"scrambling" effect).  
              
Figure 3.6–1 The principle of Fluorescence Polarization. 
                                                 
150 Jolley, M.E., Stroupe, S.D., Schwenzer, K.S., Holen, J. T., and Kelso, D.M. (1981) CLIN. 
CHEM. 27, 1575. 
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This technique works best if a small molecule is fused to a fluorophore and 
binds to a larger partner151 (this maximizes the difference in signal between 
bound and unbound states). If the fluorophore is attached to the larger protein 
in a binding pair, the difference in polarization between bound and unbound 
states will be smaller (because the unbound protein will already be fairly stable 
and tumble slowly to begin with) and the measurement will be less precise.By 
titrating the amount of one of the proteins, a binding curve can be generated 
(the amount of polarization observed is proportional to the amount of protein 
complex formed, which is proportional to the concentration of the binding 
partners in solution). Mathematical models can be applied to this binding 
curve to determine the binding constant of the protein interaction152. In another 
application of this technique, it is also possible to measure the folding of a 
protein, since an unfolded peptide chain will tumble differently than a folded 
one, giving a difference in polarization  
                                                 
151 A. Fowler, D. Swift, E. Longman, and M. Coldwell (2002) Analytical Biochemistry, 308, 
223. 
151 Hess Kenny, C., Kriz, R., and Ellestada, G. (2003) Analytical Biochemistry, 323, 224. 
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3.6.1 Measurement of eIF4E-affinity of eIF4E binding protein 
peptide analogs. 
 
In a first experiment three FP assays have been done on the linear unmodified 
peptide XVI, linear modified peptide XVII and cyclic peptide XVIIc. We 
tested the affinity for eIF4E, applying a 10nM concentration of those peptides 
to all the plate positions and using an increasing concentration of protein. The 
results showed that linear peptide XVI (4GII-FITC), unmodified peptide 
coming from the sequence of an eIF4E b.p. (4GII), and his modified linear 
analog (peptide XVII with two residues modified with alkynyl and azido 
groups), has a similar affinity (ca. 150nM) towards eIF4E (Figure 3.6–2). 
These remarkable findings suggested that the introduction into a peptide 
sequence of non-coded, alkynyl and azido amino acids doesn’t affect its 
biological properties. 
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Figure 3.6–2Fluorescence polarization assay for the measure of binding affinity 
towards eIF4E of 4GII-FITC (unmodified linear peptide XVI) (A) and linear modified 
peptide XVII (B). 
 
On the other hand, the clicked, cyclic form of peptide XVII (peptide XVIIc) 
had a very poor affinity (even with high concentration of protein, 500uM, the 
curve didn’t reach saturation) (Figure 3.6–3). These data imply that the triazole 
bridge formation completely suppress the ability of the sequence to fit the 
B 
A 
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proteins binding site. This suggested that the bridge was set in a non 
convenient position and, as can be seen in Figure 3.6–3, where is shown the  
structure of the complex eIF4E/eIF4E binding protein peptide, at the bottom of 
the peptide, because of the introduction of the triazole bridge, a new helix turn 
was formed where originally there was a coil. Besides, the Tyrosine at position 
4, which is the most important residue of the motif, is moved from its correct 
position when the bridge is formed.  
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Figure 3.6–3 Fluorescence polarization assay for the measure of binding affinity 
towards eIF4E of peptide XVIIc (clicked, cyclic form of linear modified            
peptide XVII). 
 
Starting from these results we planned the synthesis of new modified analogs 
of 4GII-FITC with the bridge stabilizing the helix part of the structure between 
positions 7 and 11. 
We synthesized a small collection of cyclic, clicked peptides, generated by 
click chemistry reaction with different ring sizes (section 3.5). 
In Figure 3.6–4 are summarized the Fluorescence Polarization measurements 
of 4E-BP linear peptide analogs XVII-XX and the corresponding cyclic 
peptides XVIIc-XXc against the eIF4E protein. 
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Figure 3.6–3 Structures of the complex eIF4E/eIF4E binging protein (from x-ray 
analysis). In evidence the position of the triazole bridge 3-7 in peptide XVIIc (between 
residue 3 and 7) and the tyrosine residue in position 4 that is destabilized by the bridge 
formation. 
 
The titration curves show that the new cyclic analogs (XVIIIc, XIXc, and 
XXc) has a far better affinity for eIF4E than the first developed cyclic peptide 
(XVIIc), around 15 nM of kd versus no affinity. This implies that the decision 
to shift the triazole bridge position from residues 3-7 to residues 7-11 was the 
correct one. The fact that the new cyclic peptides bind consistently one order 
of magnitude less tightly (kd ca. 150 nM) than the linear counterparts.  
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Figure 3.6–4 Fluorescence Polarization mesurments of 4E-BP linear peptide analogs 
XVII-XX and the corresponding cyclic peptides XVIIc-XXc against eIF4E. 
 
The latter conclusion means that under the chosen ring size parameters (a 
2+3/3+2 triazole bridge) the cyclization does not improve affinity over the 
linear peptides. However the fact that different cyclic analogs have different 
affinity towards the protein is a proof that our hypothesis of side-chain to side-
chain triazole bridge α-helix stabilization is indeed correct.  
As future developments, it remains to find which is the best combination of 
modified alkyne and azido amino acids to get the best α-helical stabilization. 
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3.7 Conformational studies  
 
In solution, most of the peptides assume multiple flexible conformations. 
Determination of the dominant conformers and evaluation of their populations 
is the aim of peptide conformational studies, in which theoretical and 
experimental methods play complementary roles.153 Cyclic peptides typically 
assume multiple conformations; these conformations are rather flexible, with 
torsional angles of the backbone (φ, ψ) as well as of the side chain groups (χi) 
fluctuating within large intervals (Figure 3.7–1). 
In addition, coupling constants between NH and CαH can give information 
about the average values of the peptide backbone torsional ϕ angles. 
 
 
Figure 3.7–1 φ and ψ Dihedral angles. 
 
Moreover, another goal of conformational investigations is to determine the 
relationship between conformation and activity of biologically important 
peptides (e.g. SAR: structure-activity relationships studies). Numerous 
biological results are strongly supported by conformational investigations, 
clearly indicating that biological peptide activity is determined not only by the 
                                                 
153 Bierzyñski, A. (2001) Acta Biochimica Polonica, 48, 1091.. 
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presence of specific functions binding to a target protein, but also dramatically 
depends on the conformational properties of the whole peptide structure. 
Cyclopeptides XIXc (C3+N2) and XXc (N3+C2) (Figure 3.7–2) were 
analyzed by NMR and CD, to understand the influence of the alkyl ring size 
containing the triazolyl moiety, the spatial orientation of triazole ring and the 
spatial arrangement of all the side chains that is fundamental for the 
interactions with the eIF4E protein. 
 
 
Figure 3.7–2 Triazole bridge orientation in eIF4E b.p. peptide analogs XIXc and XXc 
which are isomers having a different triazole orientation. 
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3.7.1 NMR and CD structural characterization of cyclopeptides XIXc 
and XXc 
 
This part of research was followed in cooperation with Prof. A. M. D’Ursi and 
M. Scrima of the department of Pharmaceutical Sciences of the University of 
Salerno. 
A preliminary screening of the conformational preferences of XIXc and XXc 
[1,2,3]triazolyl-containing peptides as a function of the environment was 
performed by means of circular dichroism (CD) spectroscopy. CD is a form of 
spectroscopy based on the differential absorption of left- and right-handed 
circularly polarized light. It can be used to determine the structure of 
macromolecules, including the secondary structure of proteins. In fact, CD 
spectroscopy is widely used to determine the secondary structures of proteins. 
Within the UV region from 180 up to 240 nm each of the structures α-helices, 
β-sheets, and the remaining, unordered part of the polypeptide backbone, 
usually referred as “random coil”, contribute in different ways to the peptide 
spectrum. 
CD spectra of both XIXc and XXc recorded in water (pH=5) presented a 
negative band at 201 nm. CD spectra (Figure 3.7–3 and Figure 3.7–4) recorded 
in water and water/HFA (50:50, v/v) mixtures154 (a secondary structure 
stabilizing solvent), show for XXc the negative bands at 208 and 222 nm and 
an additional positive band at 192 nm, for XIXc presented  two minima around 
220nm. A single value deconvolution method154 estimates for both 
cyclopeptides in water almost 80% of random coil structures, for cyclopeptides 
in water/HFA high amounts of alfa-helical structures for XXc and significant 
amounts of beta-structures for XIXc. 
                                                 
154 Johnson, J.W. (1990) In Protein secondary structure and circular dichroism: a practical 
guide, 205. 
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Figure 3.7–3 CD spectra of XXc (Continue line) and XIXc (dotted line) in H2O pH 
5. 
 
 
Figure 3.7–4 CD spectra of XXc (Continue line) and XIXc (dotted line) in H2O/HFA 
50/50 v:v. 
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These preliminary results require further detailed analyses, nevertheless, they 
prelminarly suggest a different conformational behavior of XIXc and XXc 
which on chemical point of view are different only for the orientation of the 
triazolyl ring. 
A preliminary NMR analysis was undertaken in water solution. NMR spectra 
of sc152 were acquired in water solution at pH 5.5. To exclude potential 
aggregation, we recorded the 1D proton spectra of the cyclopeptides at a 
concentration range spanning 1-0.1 mM. At a peptide concentration of 0.1 
mM, the peptides did not display any noticeable effect of aggregation. 
Chemical shift assignments of the proton spectra of XXc (Table 3.7-1) were 
achieved via the standard systematic application of DQF-COSY,155 
TOCSY,156 and NOESY157 experiments, using the SPARKY158 software 
package according to the procedure of Wüthrich.159 
It is well known that water solutions are considered the most biocompatible 
media suitable for NMR analysis of biomolecules. However water solutions 
enhance the flexibility of short peptides and avoid the collection of a sufficient 
NMR data to build reliable 3D models. To overcome this proble usually 
mixtures of water and organic solvents are used. The preliminary screening of 
the conformational analysis in water solution is advisable. 
In our case the preliminary NMR investigation of XXc strted with the 
acquisition of NMR experiments in water solutions. Figure 3.7–5 shows the 
low-field region of NOESY spectrum of XXc in water solution. In agreement 
with the expectations for a spectrum in water solution a high number of 
TOCSY and NOESY correlations is not observable. In any case a careful 
                                                 
155 Piantini, U., Sorensen, O.W., Ernst, R.R., (1982) J. Am. Chem. Soc., 104, 6800. 
156 Bax, A. and Davis, D.G. (1985) J. Magn. Res., 63, 207. 
157 Jeener, J., Meyer, B.H., Bachman, P., and Ernst, R.R. (1979) J. Chem. Phys., 71, 4546. 
158 Goddard, T.D., Kneller, D.G., SPARKY 3 NMR software. University of California, San 
Francisco (2001). 
159 Wüthrich, K. NMR of Proteins and Nucleic Acids. John Wiley and Sons: New York, (1986), 
44. 
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analysis of the correlations present, allowed the assignment of a high percent 
of proton resonances (Table 3.7-1). 
The amide and fingerprint regions of NOESY spectra of peptide XXc in water 
(Figure 3.7–5) showed a significant number of non-trivial dNN(i, i+1) dαN(i, 
i+3) medium-range NOE correlations. These correlations suggest that in spite 
of the flexibility of the peptide and the polarity of the aqueous environment, 
XXc has an intrinsic tendency to assume ordered turn-helical structures.  
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                                   Table 3.7-1 Chemical shifts of XXc in water solution pH 5.5 (600MHz, 300K). 
Cyclopeptide XXc in Water 
Residue HN CαH CβH CγH CδH CεH Others 
Lys1 8.105 4.673 1.879/1.624 1.259 1.532 2.814 Qζ7.759 
Lys2 8.167 4.144 1.756/1.532 1.226 1.449 2.782 Qζ7.637 
Gln3 8.107 4.112 2.831 2.411    
Tyr4 8.278 4.546 2.740/2.607  7.204 7.123  
Asp5 7.911 4.682 2.569     
Arg6 8.082 4.679 1.412 1.645  2.952 Qζ7.755 
Orn7 7.847 4.387 1.653 1.705 3.694   
Phe8 8.395 4.362 2.828  6.490 7.165 Hζ6.884 
Leu9 8.468 4.451 1.760 1.490 0.797/0.724   
Leu10 8.454 4.672 1.499 1.396  0.752/0.700   
Orn11 7.751 4.391 1.602 1.982    
Phe12 8.262 4.724 2.946  7.290 7.400 Hζ7.270 
Gln13 7.922 4.451 3.399 3.029      
Phe14 8.261 4.675   2.821    7.254 7.277 Hζ 7.269 
Lys15 8.399 4.100   1.855/1.721 1.278   1.516   2.836  7.751  
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Figure 3.7–5 CH-α (top) and NH-NH (bottom) regions of NOESY spectrum of XXc 
in water pH. 5.5. The spectra were recorded at 600MhH and 300K. 
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3.8 Conclusions and future developments B 
 
The goal of this project was the development of new eIF4E binding protein 
peptide inhibitors with stabilized conformation to be used as suppressors of 
Translation Initiation in a context of cancer therapy (section 3.3). 
A collection of Nα-Fmoc protected unnatural amino acids bearing on the side 
chain azide or alkynyl functions was synthesized and introduced by SPPS in 
the fluoresceinated-4E-BP(621-636) peptide sequence to afford by Cu(I) 
catalyzed Huisgen reaction, a new collection of cyclopeptides containing the 
triazolyl moiety (section 3.5). The side-chain-to-side chain cyclization of 
linear peptides generated via click chemistry lead to cyclopeptides containing 
the triazolyl moiety linked to the α-carbon of the amino acids by alkyl chains 
of different lengths. 
The collection of linear and cyclic peptides has been tested with Fluorescence 
Polarization Assay to measure the affinity for the eIF4E protein. The position 
and length of the triazole-bridge appears to play a critical role in enhancing 
and decreasing the affinity of the binding protein peptide analogs (4E-BP) for 
the target protein (eIF4E) (section 3.6.1). 
A NMR/CD conformational study has been carried out on the cyclopeptides 
analogs containing triazolyl moiety. From preliminary data the triazole bridge 
seems, as expected, to stabilize the α-helical structure of the peptides (section 
3.7.1). 
The completion of the synthesis and characterization of the 4E-BP 
cyclopeptides collection is in progress. The peptides presenting the best 
affinity with eIF4E will be selected for experiments of templated click 
cyclization free from metal catalyst and in presence of the protein (eIF4E) 
(3.5.2.4). The cell membrane permeability of the fluoresceinated peptides will 
also be assessed with a confocal microscope.  
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4 PART C: The Fmoc/tBu Solid Phase Peptide Synthesis  
The following section contains material coming from the book chapter 
“Orthogonal protecting group in Fmoc/tBu strategy” edited by the author 
together with Prof. Anna Maria Papini under press in “Amino, Peptides, and 
Proteins in Organic Chemistry”, Wiley. 
4.1 The Fmoc/tBu-strategy 
The Fmoc/tBu combination is an orthogonal system that was described in 
1978160, a decade and a half after Boc/Bzl chemistry, and it nowadays, by far, 
the most widely used strategy for the SPPS. It is based on the Nα-protecting 
group 9-fluorenylmethoxycarbonyl developed by Carpino and coworkers in 
1970161. Nα-Deprotection is mediated by a base, usually piperidine (Scheme 
4.1-1), so the amino group is available for the next coupling as soon as the 
protector is removed, and there is no loss of side-chain protectors during chain 
assembly162.  
O N
RH
N
H
O
H
-CO2 + H2N R
N
 
Scheme 4.1-1 Piperidine mediated Fmoc deprotection 
                                                 
160 Chang, C.D. and Meienhofer, J. (1978) International Journal of peptide and Protein 
research, 539. 
161 Carpino, L.A. and Han, G.Y. (1970) Journal of the American Chemical Society, 92, 5748. 
162 Benoiton, N.L. (2006) In Chemistry of Peptide Synthesis, Taylor and Frensis, 142. 
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Final deprotection is by acid of moderate strength, so no special equipment is 
necessary (contrary of what is required for Boc/Bzl strategy), and the linker 
need not be especially stable to acid. Fmoc–amino acids cost more than Boc–
amino acids, but their use involves one step less (since the acid employed for 
Nα-Boc deprotection leaves the amino group protonated, a neutralization step 
is required to convert the amino group to a nucleophile), thus reducing 
consumption of solvent, which is a significant cost savings163. 
                                                 
163 Atherton, E., Logan, C.J., and Sheppard, R.C. (1981) Journal of the Chemical Society 
Perkin Transactions 1, 538. 
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4.1.1 Orthogonal protecting groups in Fmoc/tBu strategy 
4.1.1.1 Arginine  
 
During SPPS the three nitrogen atoms of the guanidine group of Arginine 
(Figure 4.1–1) being strongly nucleophilic are prone to alkylation and sub 
sequential Ornitine formation upon base–mediated decomposition164 and 
therefore need to be protected. However, in common practice, most protecting 
groups block only the ω-nitrogen. In addition, free unprotected Arginine 
residues tend to cyclize upon activation of the α-carboxylic group to form δ-
lactams  
 
 
 
 
 
 
Figure 4.1–1 The guanidino group of Arginine. 
In Fmoc/tBu strategy the most commonly used protecting groups of Arginine 
are the arylsulfonyl-based derived from the tosyl group (Tos)165 such as 4-
methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr) group 1, now superseded by 
the two cyclic ether derivates 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) 
2 and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) 3 group. Mtr 
removal requires several hours of TFA treatment and often causes sulfonation 
of Trp residues166, which can be avoided using 1M TMSBr in TFA167. 
                                                 
164 Rink, H., Sieber, P., and Raschdorf, F. (1984) Tetrahedron Letters, 25, 621. 
165 Ramage, R., Green, J., and Blake, A.J. (1991) Tetrahedron, 47, 6353. 
166 Sieber, P. (1987) Tetrahedron Letters, 28, 1637.  
167 Fujii, N., Otaka, A., Sugiyama, N., Hatano, M., and Yajima, H. (1987) Chemical and 
Pharmaceutical Bulletin, 35, 3880. 
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Moreover long TFA treatment can cause O-sulfonation of Ser and Thr which 
can be suppressed adding thiocresol to the cleavage cocktail168. Pmc group 
being much acid sensitive than Mtr can be removed faster and the Trp/Tyr 
modifications are less pronounced169 and can be overcome if the Trp indole 
ring is Boc protected170. The Pbf group171, the dihydrofuran analog of Pmc 
group, is at present the most widely used Arginine protecting group. It has 
proved to be more acid labile than Pmc (its removal is 1-2 time faster) and 
generates less alkylation than the other arylsulfonyl-protecting groups.  
Me
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Other reported protecting strategies have not gained popularity due to several 
different shortcomings. For example, the nitro group (NO) is used to protect 
the ω-Nitrogen and can be removed with H2/Pd or with hydrazinium 
monoformate and magnesium172 but it is not completely stable under coupling 
conditions173. It generally requires long deprotection times and it is prone to 
                                                 
168 Jaeger, E., Remmer, H.A., Jung, G., Metzger, J., Oberthur, W., Rucknagel, K.P., Schafer, 
W., Sonnenbichler, J., and Zetl, I. (1993) Biological Chemistry Hoppe Seyler, 5, 349.  
169 Green, J., Ogunjobi, O.M., Ramage, R., and Stewart, A.S. (1988) Tetrahedron Letters, 29, 
4341. 
170 White, P. (1992) in Peptides, Chemistry, Structure and Biology, Pro. 12th American peptide 
Symposium, Smith, J.A. and Rivier, J.E. (Eds.), ESCOM, Leiden, 537. 
171 Carpino, L.A., Shroff, H., Triolo, S., Mansour, E.M., Wenschuh, H., and Albericio, F. 
(1993) Tetrahedron Letters, 34, 7829. 
172 Gowda, D.C. (2002) Tetrahedron Letters, 43, 311. 
173 Wunsch, E. (1974) In Houben-Weyls methods der Organischen Chemie, Muller, E. (Ed.), 
15, Parts 1 and2, Thieme, Stuttgart. 
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generate partially reduced products174. The urethane protections, ω-Boc175 and 
δ, ω-bis adamantyloxycarbonyl (Adoc)2 176 4 are unable to completely suppress 
the guanidine group nucleophilicity. On the other hand bis-urethane Arginine 
derivate with both ω and ω’-Nitrogen Boc protected177 does not show any side 
reaction on deprotection but it is highly hindered adduct and the coupling time 
need to be extended. The trityl group is not normally used for Arginine 
protection because it gives an adduct with poor solubility in DMF/DCM178. 
A completely different approach to the problem of Arg protection is the use of 
a suitably protected Ornitine residue that can be converted into Arginine at the 
end of the synthesis by guanylation with reagents such as 1H-pyrazole-1-
carboxamide hydrochloride179. An additional level of orthogonality is needed 
for the Ornitine δ-amino group, which has to be selectively deprotected before 
the conversion. Protecting groups such as the 1-(4-
methoxyphenyl)ethyloxycarbonyl (Mpeoc) 180 4a, cleavable under mild acidic 
conditions, have been specifically developed for this application. 
 
 
                                                 
174 Turàn, A., Patthy, A., and Bayusz, S. (1975), Acta Chimica Academiae Scientiarum, 85, 
327. 
175 Gronvald, F.C., Johansen, N.L., and Lundt, F.G. (1981), In Peptides 1980, Brunfeldt K. ed, 
Scriptor. Copenhagen, 111. 
176 Presentini, A. and Antonui, G. (1986), International Journal of Peptide and Protein 
Research, 27, 123. 
177 Verdini, A., Lucietto, P., Fossati, G., and Giordani, C. (1992) Tetrahedron Letters, 33, 
6541. 
178 Caciagli, V. and Verdini, A.S. (1988) In Peptide Chemistry 1987, (Shiba T. and Sakakibara 
S. eds.), Protein Research Foundation Osaka, 283. 
179 Bernatowicz, M.S., Wu, Y., and Matsueda, G.R. (1992), The Journal of Organic Chemistry, 
57, 2497. 
180 Bernatowicz, M.S. and Matsueda, G.R. (1994) In Peptides, Chemistry, structure and 
Biology, proc. 13th American Peptide Symposium, Hodges, R.S. and Smith, J.A. (Eds.) 
ESCOM, Leiden, 107. 
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4.1.1.2 Asparagine and Glutamine 
Asparagine and Glutamine could in principle be incorporated into peptides 
without protection but the unprotected derivates display a low solubility in 
solvents commonly used in peptide synthesis and have low coupling rates. In 
addition the amide side chain, especially Asparagine’s one, can suffer partial 
dehydratation on activation181. Finally, although more common for the 
Boc/Bzl chemistry, Glutamine in the N-terminal position can undergo weak 
acid catalized cyclization forming pyroglutamyl residues that cause the 
truncation of the peptide sequence182.   
Side chain protection prevents all this undesired reactions and, in addition, 
inhibits hydrogen bond interactions of the amide, which stabilizes secondary 
structures causing incomplete deprotection and reduced coupling rate.  
The most common amide protecting group for Fmoc/tBu SPPS is the  
triphenylmethyl group (Trt)183 5, which requires care in the choice of the 
cleavage scavengers since it generates stable carbocations that tend to alkylate 
Tryptophan. Such alkylation is reduced by using the 9-xanthenyl (Xan) group 
6 and its 2-methoxy derivate (2-Moxan)184 7 but, on the other hand, it 
generates less soluble derivates. 
 
                                                 
181 Gausepohl, H., Kraft, M., and Frank, R. (1989) International Journal of Peptide and 
Protein Research, 34, 287.  
182 Dimarchi, R., Tam, J., and Merrifield, R. (1982) Journal of Peptide Research, 19, 88. 
183 Sieber, P. and Riniker, B. (1991) Tetrahedron Letters, 32, 739. 
184 Han, Y., Solè, N., Tejibrant, J., and Barany, G. (1996) Journal of Peptide Research, 9, 166. 
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When Asn is the N-terminal amino acid, trityl deprotection it is slower, due to 
the vicinity of the free α-amino group185. In this case cleavage time needs to be 
extended or methyltrityl protection can be used instead of Trt.  
N-dimethylcyclopropylmethyl (Dcmp) group 8 represents a convenient 
alternative to Trt with several advantages like rapid removal (even at the N-
terminal position), faster coupling rate (due to the minor steric hindrance) and 
better solubility in DMF186. 
To overcome the problem of the slow and troublesome attachment to most 
resins the resin can be linked to the amide side chain187 (Figure 4.1–2) instead 
to the carboxylic function (that needs to be protected during the synthesis) 
 
Figure 4.1–2 Side chain anchoring of C-terminal Asn and Gln containing peptides 
More used in the past than now, before the Trt protection gained popularity, 
are 2,4,6-trimethoxybenzyl group (Tmob)188 9 and 4,4’-dimethoxybenzhydryl 
group (Mbh)189  10 both less acid-labile and soluble than Trt183.  
 
                                                 
185 Friede, M., Denery, S., Neimark, J., Kieffer, S., Gausepohl, H., and Briand, J. (1992) 
Journal of Peptide Research, 5, 145. 
186 Carpino, L.A., Chao, H., Ghassemi, S., and Mansour, E.M. (1995) The Journal of 
Organic Chemistry, 60, 7718. 
187 Greipohl, G., Knolle, J., and Stuber, W. (1990) International Journal of Peptide and 
Protein Research, 35, 281. 
188 Weyand, F., Steglich, W., Bjarnason, J., Ahktar, R., and Chytil, N. (1968) Chemische 
Berichte, 101, 3623. 
189 Konig, W. and Geiger, R. (1970) Chemische Berichte, 103, 2041. 
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4.1.1.3 Aspartic and Glutamic acid  
 
The carboxylic acid side chains of Asp and Glu need to be protected during 
peptide synthesis in order to prevent amide bond formation with incoming 
amino acids and, as a consequence, branching of the peptide190. 
Although protected Asp and Glu residues could still be affected from side 
reactions, particularly acid or base (particularly in Fmoc/tBu-chemistry) 
catalized cyclization to form aspartimides and glutarimides respectively191. 
Subsequent hydrolysis of the imide-containing peptides lead to a mixture of 
the desired peptide along with a product, called β-peptide in which the side 
chain carboxylic group forms part of the backbone and a β-piperidide 
adduct192. 
The reaction occurs less often with Glu193 and is highly sequence dependent. 
Susceptible sequences are Asp-Xxx with Xxx being Gly, Asn, Ala, and Gln194.  
Since the beginning of Fmoc/tBu SPPS, Asp and Glu have been successfully 
protected by t-butyl (tBu) 11 group, which is base stable and TFA labile288.  
Equally favourable properties are displayed by 1-adamantyl (1-Ada) 
protection195 12. Both tBu and 1-Ada minimize piperidine-catalized 
aspartimide formation although several bulky tBu derivates give better results 
in this respect like the 3-methylpent-3-yl (Mpe)196 group 13 and β-2,4-
dimethyl-3-penty (Dmp)197 group 14.  
                                                 
190 Natarajan, S. and Bodanszky, M. (1976) The Journal of Organic Chemistry, 41,1269. 
191 Tam, J., Riemen, M., and Merrifield, R. (1988) Journal of Peptide Research, 1, 6. 
192 Dolling, R., Beyermann, M., Haenel, J., Kernchen, F., Krause, E., Franke, P., Brudel, M., 
and Bienert, M. (1994) Journal of the Chemical Society, Chemical Communications, 853. 
193 Kates, S. and Albericio, F. (1994) Letters in Peptide Science, 1, 213. 
194 Yang, Y., Sweeney, V., Schneider, K., Thornqvist, S., Chait, B., and Tam, J. (1994) 
Tetrahedron Letters, 35, 9689. 
195 Okada, Y., Igushi, S., and Kawasaki, K., (1987) Journal of the Chemical Society, Chemical 
Communications, 1532.  
196 Karlstrom, A. and Unden, A. (1996) Tetrahedron Letters, 37, 4243. 
197 Karlstrom, A. and Unden, A. (1995) Tetrahedron Letters, 36, 3909. 
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Aspartimide formation is also greatly reduced by adding either 1-
hydroxybenzotriazole (HOBt) or 2,4-dinitrophenol to the piperidine 
deprotection solution198 but can be completely eliminated, especially with 
susceptible sequences in long peptide sequences, only by employing amide-
backbone protection for the introduction of residues preceding Asp. This is 
achieved using the 2-hydroxy-4-methoxybenzyl (Hmb)199 15 or the 2,4-
dimethoxybenzyl (Dmb)200 16 (only applied to glycine residues) amide 
protecting groups. Hmb and Dmb, removed contemporary with the final 
cleavage, prevent undesired side reactions and suppress aggregation during 
chain extension. 
 
When an additional degree of orthogonality is required, as for example in the 
case of lactam-bridged peptide synthesis, a number of different Asp and Glu 
protecting groups exist. For example the benzyl group (Bzl) 201 17, the 2-
amantyl (2-Ada) 202 18, and allyl eters277 (thought more prone to imide 
                                                 
198 Martinez, J. and Bodansky, M. (1978) International Journal of Peptide and Protein 
Research, 12, 277. 
199 Quibell, M., Owen, D., Packmann, L., and Johnson, T. (1994) Journal of the Chemical 
Society, Chemical Communications, 2343. 
200 Zahariev, S., Guarnaccia, C., Pongor, C.I., Quaroni, L., Cemazarc, M. and Pongora, S. 
(2006) Tetrahedron Letters, 47, 4121. 
201 Benoiton, L. (1962) Canadian Journal of Chemistry, 40, 570. 
202 Okada, Y. and Igushi, S., (1988) Journal of the Chemical Society, Perkin Transactions I, 
2129. 
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formation than tBu) all removed by palladium-catalized transfer to a suitable 
nucleophile. Alternatively super-acid-labile groups can be used such as the 2-
phenyl isopropyl (Pp)203 group 19, removable in presence of tBu/Boc with 1% 
TFA in DCM and the phenyl-3,4-ethylenedioxy-2-thenyl (EDOT-Ph)204 20 
cleaved by 0.1-0.5% TFA in DCM. 
 
Another orthogonal protecting group is 4-[N-[1-(4,4’-dimethyl-2,6-
dioxocyclohexylidene)-3-methylbutyl]aminobenzyl group (Dmab)205 21, 
removed with 2% hydrazine in DMF. With aspartimide susceptible sequences 
it is recommended to use Dmab along with additional precautions such as 
backbone-amide protection206. 
For applications in native chemical ligation it has recently been described a 
new photo-labile protecting group, {7-[bis(carboxymethyl)amino]coumarin-4-
yl}methyl (BCMACM)207 group 22, removed with UV irradiation at 405 nm. 
                                                 
203 Kunz, H., Waldmann, H., and Unverzagt, C. (1985) International Journal of Peptide and 
Protein Research, 26, 493. 
204 Isidro-Llobet, A., Alvarez, M., and Albericio, F. (2008) Tetrahedron Letters, 49, 3304. 
205 Chan, W., Bycroft, B., Evans, D., and White, P. (1995) Journal of the Chemical Society, 
Chemical Communications, 2209. 
206 Nski, J.R., Lewandowska, B., Mucha, P., and Retowski, P. (2008) Journal of Peptide 
Science, 14, 335. 
207 Briand, B., Kotzur, N., Hagen, V., and Beyermann, M. (2008) Tetrahedron Letters, 49, 85. 
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Figure 4.1–3 Internal solvation with the TEGBz group. 
 
A special carboxylic protecting group, the 4-(3,6,9-trioxadecyl)oxybenzyl 
(TEGBz)208 23, has been developed to suppress aggregation of those ‘difficult 
sequences’, in which intermediate resin-bound peptide chains associate into 
extended β-sheet type structures. TEGBz forms hydrogen bond with the 
backbone amino groups enabling the so called ‘internal solvation’ that inhibits 
aggregation by enhancing backbone linearity (Figure 4.1–3). 
                                                 
208 Kocsis, L., Bruckdorfer, T., and Orosz, G. (2008) Tetrahedron Letters, 49, 7015. 
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4.1.1.4 Cysteine 
 
In SPPS protection of the Cysteine side chain sulfhdryl group is mandatory 
otherwise it would easily undergo alkylation and acylation. Free Cysteine 
residues are also prone to oxidation, even by atmospheric oxygen, to form 
intra- and inter-molecular disulfide bonds. 
The chemistry of Cysteine protecting groups is particularly rich due to the key 
importance of this amino acid in forming inter- and intra-molecular disulfide 
bridges and in consideration of the versatile reactivity of the thiol group.  
With the Fmoc/tBu strategy trityl (Trt)209 24 is the most used Cysteine 
protection. Since acid S-detritylation is an equilibrium reaction it needs to be 
driven to completion by capture of the forming carbocation. This can be 
achieved by adding H2O, thiols and especially silanes. Triisopropylsilane (TIS) 
in particular has to be preferred over triethylsilane210 which can lead to 
reduction of free Trp residues. In spite of its popularity Cys(Trt) is prone to 
racemization (up to 10-20%) during peptide coupling by base mediated in situ 
activation211, especially with the TBTU/DIPEA system. The use of HBTU, 
PyBOP/HOBt or preactivated reagents such as symmetrical anhydrides, OPfp 
esters and DIPCDI/HOBt minimize this problem212. Enantiomerization occurs 
also with the attachment of Cys(Trt) to Wang type resins and during chain 
extension when Cys(Trt) is the C-terminal residue. The use of Cl-trityl resins 
is recommended213. 
                                                 
209 Fujii, N., Otaka, A., Funakoshi, S., Bessho, K., and Yajima, H., (1987) Journal of the 
Chemical Society, Chemical Communications, 163. 
210 Pearson, D.A., Blanchette, M., Blaker, M.L., and Guindon, C.A., (1989) Tetrahedron 
Letters, 30, 2739. 
211 Kaiser, T., Nicholson, G.J., Kohlbau, H.J., and Voelter, W. (1996) Tetrahedron Letters, 37, 
1187. 
212 Angell, Y.M., Alsina, J., Albericio, F., and Barany, G. (2002) Journal of Peptide Research, 
5, 292. 
213 Fujiwara, Y. (1994) Chemical and Pharmaceutical Bulletin, 42, 724. 
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In alternative to Trt, other protecting groups removed with concentrated 
TFA214 are 1,4,6-trimethoxybenzyl (Tmob) 25 and 9-phenylxanthen-9-yl 
(pixyl) 26 whereas monomethoxytrityl (Mmt) 27, 9H-xanthen-9-yl (xanthyl) 
28 and 2-methoxy-9H-xanthen-9-yl (2-Moxan) 7 are more acid-labile215 and 
can be selectively cleaved in presence of tBu groups.  
 
The t-buthyl (tBu), S-(1-adamantyl) (1-Ada) 29, acetamidomethyl (Acm) 30, 
trimethylacetamidomethyl (Tacm) 31, and phenylacetamidomethy (Phacm) 32 
groups (last two developed to avoid formation of thiazolidine-2-carboxylic 
acid) are stable to acid and compatible with both Boc and Fmoc SPPS 
strategies. Those groups can be removed in several ways (see Table 4.1-1) 
enabling concomitant disulfide bridge formation even multiple, selective 
cyclization if used in combination216. Phacm has an additional level of 
orthogonality since it is enzimatically-cleavable by penicillin G acylase217 
A different protecting approach is to use mixed disulfides such as the S-tert-
butylmercapto (StBu) group 33, which are stable to TFA and are removed with 
thiols218 or tributylphoshine219. Coupling efficiency is reported to be highly 
                                                 
214 Munson, M.C., Garcia-Echevarria, C., Albericio, and F., Barany, G. (1992) The Journal of 
Organic Chemistry, 57, 3013. 
215 Han, Y. and Barany, G. (1997) The Journal of Organic Chemistry, 62, 3841. 
216 Albericio, F. (2000) In Fmoc Solid Phase Peptide Synthesis W. C. Chan and White, P.D. 
(Eds.) Oxford University press, oxford, 77. 
217 Greiner, G. and Hermann, P. (1991) In Peptides (1990) Giralt E., Andreu D., Eds. ESCOM, 
Leiden, 277. 
218 Weber, U. and Hartter, P. (1970) Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 
351, 1384. 
219 Beekman, N.J., Schaaper, W.M., Tesser, G.I., Dalsgaard, K., Kamstrup, S., Langeveld. J.P., 
Boshuizen. R.S., and Meloen. R.H. (1997) Journal of Peptide Research, 50, 357. 
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sequence dependent220. Allyl-based Cys protecting groups are base labile and 
therefore cannot be used in Fmoc/tBu-SPPS221. 
Finally, several non-conventional protecting groups have been developed for 
those Chemical Ligations based on Cysteine. The thiazolidine (Thz)222 34 
protection has found a special application allowing to mask N-terminal 
Cysteines during Tandem Native Chemical Ligation (TNCL) reaction. It 
simultaneously protects the α-amino and the side chain thiol groups of 
protected N-terminal free Cysteines and is stable to acids and can be removed 
in aqueous conditions in presence of methoxylamine. The thiosulfonate group 
(S2O3)223 can be used as well for Cysteine protection during TNCL. It is 
introduced with sodium tetrathionate (Na2S4O6) in a solvent, which can then be 
removed by treatment with dithiothreitol (DTT). 
 
                                                 
220 Berangere, D. and Trifilieff, E. (2000) Journal of Peptide Science, 6, 372. 
221 Loffet, A. and Zhang, H.X. (1993) International Journal of Peptide and Protein Research, 
42, 346. 
222 Bang, D. and Kent, S.B.H. (2004) Angewandte Chemie International Edition, 43, 2534. 
223 Sato, T. and Aimoto, S., (2003) Tetrahedron Letters, 44, 8085. 
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Protecting group Structure Removed by Stable to 
Trityl  
(Trt) 
 
 Dil TFA/scavengers, Ag(I)224, Hg(II)225, RSCl, 
I2226, Tl(III) trifuoracetate241 TFA/DMSO/Anisole227 
Base, 
nucleophiles, 
RSH 
1,4,6-trimethoxybenzyl  
(Tmob) 
 
Dil TFA/DCM/silanes228 
I2229, Tl(III) trifuoracetate 
Base, 
nucleophiles 
monomethoxytrityl  
(Mmt) 
27
MeO
 
Dil TFA/DCM/TIS230, AcOH/TFE/DCM (1:2:7)231, I2232 Base, 
nucleophiles, 
RSH 
                                                 
224 Zervas, L. and Photaki, I. (1962) Journal of the American Chemical Society, 84, 3887. 
225 Photaki, I., Taylor-Papadimitriou, J., Sakarellos, C., Mazarakis, P. and Zervas, L. (1970) Journal of the American Chemical Society, 2683. 
226 Kamber, B. and Rittel, W. (1968) Helvetica Chimica Acta, 51, 2061. 
227 Otaka, A., Koide, T., Shide, A. and Nobutaka, F. (1991) Tetrahedron Letters, 32, 1223. 
228 Munson, M.C., Garcìa-Echeverrìa, C., Albericio, F. and Barany, G. (1992) The Journal of Organic Chemistry, 57, 3013. 
229 Munson, M.C. and Barany, G. (1993) Journal of the American Chemical Society, 115, 10203. 
230 Pearson, D.A., Blanchette, M. and Baker, M.L. (1989) Guindon CA., Tetrahedron Letters, 30, 2739. 
231 Barlos, K. Gatos, D., Kallitsis, J., Papaphotiu, G., Sotitiu, P., Wenqing, Y., and Scafer, W. (1989) Tetrahedron Letters, 30, 3943. 
232 Barlos, K., Gatos, D., Kallitsis, J. Papaphotiu, G., Poulos, C., and Tsegenidis, T. (1991) International Journal of Peptide and Protein 
Research, 38, 562. 
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9H-xanthen-9-yl  
(Xan) 
 
Dil TFA/TIS233 
I2, Tl(III) trifuoracetate234 
Base, 
nucleophiles 
t-buthyl  
(tBu) 
 
TFMSA235, TMSBr/TFA/RSH236, tetrafluoroboric 
acid237, Hg(II) acetate238, Tl(III) trifuoracetate241, 
MeSiCl3/Ph2SO/TFA239, TFA/DMSO/Anisole 
TFA, Ag(I), base, 
I2, RSH 
1-adamantyl 
(1-Ada) 
 
TfOH/TFA/RSH240, Hg(II) acetate238, Tl(III) 
trifuoracetate241 
TFA, Ag(I), base, 
I2, 
S-tert-buthylsulfanyl  
(StBu),  
 
RSH242, NaBH3243, phosphines244  TFA, TFMSA, 
base, RSCl 
                                                 
233 Han, Y. and Barany, G. (1997) The Journal of Organic Chemistry, 62, 3841. 
234 Hargittai, B. and Barany, G.J. (1999) Journal of Peptide Research, 54, 468. 
235 McCurdy, S. (1989) Journal of Peptide Research, 2, 147. 
236 Wang, H., Miao, Z., Lai, L., and Xu, X. (2000) Synthetic Communications, 30, 727. 
237 Akaji, K., Yoshida, M., Tatsumi, T., Kimura, T., Fujiwara, Y., and Kiso, Y. (1990) Journal of the Chemical Society, Chemical 
Communications, 288. 
238 Atherton, E., Pinori, M., and Sheppard, R. (1985) Journal of the Chemical Society, Perkin Transactions I, 2057. 
239 Akaji, K., Tatsumi, T., Yioshida, M., Kimura, T., Fujiwara, Y., and Kiso, Y. (1991) Journal of the Chemical Society, Chemical 
Communications, 167. 
240 Fujii, N., Otaka, A., Funakoshi, S., Watanabe, T., Akaji, K., and Yajima, H. (1987) Chemical and Pharmaceutical Bulletin, 35, 2339. 
241 Yajima, H., Fujii, N., Funakoshi, S., Watanabe, T., Murayama, E., and Otaka, A. (1988) Tetrahedron, 44, 805. 
242 Threadgill, M. and Gledhill, A. (1989) The Journal of Organic Chemistry, 54, 2940. 
243 Wunsch, E. (1974) In Houben-Weyl, 15/1, 789. 
244 Moroder, J., Gemeiner, M., Gohring, W., Jaeger, E., and Wunsch, E. (1981) In Peptides 1980 Brunfeldt K., Ed. Scriptor Copenhagen, 121. 
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acetamidomethyl  
(Acm),  
 
Hg(II) acetate245, Ag(I)/TFA246, I2247, Tl(III) 
trifuoracetate241, AgBF4/TFA248, AgTMS/DMSO-aq. 
HCl249 
TFA, TFMSA, 
base,  RSH 
trimethylacetamidomethyl  
(Tacm)  
 
AgBF4/TFA248, Hg(II) acetate250, I2251, Tl(III) 
trifuoracetate,  
TFA, TFMSA, 
base RSH 
Thiazolidine 
(Thz) 
S
NH
OH
O
35  
Methoxylamine/H2O252 TFA, base, RSH,  
Table 4.1-1 Deprotection and deprotecti n/oxidation conditions of the most common Cys protecting groups (concomitant disuldife formation in 
green)
                                                 
245 Sakakibara, S. (1995) Biopolymers, 37, 17. 
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247 Kamber, B. (1971) Helvetica Chimica Acta, 54, 927. 
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249 Tamamura, H., Otaka, A., Nakamura, J., Okubo, K., Koide, T., Ikeda, K., Ibuka, T., and Fujii, N. (1995) International Journal 
of Peptide and Protein Research, 45, 312. 
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4.1.1.5 Histidine 
 
Under standard SPPS conditions the two imidazole nitrogens of unprotected 
Histidine react with electrophilies such N,N’-cyclohexylcarbodiimide253, 
catalyze acyl-transfer reactions254, and above all, promote the racemisation of 
the chiral α-carbon255. 
To prevent both alkylation and racemisation the π nitrogen of the imidazole 
ring must be protected or rather the protection can be located on the τ 
position, reducing the nucleophilicity of the π nitrogen by inductive effects. 
Between the two non-equivalent nitrogen atoms (π and τ), of the imidazole 
ring a rapid proton exchange takes place and makes the two tautomers 
inseparable (Figure 4.1–4).  
 
Figure 4.1–4 Tautomeric equilibrium of Histidine side chain imidazole ring 
 
The two positions have almost the same basicity, however their 
nucleophilicity is significantly different and upon reaction with electrophiles 
the N-τ product is usually the major one. Thus regiospecific protection of the 
π position first requires an orthogonal protection of the τ nitrogen and counts 
for the fact that the synthesis of π products is often troublesome. 
                                                 
253 Rink, H. and Riniker, B. (1974) Helvetica Chimica Acta, 57, 831. 
254 Bodansky, M., Fink, M., Klausner, Y., Natarajan, S., and Tatemoto, K. (1977) The 
Journal of Organic Chemistry, 42, 149. 
255 Jones, J. and Ramage, W. (1978) Journal of the Chemical Society, Chemical 
Communications, 472. 
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The trytyl group (Trt) 36 on the τ-position is the most commonly used 
protecting group of His for the SPPS with Fmoc strategy256. It is stable, 
commercially available at an affordable price and its mild acidolitic 
deprotection is fast and smooth. Despite early cautious claims, Trt protection 
keeps racemisation at a very low rate under normal SPPS conditions and it is 
regarded to be an exception to the rule that τ-located protection does not 
completely suppress racemisation257. Except in those cases where significant 
steric hindrance is displayed as for the coupling of His to Pro in which case a 
small amount of enantiomerization (5%) occurs258. However racemisation 
becomes a serious issue upon esterification of His carboxylic group. For 
example when hydroxyl-resins are used and His is the first amino acid of a 
sequence. In this case enatiomerization can be reduced using the Trt group 
for the α nitrogen protection as well259. The best solution to this problem is 
the use of 2-clorotrityl resin, which can be estherified without 
racemisation260. The protection with the super acid-labile methyltrityl (Mtt) 
37 and momomethoxytrityl (Mmt) 38 groups have also been described261.  
                                                 
256 Barlos, K., Papaioannu, D., and Theodoropoulos, D. (1982) The Journal of Organic 
Chemistry, 47,1324. 
257 Harding, S., Heslop, I., Jones, J., and Wood, M. (1992) In Peptides 1994, Proceedings of 
the 23th European peptide Symposium, Maia H, Ed ESCOM, Leiden, 641. 
258 Mergler, F., Dick, F., Sax, B., Shwindling, J., and Vorherr, T.H. (2001) Journal of 
Peptide Science, 7, 502. 
259 Sieber, P. and Riniker, B. (1987) Tetrahedron Letters, 28, 6031. 
260 Barlos, K., Chatzi, O., Gatos, D., and Stravropoulos, G. (1991) International Journal of 
Peptide and Protein Research, 37, 513. 
261 Barlos, K., Chatzi, O., Gatos, D., Stravropoulos, G., and Tsegenidis, T. (1991) 
Tedrahedron Letters, 32, 475. 
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In the case of His rich peptides the tert-butoxymethyl (Bum) 39 protection of 
the π imidazole position is recommended instead of τ-Trt because it 
minimizes racemization during peptide coupling reactions262. A significant 
drawback, common to all π-protected derivates, is their difficult synthesis 
due to the presence of the more reactive τ-position. Bum cleavage with TFA 
requires slightly longer times compare to tBu, Boc, and Trt.  In the case of  
sequences containing N-terminal Cys,  methoxylamine should be added to 
the cleavage mixture as a scavenger since Bum deprotection generates 
formaldehyde that can mask Cys as thioazolidine (Thz) giving an adduct 
with a 12 mass unit difference 263,258. 
Another protection of the π imidazole position is the 1-adamantyloxymethyl  
(1-Adom) 40, whose derivatives are more soluble in organic solvents than 
Bum ones and give better synthetic yields264.  
 
                                                 
262 Colombo, R., Colombo, F., and Jones, J. (1984) Journal of the Chemical Society, 
Chemical Communications, 292. 
263 Gesquiere, J., Najib, J., Diesis, E., Barbry, D., and Tartar, A. (1992) In Peptides 
Chemistry and Biology, Proceedings of the 12th American peptide Symposium, Smith J. and 
River J Eds. ESCOM, Leiden, 641.  
264 Okada, Y., Wang, J., Yamamoto, T., and Mu, Y. (1996),Chemical and Pharmaceutical 
Bulletin, 44, 871. 
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4.1.1.6 Lysine 
 
Lysine side chain protection it is a must in solid phase peptide synthesis, 
otherwise the ε-amino group would react with acylating agents leading to 
uncontrolled peptide branching. 
The standard protection in Fmoc-strategy is the t-butyloxycarbonyl (Boc) 41, 
cleaved with concentrated TFA, which represents a perfect combination 
together with Fmoc/tBu265. 
Lysine residues are often post-synthetically modified in modern peptide 
synthesis of bioactive and modified peptides. Usually the goal is to 
introduce, on a given sequence, post-translational modifications as for 
example glycations266 and glycosylations267 or taking advantage of the ability 
to form amide bonds between Lysine side chains and molecular devices 
bearing carboxylic groups268. This latter application applies to a broad range 
of peptide modifications like linking to cromophores, chelating agents, 
radioactive molecules and many more substituents each conferring a specific 
property to the modified peptide. The amide bond formation is a 
straightforward one and highly compatible with on resin peptide synthesis. 
For all those applications of selective modifications a broad panel of 
orthogonal Lysine side chain protecting groups was developed. 
                                                 
265 Schwyzer, R. and Rittel, W. (1961) Helvetica Chimica Acta, 44, 159. 
266 Carganico, S., Rovero, P., Halperin, J.A., Papini, A.M., and Chorev, M. (2009) Journal of 
Peptide Science, 15, 67. 
267 Paolini, I., Nuti, F., Pozo-Carrero, M., Barbetti, F., Kolesinska, B., Kaminski, Z.J., Chelli 
M., and Papini, A.M. (2007) Tetrahedron Letters, 48, 2901. 
268 Grandjean, C., Rommens, C., Gras-Masse, H., and Melnyk, O., (1999) Tetrahedron 
Letters, 40, 7235. 
  160 
 
 
Particularly popular among orthogonal Lysine side chain protection is  
1-(4,4’-dimethyl-2,6-dioxocyclohexylidene)ethyl group (Dde) 42 removed 
with 2% hydrazine in DMF269 (Scheme 4.1-2). However Dde has same 
limitations, it is partially labile to piperidine (once removed it can migrate to 
other unprotected Lysines), and then hydrazine partially removes the Nα-
Fmoc270. In addition hydrazine can also reduce the Alloc protection 
preventing its subsequent removal271. In order to prevent this, allyl alcohols 
need to be added as scavengers when Dde is deprotected.  
Several hindered Dde variants, in particular 1-(4,4’-dimethyl-2,6-
dioxocyclohexylidene)-3-methylbutyl (ivDde)272 43, and the structurally 
similar 2-acetyl-4-nitroindane-l,3-dione (Nde)273 44, completely overcome 
those side reactions. Dde, ivDde, and Nde deprotection can be monitored 
both spectrophotometrically at various UV wavelengths and by mass 
spectrometry because of the different hydrazine adducts 42a. Nde removal 
can be also followed by a change of colour of the resin and solution.  
                                                 
269 Rohwedder, B., Mutti, Y., and Mutter, M., (1998) Tetrahedron Letters, 39, 1175. 
270 Augustyns, K., Kraas, W., and Jung, G. (1998) Journal of Peptide Research, 51, 127. 
271 Eichler, J., Lucka, W.A., and Houghten, R.A. (1994) Journal of Peptide Research, 7, 300. 
272 Chhabra, S.R., Hothi, B., Evans, D.J., White, P.D., Bycroft, B.W., and Chan, W.C. (1998) 
Tetrahedron Letters, 39, 1603. 
273 Kellam, B., Bycroft, B.W., Chan, W.C. and Chhabra, S.R. (1998) Tetrahedron, 54, 6817. 
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Scheme 4.1-2 Mechanism of hydrazine mediated Lys(Dde) deprotection. 
The acid sensitivity of the trityl group, removed with 20% TFA in DCM, is 
increased by the introduction of electron spending substituents leading to 
super-acid-labile groups as 4-methyltrityl (Mtt)274 45 monomethoxytrityl 
(Mmt) 46, and dimethoxytrityl (Dmt)275 47.  
 
Mtt and Dmt deprotection occurs with 1% TFA in DCM or 
(DCM/HFIP/TFE/TES 6.5:2:1:0.5) allowing selective removal in presence of 
other acid-labile protecting groups, like tBu and Boc, that are cleaved by 
concentrated TFA276. Mmt deprotections takes place at even milder 
conditions, with AcOH/TFE/DCM (1:2:7) and even in the presence of 
                                                 
274 Alestras, A., Barlos, K., Gatos, D., Koutsogianni, S., and Mamos, P. (1995) International 
Journal of Peptide and Protein Research, 45, 488. 
275 Matysiak, S., Bidicke, T., Tegge, W., and Frank, R. (1998) Tetrahedron Letters, 39, 1733. 
276 Barlos, K., Gatos, D., Chatzi, O., Koutsogianni, S., and Schaefer, W. (1993) In Peptides 
1992, Proceedings of the 22th European Peptide Symposium C. H. Schneider and A. N.Eberle 
(Eds), ESCOM, Leiden, 283. 
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hydrophilic resins such as Tentagel and cellulose that display quenching 
effect for Mtt and Dmt removal.   
The N-ε function in Lysine can bear the allyloxycarbonyl (Alloc) protection 
48, compatible with both Boc/Bzl and Fmoc/tBu strategies and can be  
removed by palladium catalyst in presence of nucleophiles like NMM277. 
Other groups removed by palladium catalyzed hydrogenolysis, like 
benzyloxycarbonyl (Z) 49 and 2-chlorobenzyloxycarbonyl (2-Cl-Z)278 50 or 
the benzyl group (Bzl)279 51 are also used. 
 
The trifluoroacetyl group (Tfa) 52, stable to both acid and mild base, 
removed by strong alkaline aqueous solutions or sodium borohydride, 
although more common of the Boc-strategy, has found some applications in 
the Fmoc-chemistry as well280. 
O2N
O
O
F3C
O
52 53  
Another semipermanent side-chain protection of Orn and Lys is  
p-nitrobenzyloxycarbonyl (pNZ) 53 for Fmoc/tBu chemistry that does not 
result in partial removal of Nα-Fmoc that occurs when groups such as Alloc 
derivates are used for the same application due to the formation of highly 
                                                 
277 Lyttle, M. and Hudson, D. (1992) In Peptides Chemistry and Biology. Proceedings of the 
12th American Peptide Symposium, Smith J. River J. ESCOM, Leiden, 583. 
278 Erickson, B. and Merrifield, R., (1973) Journal of the American Chemical Society, 95, 
3757. 
279 Huang, Z., Su, X., Du, J., Zhao, Y., and Li, Y., (2006) Tetrahedron Letters, 47, 5997. 
280 Stetsenko, D.A. and Gait, M.J. (2001) Bioconjugate Chemistry, 12, 576. 
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basic free amine281. Furthermore, pNZ, removed by 6 MSnCl2 and 1.6 mM 
HCl/dioxane in DMF, can be used in conjunction with p-nitrobenzyl ester 
(pNB) to prepare cyclic peptides282. 
Finally, the Fmoc protection of both α- and ε-nitrogen represents a 
specialized derivate for simultaneous multiple peptide synthesis, where side 
chain branching is desired after α-amino deprotection283 . 
 
 
                                                 
281 Farrera-Sinfreu, J., Royo, M., and Albericio, F. (2002) Tetrahedron Letters, 43, 7813. 
282 Llobet, A. I. (2005) Tetrahedron Letters, 46, 7733. 
283 Tam, J. (1988) The Proceedings of the National Academy of Science US, 85, 5409. 
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4.1.1.7 Methionine 
 
The thioether function of Methionine can undergo acid catalyzed oxidation 
forming methionyl sulfoxide and can also be alkylated. In standard Fmoc-
based peptide synthesis is common practise to use unprotected Methionine 
because the use of the proper scavengers like thioanisole284 in the cleavage 
mixture greatly reducing both the side reactions. 
Sulfoxides are also generated by prolonged air exposure but can be reduced 
back to the sulphide in several ways such as NH4I/Me2S in TFA at low 
temperatures285 (Scheme 4.1-3) or NaI/CH3COCl in DMF286 
 
Scheme 4.1-3 Acid NH4I/Me2S mediated Met(O) reduction mechanism. 
 
Another approach to the oxidation problem, although more common of the 
Boc strategy, is introducing Methionine as the sulfoxide derivate Met(O)287 
prepared by treatment with H2O2 and then reducing it at a convenient time of 
the synthesis. 
                                                 
284 Yajima, H., Kanaki, J., Kitajima, M., and Funakoshi, S. (1980) Chemical and 
Pharmaceutical Bulletin, 28, 1214.  
285 Vilaseca, M., Nicolfis, E., Capdevila, F., and Giralt, E. (1998) Tetrahedron, 54, 15273. 
286 Norris, K., Halstrom, J., and Brunfeldt, K. (1971) Acta Chemica Scandinavica, 25, 945. 
287 Iselin, B. (1961) Helvetica Chimica Acta, 44, 61. 
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4.1.1.8 Serine and Threonine  
 
The side reactions affecting unprotecded hydroxyl group of Ser, Thr and Tyr 
side chains, under the standard synthetic conditions used in peptide 
chemistry, are less severe compared to amino and carboxylic function. As a 
consequence a number of synthesis describing unprotected amino acid 
incorporation has been reported, especially in the past. However unprotected 
hydroxyl groups can suffer acylation and dehydratation and it is therefore 
normal practice to protect them. 
Ser and Thr have very similar behaviour and characteristics but the minor 
steric hindrance of the former’s hydroxyl makes it more easy to protect but 
also more reactive toward acylating reagents.   
The classical protection of such amino acids is tBu removed under strong 
acidic conditions288.Selective deprotection of hydroxyl side chains is often 
performed during post-synthetic modification of Ser and Thr, especially with 
phosphorylation and glycosylation. This can be achieved by the trytyl 
protection, removed orthogonally from tBu and Boc under mild acidic 
conditions, 1%TFA and 5% TIS in DCM289 or 20% dichloroacetic acid in 
DCM290. Another acid-lable group is t-butyldimethylsilyl (TBDMS) 54 
which can be removed with AcOH/THF/H2O/ 3:1:1291.  
 
 
                                                 
288 Chang, C., Waki, M., Ahmad, M., Meienhofer, J,. Lundell, E., and Huang, J. (1980) 
International Journal of Peptide and Protein Research, 15, 59. 
289 Barlos, K., Gatos, D., and Koutsogianni, S. (1998) Journal of Peptide Research, 51, 194. 
290 Coba, M.P., Turyn, D., and Pena, C. (2003) Journal of Peptide Research, 61,17. 
291 Fisher P. (1992) Tetrahedron Letters, 33, 7605. 
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The photocleavable 4,5-dimethoxy-2-nitrobenzyl group292 55 has been used 
for Serine protection. Finally Ser and Thr side chains can be protected as 
benzyl esthers, removed with TFA.  
 
                                                 
292 Pirrung, M.C. and Nunn, D.S. (1992) Bioor. Med. Chem. Lett, 2, 1489. 
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4.1.1.9 Tryptophan 
 
The two main side reactions affecting Tryptophan residues in Fmoc-
chemistry are oxidation and alkylation of the indole ring by carbonium ions 
generated during the TFA cleavage293. Alkylation of unprotected Tryptophan 
could be kept under control by using EDT as a cleavage mixture 
scavenger294. However sulfonation by the by-products of Mtr, Pmc and Pbf 
protected Arginines cannot be completely eliminated. This problem has been 
solved by developing t-butoxycarbonyl (Boc) protected Trp295, which 
generates after the cleavage step a TFA stable-N-carboxy indole 
intermediate, capable of reducing the susceptibility of the heterocyclic ring to 
the electrophilic attack296 (Scheme 4.1-4). The carbamic acid derivate, 
associated with a 44 mass unit gain, is not stable in solution and decomposes 
slowly in water during the routine work-up stages, leaving the indole ring 
free. 
 
Scheme 4.1-4 Mechanism of Trp(Boc) deprotection. 
 
                                                 
293 Fields, C. and Fields, G. (1993) Tetrahedron Letters, 34, 6661. 
294 Fields, G., Noble, R. (1990) International Journal of Peptide and Protein Research, 35, 
161. 
295 White, P. (1992) In Peptides, Chemistry, Structure and Biology, Pro. 12th American 
peptide Symposium, J.A. Smith and J.E.Rivier(Eds.), ESCOM, Leiden, 537. 
296 Franzen, H., Grehn, L., Ragnarsson, U. (1984) Journal of the Chemical Society, Chemical 
Communications, 1699. 
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Tryptophan can also suffer partial reduction by triethylsilane used as a 
scavenger of trityl groups297 and is affected by the presence of silver salts 
(used for removal of several Cysteine-protecting groups). The latter side 
effect can be avoided by adding an excess of free Tryptophan in the 
deprotection mixture298 
Also the allyloxycarbonyl (Alloc) protection eliminates the oxidation-
alkyklation problems and, although unstable to 20% piperidine, it is stable to 
DBU that needs therefore to be used for Fmoc removal299. 
Recently a new TFA stable Tryptophan protection has been proposed, 4-(N-
methylamino)butanoyl (Nmbu), whose function is to improve the solubility 
of the peptides in view of HPLC purification300. Nmbu is stable to TFA 
cleavage and on treatment of the purified peptide at pH 9.5 it undergoes an 
intramolecular cyclization reaction (Scheme 4.1-5) that results in the fully 
deprotected peptide and N-methylpyrrolidone. 
 
Scheme 4.1-5 Mechanism of Trp(Nmbu) deprotection. 
 
                                                 
297 Pearson, D., Blanchette, M., Guindon, C. (1989) Tetrahedron Letters, 30, 2739. 
298 Najib, J., Letailleur, T., GesQuire, J., Tartar, A. (1996) Journal of Peptide Science, 2, 309. 
299 Vorherr, T., Trzeciak, A., Bannwarth, W., (1996) International Journal of Peptide and 
Protein Research, 48, 553. 
300 Wahlström, K. and Undén, A.  (2009) Tetrahedron Letters, 50, 2976. 
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4.1.1.10 Tyrosine 
 
Tyrosine side chain, if left unprotected during the peptide synthesis, is prone 
to O-acylation because the basic conditions of Fmoc removal generates the 
phenolate anion which is acylated due to its strong nucleophilicity. Tyrosine 
is commonly protected with tBu group301, which generates very little of the 
3-alkylated product (see side reaction section).  
The TBDMS ether protection 56, although less acid-labile than the 
corresponding analogs of Serine and Threonine, can nethertheless be 
removed selectively using tetrabuthylammonium fluoride (TBAF)291. 
 
Despite some misunderstandings302, the 2,4-dinitrophenyl (Dnp) group 57, 
deprotect with 2-thiophenol/pyridine/DMF 2:1:10, is another suitable choice 
for Tyrosine selective protection as for example during on resin post-
synthetic modifications (such as phosphorilation or glycosylation). However 
since Dnp is readily cleaved by 20% piperidine or 2 % DBU in DMF303, 
Dnp-protected Tyrosine should be employed as the N-terminal residue or 
could be immediately modified after incorporation. Another possibility is 
                                                 
301 Adamson, J., Blaskowitch, M., Groenvelt, H., Lajoie, G. (1991) The Journal of Organic 
Chemistry, 56, 3447. 
302 Doherty-Kirby, A., Lajoie, G. In Solid-Phase Synthesis A Practical Guide (2000), Kates, 
S.A. and Albericio F., Marcel Dekker Inc, 148. 
303 Philosof-Oppenheimer, R., Pecht, I., Fridkin, M. (1995) International Journal of Peptide 
and Protein Research, 45, 116. 
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using the more flexible 2-ClTrt group 58 that can be selectively removed any 
time of the synthesis with 1% TFA / 5% TIS in DMF289.  
Same photo-cleavable Tyrosine protecting groups have been reported, 
particularly useful for the synthesis of those molecular devices whose 
activity is controlled by light (caged compounds). One example is the 2-
nitrobenzyl group (NB) 59, removed by UV light304 (Scheme 4.1-6). Upon 
irradiation the exited nitro compound abstracts a hydrogen from the benzylic 
position and the intermediate rapidly rearranges into a nitoso hemiacetal  
 
 
Scheme 4.1-6 Mechanism of Tyr(NB) deprotection. 
 
                                                 
304 Tatsu, Y., Shigeri, Y., Sogabe, S., Yumoto, N., and Yoshikawa, S. (1996) Biohemical and 
Biophysical Research Communications, 227, 688. 
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5 EXPERIMENTAL PART A 
5.1 Materials and methods 
The chemicals were purchased from Sigma-Aldrich and used without further 
purification. TLC were carried out on silica gel precoated plates (Merck; 60 
Å F254) and spots located with: (a) UV light (254 and 366 nm), (b) 
ninhydrin (solution in acetone), (c) Cl2/toluidine, (d) fluorescamine, (e) I2, (f) 
a basic solution of permanganate [KMnO4 (3 g), K2CO3 (20 g), and NaOH 
(0.25 g) in water (300 ml)], (g) 10% H2SO4 in EtOH. Flash Column 
Chromatography (FCC) was performed on Merck silica gel 60 (230-400 
mesh) according to Still et al.305 
1H and 13C NMR spectra were recorded at 400 and 100 MHz, and 200 and 50 
MHz respectively, on a Varian spectrometer in deuterated solutions and are 
reported in parts per million (ppm), with solvent resonance used as reference. 
Melting points were determined on a Büchi mod. 510 apparatus. Elemental 
analyses were performed on a Perkin Elmer 240 C Elemental Analyzer. 
Infrared spectra were recorded on a Perkin Elmer mod. BX II FT-IR 
spectrometer. The [α]D were obtained on Perkin Elmer mod. 343 polarimeter 
in cell of 1 dm. Products were analyzed and characterized by ACQUITY 
UPLC (Waters Corporation, Milford, Massachusets) coupled to a single 
quadrupole ESCI-MS (Micromass ZQ) using a 2.1 x 50 mm 1.7 μm 
ACQUITY BEH C18 at 30 °C, with a flow rate of 0.45mL/min. The solvent 
systems used were A (0.1% TFA in H2O) and B (0.1% TFA in CH3CN). 
High performance liquid chromatography -grade acetonitrile (MeCN) was 
purchased from Carlo Erba (Italy). 
                                                 
[305] Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
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Protected amino acids were obtained from Novabiochem AG (Laufelfingen, 
Switzerland). TBTU and HOBt were purchased from Iris-Biotech. Peptide-
synthesis grade N,N-dimethylformamide (DMF) was purchased from 
Scharlau (Barcelona, Spain). TFA, DCM, Piperidine, Ac2O, and NMM were 
purchased from Aldrich.  
Peptides were analyzed by analytical RP-HPLC (Alliance, model 2695 
equipped with a diode array detector, Waters) using a Jupiter C18 (5 μm, 250 
× 4.6 mm) column (Phenomenex) at 1 mL/min. The solvent systems used 
were A (0.1% TFA in H2O) and B (0.1% TFA in CH3CN). Peptides were 
purified by preparative RP-HPLC (model 600, Waters) on a Jupiter C18 or 
C8 column (10 μm, 25 cm × 10 mm) at 4 mL/min by using the same solvent 
systems reported above.  
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5.2 Glycated building blocks for the synthesis of post-
translationally modified glycated peptides and proteins 
5.2.1 Nα-Fmoc-Lys[Nε-(Deoxyfructopyranosyl)]-OH 
Nα-Fmoc-Lys-OH (1 g, 2.71 mmol, 1 eq) and D-glucose (1.22 g, 6.77 mmol, 
2.5 eq) were suspended in 40 ml of anhydrous DMF under N2 atmosphere70. 
The reactionmixture was thenwarmed at 110 ◦C for about 10 min: Fmoc-Lys-
OH dissolved and before the colour of the reaction mixture changed from 
yellow to brown (index of diglycation), the solution was immediately cooled 
in an ice bath. DMF was evaporated under vacuum and the crude residue was 
purified by RP-FC using a gradient 15–40% B in A over 20 min, elution 
occurred at 25% B. Homogeneous fractions were then evaporated and the 
water solution lyophilized yielding pure 1a as a white, highly hygroscopic 
solid (390 mg, 67%).  
LC-ESI-MS (m/z): [M+H]+ calcd for C27H34N2O9 531.23; found, 531.38. 
M.p.= 115°C (caramelization and decomposition were observed). [α]26D = 
−20.70 (c = 1.015, H2O). Elemental analysis calcd for C27H34N2O9 
·TFA·H2O: C, 49.86; H, 5.92; N, 4.01; found: C, 49.88; H, 6.26; N, 4.10. 
1H NMR (D2O, 400 MHz): δ 7.2 ( broad s, 4H, fluorenyl 4-H, 5-H, 1-H and 
8-H), 6.9 (broad s, 4H, fluorenyl 3-H, 6-H, 2-H and 7-H),  4.1-3.9 (m, 2H, 
CH2, Fmoc), 3.85 ( broad s, CH Fmoc) 3.8 (broad s,CHα, Lys), 3.8-3.7 (m, 
CHOHx3, 1-deoxyfructosyl),  3.6 (t, 2H, J=10.0 Hz, 1-deoxyfructosyl), 3.1-
2.9 (m,CH2NH, 1-deoxyfructosyl), 2.8-2.6 (m, CH2ε, Lys), 1.6-1.2 (m, 4H, 
CH2β,δ), 1.1-0.8 (m, CH2γ, Lys) 
13C NMR (CDCl3, 50 MHz) δ 175.8 (C, COOH), 162.7 (q, J=35.4 Hz, C, 
COOH, TFA), 157.1 (C, CONH, Fmoc), 116.3 (q, J=291.0 Hz, CF3, TFA), 
143.2 (CHAr x2, Fmoc), 140.6 (CHAr x2, Fmoc), 127.5 (CHAr x2, Fmoc), 
126.9 (CHAr x2, Fmoc), 124.7 (CHAr x2, Fmoc), 119.7(CHAr x2, Fmoc), 95.3 
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(C4, C1 1-deoxyfructosyl), 69.5, 69.3, 68.9 (CHOH x3, 1-deoxyfructosyl), 
69.4 (CH2, 1-deoxyfructosyl), 63.9 (CH2, Fmoc), 53.9, 52.8 (CH2NH 
ideoxyfructosyl, Cα Lys) 48.0 (CH2ε, Lys), 46.7 (CH, Fmoc), 30.5 (CH2β, 
Lys), 24.8 (CH2γ, Lys), 22.2 (CH2δ, Lys). 
 
5.2.2 Nα-Fmoc-Lys[Nε-(Deoxyfructopyranosyl),Nε-Boc]-OH 
A solution of Boc2O (514 mg, 2.35 mmol, 2.5 eq) in 5 mL of MeOH was 
added, in N2 atmosphere, under stirring at 0° C, to a solution of 1a (500 mg 
0.94 mmol, 1eq). The reaction was left under stirring at rt for 1.5 h and then 
the solvent was evaporated and the residue purified by RP-FC with a linear 
gradient of 30-55% B in A over 20 min. Elution occurred at ~50% B. 
Homogeneous fractions were then evaporated and the water solution 
lyophilized yielded pure 1 as a white hygroscopic solid (270 mg, 45%). 
LC-ESI-MS (m/z): [M+Na]+ calcd for C32H42N2O11 653.28; found, 653.26. 
M.p. = 105°-106°C. [α]26D = − 16.18 (c = 0.94, MeOH). Elemental analysis 
calcd for C32H42N2O11·5H2O: C, 53.32; H, 7.27; N, 3.88; found: C, 53.03; H, 
7.09; N, 4.09. 
1H NMR (CDCl3, 400 MHz): δ 7.8-7.6 (m, 2H, fluorenyl 4-H, 5-H), 7.6-7.4 
(m, 2H, fluorenyl 1-H and 8-H), 7.4-7.2 (m, 4H, fluorenyl 3-H, 6-H, 2-H and 
7-H),  4.5-4.3 (m, 2H, CH2, Fmoc), 4.3-4.1 ( m, 2H, CH Fmoc and CHα Lys), 
4.1-3.8 (m, CHOHx3, 1-deoxyfructosyl),  3.8-3.5 (m, 1-deoxyfructosyl), 3.5-
2.9 (m, 4H, CH2NH 1-deoxyfructosyl and CH2ε Lys), 2.0-1.4 (m, 4H, 
CH2β,δ), 1.4 (s, CH3x3, Boc), 1.4-1.0 (m, CH2γ, Lys). 
13C NMR (CDCl3, 50 MHz) δ 174.9 (C, COOH), 158.5 (C, CONH, Boc), 
156.0 (C, CONH, Fmoc), 143.5 (CHAr x2, Fmoc), 141.1 (CHAr x2, Fmoc), 
127.6 (CHAr x2, Fmoc), 127.0 (CHAr x2, Fmoc), 125.0 (CHAr x2, Fmoc), 
119.9 (CHAr x2, Fmoc), 98.7 (C4, C1 1-deoxyfructosyl), 81.4 (C4, Boc), 70.6, 
70.1, 69.5 (CHOH x3, 1-deoxyfructosyl), 67.2 (CH2, 1-deoxyfructosyl), 63.3 
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(CH2, Fmoc) 54.6, 53.6 (CH2NH ideoxyfructosyl, Cα Lys) 50.0 (CH2ε, Lys), 
47.2 (CH, Fmoc), 31.9 (CH2β, Lys), 28.5 (CH3x3, Boc), 27.8 (CH2δ, Lys), 
22.2 (CH2γ, Lys). 
 
5.2.3 Nα-Fmoc-Lys[Nε-(2,3:4,5-Di-O-Isopropylidene-1-
Deoxyfructopyranosyl)]-OH 
A fresh solution of NaCNBH3 (600 mg, 9.5 mmol, 2.5eq) in 5 mL H2O/THF 
(1:1, v/v) was added to a stirred solution of Nα-Fmoc-Lys-OH (1.4 g, 3.8  
mmol, 1eq) and 2,3:4,5-di-O-isopropylidene-aldehydo-β-D-arabino-hexos-2-
ulo-2,6-pyranose70,71,72 (2.45 g, 9.5 mmol, 2.5eq) in 15 mL H2O/THF (1:1, 
v/v) under N2 at 50° C. After 4h the solvent was removed under reduced 
pressure and the crude product was purified by RP-FC, eluted with the linear 
gradient 30-50% B in A over 20 min (eluted at ~37% B). The homogeneous 
fractions were pooled, evaporated and liophylized yielding the pure 2a as a 
white solid (500 mg, 22 %). 
LC-ESI-MS (m/z): [M+H]+ calcd for C33H42N2O9 611.29; found, 611.17. 
M.p.= 92°-93°C. [α]26D= −12.04 (c= 0.89, MeOH). Elemental analysis calcd 
for C33H42N2O9 ·TFA ·2H2O: C, 55.26; H, 6.23; N, 3.68; found: C, 55.35; H, 
6.15; N, 3.39. 
1H NMR (CDCl3, 400 MHz): δ 7.74 (d, 2H, J= 7.4 Hz, fluorenyl 4-H and 5-
H), 7.59 (d, 2H, J = 7.4 Hz, fluorenyl 1-H and 8-H), 7.37 (t, 2H, J= 7.4 Hz,  
fluorenyl 3-H and 6-H), 7.28 (t, 2H, J= 7.4 Hz,  fluorenyl 2-H and 7-H), 5.85 
(broad d, NHα), 4.65-455 (m, CH Fmoc), 4.4-4.3 (3H, CH2, Fmoc and CHα 
Lys), 4.25-4.15 (m, CHOHx3, 1-deoxyfructosyl),  3.8-3.7 (m, CH2 1-
deoxyfructosyl), 3.35-3.30 (m, CH2NH 1-deoxyfructosyl), 3.30-3.20 (m,CH2ε 
Lys), 1.95-1.65 (m, 4H, CH2β,δ) 1.5-1.45 (m, CH2γ, Lys) 1.47, 1.41, 1.33, 
1.28 (s, CH3x4, isopropylidene). 
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13C NMR (CDCl3, 50 MHz) δ 174.5 (C, COOH), 161.9 (q, J=38.2 Hz, C, 
COOH, TFA), 156.2 (C, CONH, Fmoc), 116.5 (q, J=290.9 Hz, CF3, TFA), 
143.6 (CHAr x2, Fmoc), 141.1 (CHAr x2, Fmoc), 127.6 (CHAr x2, Fmoc), 
127.0 (CHAr x2, Fmoc), 125.1 (CHAr x2, Fmoc), 119.8 (CHAr x2, Fmoc), 
110.0 (C4, isopropylidene), 109.3 (C4, isopropylidene), 99.56 (C4, C1 1-
deoxyfructosyl), 72.2, 70.3, 69.6 (CHOH x3, 1-deoxyfructosyl), 67.1 (CH2, 
1-deoxyfructosyl), 61.58 (CH2, Fmoc) 54.3, 53.7 (CH2NH ideoxyfructosyl, 
Cα Lys) 48.7 (CH2ε, Lys), 47.2 (CH, Fmoc), 31.7 (CH2β, Lys), 26.1, 25.9, 
24.6, 24.1 (CH3x4, isopropylidene), 25.5 (CH2γ, Lys), 22.0 (CH2δ, Lys). 
 
5.2.4 Nα-Fmoc-Lys[Nε-(2,3:4,5-Di-O-Isopropylidene-1-
Deoxyfructopyranosyl),Nε-Boc]-OH 
A stirred solution of 2a (500 mg 0.81 mmol, 1eq) in methanol (5 mL) at 0° C 
was treated with Boc2O (445 mg, 2.07 mmol, 2.5 eq). The reaction was left 
stirring at rt for 1.5 h and then the solvent was evaporated and the residue 
purified by RP-FC employing a linear gradient of 50-100% B in A over 20 
min (the product 2 eluted at ~70% B). Acidification of the concentrate, 
obtained after evaporation of acetonitrile from the pooled fractions, to pH 3 
with acetic acid, resulted in a white precipitate that was filtered off, washed 
with water and dried under vacuum. The pure 2 was obtained as a white solid 
(390 mg, 67 %). LC-ESI-MS (m/z): [M+H]+ calcd for C38H50N2O11 711.34; 
found, 711.43. M.p.= 97-98° C. [α]26D= −16.97 (c= 1.03, MeOH). Elemental 
analysis calcd for C38H50N2O11 ·H2O: C, 62.62; H, 7.19; N, 3.84; found C, 
62.56; H, 7.29; N, 3.84.  
1H NMR (CDCl3, 400 MHz): δ 7.75 (d, 2H, J= 7.4 Hz, fluorenyl 4-H and 5-
H), 7.59 (d, 2H, J = 7.4 Hz, fluorenyl 1-H and 8-H), 7.38 (t, 2H, J= 7.4 Hz,  
fluorenyl 3-H and 6-H), 7.30 (t, 2H, J= 7.4 Hz,  fluorenyl 2-H and 7-H), 5.45 
(broad d, NHα), 4.6-4.55 (m, CH Fmoc), 4.50-4.5 (m, CHα Lys), 4.45-4-30 
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(m, CHORx3, 1-deoxyfructosyl), 4.25-4.15 (m, CH2 Fmoc) 3.75-3.60 (m, 
CH2 1-deoxyfructosyl), 3.35-3.25 (m, CH2NH 1-deoxyfructosyl), 3.35-2.25 
(m,CH2ε Lys), 2.00-1.70, 1.55-1.45, 1.35-1.25 (m, 6H, CH2β,δ,γ, Lys) 1.44 (s, 
CH3x3, Boc),1.50, 1.47, 1.34, 1.31 (s, CH3x4, isopropylidene).  
13C NMR (CDCl3, 50 MHz) δ 175.5 (C, COOH), 159.1 (C, CONH, Boc), 
156.1 (C, CONH, Fmoc), 143.7 (CHAr x2, Fmoc), 141.1 (CHAr x2, Fmoc), 
127.6 (CHAr x2, Fmoc), 127.0 (CHAr x2, Fmoc), 125.0 (CHAr x2, Fmoc), 
119.8 (CHAr x2, Fmoc), 108.8 (C4, isopropylidene), 108.0 (C4, 
isopropylidene), 104.5 (C4, C1 1-deoxyfructosyl), 80.8 (C4, Boc),  71.4, 70.7, 
70.5 (CHOH x3, 1-deoxyfructosyl), 67.2 (CH2, 1-deoxyfructosyl), 61.3 
(CH2, Fmoc), 53.9, 51.4 (CH2NH ideoxyfructosyl, Cα Lys) 48.5 (CH2ε, Lys), 
47.3 (CH, Fmoc), 32.5 (CH2β, Lys), 28.6 (CH3x3, Boc), 27.4 (CH2δ, Lys), 
26.4, 26.1, 25.1, 24.1 (CH3x4, isopropylidene), 22.7 (CH2γ, Lys). 
 
5.3 Synthesis of a glycated hCD59 antigen 
5.3.1 Synthesis of hCD59(37-50) peptide analogs  
Intermediate peptide I and II for post-synthetic modifications and 
peptide III (stepwise synthesis) were synthesized by SPPS according 
to the methodologies described in chapter 5.6 (Table 5.3-1)  
 
 Sequence and side chain protections 
I Ac-N(Trt)-K(Boc)-A-W(Boc)-K(ivDde)-F-E(OtBu)-H(Trt)-A-N(Trt)-F-N(Trt)-D(OtBu)-C(Trt)-OH  
II Ac-N(Trt)-K(ivDde)-A-W(Boc)-K(Boc)-F-E(OtBu)-H(Trt)-A-N(Trt)-F-N(Trt)-D(OtBu)-C(Trt)-OH 
III Ac-N(Trt)-K(Boc)-A-W(Boc)-K*-F-E(OtBu)-H(Trt)-A-N(Trt)-F-N(Trt)-D(OtBu)-C(Trt)-OH 
Table 5.3-1 Peptide analogs for the convergent synthesis of glycated hCD59(37-50) 
antigen. K* is Fmoc Lysine derivate 2 (section 5.2.4). 
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5.3.2 On resin direct glycation  
The peptide I was synthesized by SPPS and acetylated according to the 
procedures described in section 5.6. Residue 41 was then deprotected from 
ivDde by treatment with hydrazine 2% in DMF for 10min. This removal was 
repeated 3 times and monitored by LCMS (ivDde deprotection-product 
mass=221) obtaining intermediate peptide Ia. Direct glycation was 
performed on resin with a 40-fold excess (base on the resin substitution) of 
Glucose under stirring at 110 C and N2 atmosphere in DMF, stopped after 45 
min. The reaction was monitored with microcleavage LCMS analysis, linear 
gradient of 10-20% B in A over 15 min, Rt=4.66 for peptide III  
The mass spectrometry shows the presence of un-glycated peptide and of an 
overall poor conversion of the free epsilon amino into the Amadori form due 
to the presence of undesired oxidation reactions and di-glycation. 
 
[M+H]+= 1927.2  [M+H]2+= 963.96  glycated product 
[M+H]+= 1765    [M+H]2+= 883  un-glycated product 
[M+H]+= 1969.5  [M+H]2+= 985  oxidation-product 
[M+H]+= 2089   [M+H]2+= 1045  di-glycated-product 
 
The crude peptide was purified by flash chromatography Waters delta 
prep3000, delta-pak cartridge C18 15 microm, 300 Angstrom 2inc (diam) x 
12 inc, 50 mL/min HPLC analysis using a very shallow gradient shown 
indeed two peaks (glycated and un-glycated with the oxidation product, of 
mass 985, present in both. Further purification by semi-preparative reverse 
phase HPLC using very shallow and isocratic gradients was unsatisfactory in 
terms of yield due to the poor separation of the two forms (glycated and un-
glycated).  
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5.3.3 On resin reductive amination  
Peptide I was treated as in 5.3.2 achieving intermediate peptide Ia and the 
Amadori modification was  on Lys 41 by reductive amination treating the 
peptidyl-resin with a 25-fold molar excess of 2,3:4,5-di-O-isopropylidene-β-
D-arabino-hexos-2-ulo-2,6-pyranose and NaCNBH3 2.5 eq in DMF (1mL/g 
of peptidyl-resin) at 70 C under N2 atmosphere and left under agitation for 
4h. The reaction was monitored by LCMS of minicleavages of 2-3 mg of 
resin using reagent R ( TFA:Aniso:Thioanisol:Ethandithiol 90:5:3:2 v/v). 
Cleavage from the resin and work up according to 5.6. LCMS showed 
presence of partially protected isopropylidene so the crude peptide was 
treated with TFA/TIS (95:5) and precipitated in cold ether after 2 h. The 
crude peptide was purified as in 5.3.2. Purified peptide, LCMS linear 
gradient of 10-60% B in A over 20 min, Rt= 4.58 min. The peak appeared in 
the first place to correspond to a pure product by LCMS analysis show it was 
a mixture of glycated ([M+H]2+= 963.9) and non-glycated peptide 
([M+H]2+= 883.1) HPLC analysis using a very shallow gradient shown 
indeed two peaks. Under the described conditions we were unable to 
glycated all the free epsilon-amino groups, at least 40% of them remained 
un-glycated. Under more vigorous conditions as higher T, reaction time and 
excess of reactants the amount of glycated product increased but di-glycation 
was seen to a significant extent. Further purification by semi-preparative 
reverse phase HPLC using very shallow and isocratic gradients was 
unsatisfactory in terms of yield due to the poor separation of the two forms 
(glycated and un-glycated). To solve the problem of isolating the glycated 
product from the non-glycated a purification using a phenyl-boronic column 
was attempted with good results in terms of separation but with poor yield 
due to the low loading capacity of those columns.  
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5.3.4 In solution direct glycation  
Peptide II was synthesized by SPPS, acetylated and cleaved from the resin 
according to the procedures described in section 5.6 obtaining intermediate 
peptide IIa. To a solution of IIa, with position 38 ivDde protected, a 40-fold 
excess of Glucose was added under stirring at 110 C and N2 atmosphere. 
Under this temperature conditions the peptide was found to be not stable. At 
lower temperature the stability increases but the glycation rate is much lower 
and that leaves the problem to separate the glycated product from the un-
glycated one. After purification as in as in 5.3.2 a solution of glycated 
peptide III was treated with 2% hydrazine in DMF 5min repeated three times 
to removed ivDde. The Amadori modification was found to be very 
susceptible to hydrazine. Degradation occurred at >2% or even 2% during 
liophylization. In conclusion it has been impossible to removed ivDde in 
presence of the unprotected Amadori modification without completely 
destroying the sugar moiety.  
 
5.3.5 In solution reductive amination  
Peptide II was treated as in 5.3.45.3.2 achieving intermediate peptide IIa. 
Reductive amination was performed on peptide IIa with a 25-fold molar 
excess of 2,3:4,5-di-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose 
and NaCNBH3 2.5 eq in DMF (1mL/mg of peptide) at 70 C under N2 
atmosphere and left under agitation. The reaction was monitored by LCMS 
and stopped after 20 min. Purification as in 5.3.2. Purified glycated peptide 
IIa was deprotection from ivDde as in 5.3.4. The resulting solution was 
purified again as in 5.3.2. The purified peptide was dissolved in 2mL  
TFA/H2O/TIS (95:2.5:2.5) in order to removed the isopropylidene 
protections affording peptide III. 
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Starting material (intermediate peptide IIa) [M+H]+ =1970 
[M+2H]2+=986.4 [M+3H]3+=658; Glycated peptide III protected [M+H]+ 
=2214 [M+2H]2+=1107.5 [M+3H]3+=738.8; Glycated peptide III (glycated 
peptide, OH free) [M+H]+ =1927.4 [M+2H]2+=964.2 [M+3H]3+=643.2. 
 
5.3.6 Step-wise synthesis by building block approach of Nα-
Ac[Lys41(Nε-1-deoxyfructosyl)]hCD59(37-50)-OH (III) 
Peptide III was synthesized by SPPS, acetylated and cleaved from the resin 
according to the procedures described in section 5.6. The Amadori 
modification in position 41 was stepwise using the glycated Fmoc Lysine 
derivate, 2 (Nα-Fmoc-Lys[Nε-(2,3:4,5-di-O-isopropylidene-1-
deoxyfructosyl,Nε-Boc)] OH ) affording the desired with excellent yield 
The other three synthesized Amadori s, without Boc protection in the ε-NH2 
2a or without isopropylidene protection on the sugar hydroxyls 1 and 1a, 
were successfully incorporated into the peptide sequence with Fmoc SPPS 
strategy. However attempts to couple the subsequent amino acids failed. 
After the standard TFA cleavage the peptide was still partially 
isopropylidene protected and displays three main peaks, corresponding to di-
isopropylidene protected, mono-isopropylidine protected and glycated 
product. To completely remove the isopropylidene protection, additional 
TFA treatment was required (95% TFA, 5% TIS) for 3h. 
The crude product was purified as in in 5.3.2. 
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5.4 Immunological studies 
5.4.1 General procedure for solid-phase non competitive indirect 
ELISA (SP-ELISA) 
Antibody titers were determined in SP-ELISA.306 96-Well activated 
Polystyrene ELISA plates (Limbro Titertek, ICN Biomedicals, Inc., Aurora, 
Ohio, USA) were coated with 1 μg/100 μl/well of peptides or glycopeptides 
in pure carbonate buffer 0.05 M (pH 9.6) and incubated at 4 °C overnight. 
After 5 washes with saline containing 0.05% Tween 20, non-specific binding 
sites were blocked by Fetal Calf Serum (FCS), 10% in saline Tween (100 
μl/well) at r.t. for 60 minutes. Sera diluted from 1:100 to 1:100.000 were 
applied at 4 °C for 16 h in saline Tween 10% FCS. After 5 washes, we added 
100 μl/well of alkaline phosphatase conjugated anti human IgM or IgG Fab2-
specific affinity purified antibodies (Sigma, St. Louis, Missouri, USA) 
diluted 1:500 in saline Tween/FCS. After an overnight incubation and 5 
washes, 100 μl of substrate solution consisting of 2 mg/mL p-
nitrophenylphosphate (Sigma, St. Louis, Missouri, USA) in 10% 
diethanolamine buffer was applied. After 30 minutes, the reaction was 
blocked with 50 μl of 1 M NaOH and the absorbance read in a multichannel 
ELISA reader (SUNRISE, TECAN, Austria) at 405 nm. ELISA plates, 
coating conditions, reagent dilutions, buffers, and incubation times were 
tested in preliminary experiments. Each serum was individually titrated to 
check for parallelism of antibody absorbances in dilutions. Within-assays 
and between-assays coefficient of variations were below 10%. Subclass 
specific anti-IgG conjugates (IgG1, IgG2, IgG3, IgG4, Southern Biotech, 
Birmingham, AL, USA) were used to detect the IgG-antibodies subclasses in 
                                                 
306 Loomans, E.E., Gribnau, T.C., Bloemers, H.P., Schielen, W.J. (1998) J. Immunol. 
Methods, 221, 119. 
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parallel experiments. The antibody levels revealed by SP-ELISA are 
expressed both as antibody titer (sample dilution which reaches the average 
plus three standard deviations of blanks) and as absorbance value at a 
dilution of 1:100 as a ratio of positive controls in the same experiment. 
Positive samples were analysed twice to evaluate the differences between the 
two determinations. The references values were set as the mean + 2 SD of 
the control groups. Within- and between-assays coefficients of variations 
were below 10%. 
 
5.4.2 Coating e blocking optimization 
The ELISA plats were coated in with 10 and 20 μg/mL of peptides dilloved 
in PBS buffer (pH 7.2) and carbonate buffer (pH 9.6). Each plate was then 
treated with two kind of blocking agents BSA 3% and FBS 5% in PBS 
buffer. A reduced number of helthy blood donors and patient sera was tested 
under this conditions as described in section 5.4.1. The best coating/blocking 
conditions for each peptide were those that lowered the most the Abs values 
for helthy blood donors compare to the patient sera 
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5.5 Protein synthesis by Chemical Ligation  
5.5.1 Synthesis of the Bio-PEG-Spacer-hCD59(1-77) fragments for 
NCL 
The seven fragments for the tandem NCL assembly of Bio-PEG-Spacer-
hCD59(1-77) (XVI) glycated and wild type (XVII) (Table 5.5-1) were 
synthesized according to the procedures described in chapter 5.6. The C 
terminal fragment IX was obtained using Wang resin and left with the N-
terminal Cysteine unprotected.  
Fragments from X to XV were synthesized on 2-Cl-Trityl resin which 
allowed a diluted acid cleavage of the peptides with all the positions 
protected but the C-terminal carboxylic function. All those sequences have 
an N-terminal Cysteine masked as a thiazolidine except product XV whose 
N-terminal residue was coupled to a biotin-PEG3500 residue. A glycated 
Lysine residue was in position 41 of peptide X using the glycated Fmoc 
Lysine 2. After cleavage the crude was coupled with an excess of p-
acetamidothiophenol/HOBt/DIPEA (2:4:4) in acetonitrile to afford the 
corresponding fully protected C-terminal p-acetamidothioester peptides 
(Thz-peptide-COSR) in good yields. The crudes were purified by direct 
phase flash chromatography and then deprotected of the side chain 
protections with a standard concentrated TFA cleavage affording the 
corresponding C-ter thioester/N-ter thiazolidine peptides free of side chain 
protections that were purified by reverse phase flash chromatography. 
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IX H-45CNFNDVTTRLRENELTYYCCKKDLCNFNEQLE77N-OH 
X Thz-39CWK*FE44H-COSR 
XI Thz-39CWKFE44H-COSR 
XII Thz-26CLITKAGLQVYN38K-COSR 
XIII Thz-13CKTAVNCSSDFD25A-COSR 
XIV Thz-3CYNCPNPTA12D-COSR 
XV BioPEG3500-GGSSGIEGRIEGR1LQ-COSR 
Table 5.5-1 Fragments for fragments for the tandem NCL assembly of Bio-PEG-
Spacer-hCD59(1-77) (XVI) glycated and wild type (XVII). 
 
5.6 Solid Phase Peptide Synthesis 
5.6.1 General procedure for in batch and manual SPPS  
Peptides were synthesized on a manual batch synthesizer (PLS 4×4, 
Advanced ChemTech) using a Teflon reactor (10 mL), following the 
Fmoc/tBu SPPS procedure. The resin was swelled with DMF (1 mL/100 mg 
of resin) for 20 min before use. 
Peptide synthesis was performed repeating the cycle described as following 
for each amino acid: 
− Swelling: DMF (1 mL/100 mg of resin) for 5 min 
− Fmoc-deprotection: resin is washed twice with 20% piperidine in 
DMF (1 mL/100 mg of resin, one wash for 5 min followed by an 
other wash for 20 min); 
− resin-washings: DMF (3×5 min); 
− coupling: scale employing TBTU/HOBt/NMM (2.5eq.:2.5 eq.:3.5 
eq.) as the coupling system and 2.5 eq. of the Fmoc protected amino 
acids, except for Xaa and Yaa (1.5 eq.), in DMF (1 mL/100 mg of 
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resin) for 40 min. Each coupling was checked by Kaiser test;307 in 
our case all tests were negative therefore it was not necessary to 
repeat the coupling reaction. 
− resin-washings: DMF (3×5 min) and DCM (1×5 min).  
 
Kaiser test procedure: to a small amount of peptide-resin placed in a test 
tube, three drops for each of the following solutions were added: ninhydrin 
(5 g) in ethanol (100 mL); phenol (80 g) in ethanol (20 mL); KCN (2 mL of 
1 mM aqueous solution) in pyridine (98 mL). The tube is heated at 100 °C 
for 5 min. A positive test (resin beads and solution appears strongly blue-
violet) states the presence of at least 5% free amino groups. 
 
5.6.2 General procedure for peptide acetylation 
The amine functions of the N-terminal fragment of peptides were acetylated 
in 2 cycles: the first one in 30 minutes followed by the second one in 1.5 
hour using Ac2O/ NMM as reagents. The reaction was monitored by Kaiser 
test. 
 
5.6.3 General procedure of deprotection, cleavage and purification 
of free peptide 
Peptides cleavage from the resin and deprotection of the amino-acids side 
chains were carried out with TFA/anisole/1,2-ethanedithiol/phenol/H2O 
solution (94:2:2:2:2 v/v/v/v/v). The cleavage was maintained for 3 h with 
vigorous stirring at room temperature. Resins were filtrated and washed with 
TFA. After partial evaporation under nitrogen flux, filtrates were precipitated 
                                                 
307 Kaiser, E., Colescott, R.L., Bossinger, C.D., Cook, P.I. (1970) Anal. Biochem., 34, 595. 
  187 
 
with cold diethyl ether, collected by centrifugation, dissolved in H2Ο and 
lyophilized with an Edwards apparatus, model Modulyo. 
Peptides were purified by semipreparative RP-HPLC using methods and 
solvent system as reported. Fractions were checked with UPLC-ESIMS. 
 
5.6.4 General procedure for solid-phase extraction SPE 
SPE are performed on RP-C18 LiChroprep columns. Main steps are reported 
here: 
Column washings with MeOH (3 column volumes) and CH3CN (3 column 
volumes) 
Column conditioning with H2O (3 column volumes) 
Dissolving the peptide in H2O (1 column volume), checking the pH that 
should be neutral. 
Adsorbing peptide solution on silica for 3 times 
Eluting with H2O (3 column volumes) 
Eluting with 5%, 10%, 15%, 20% of H2O/CH3CN (column volume for each 
concentration), and 100% of CH3CN.  
Fractions were checked by analytical UPLC-ESIMS, and then lyophilized. 
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6 XPERIMENTAL PART B 
6.1 Synthesis of Nα-Fmoc-ω-azido-α-amino acids 
6.1.1 Synthesis of Nα-Fmoc-ε-azido-Norleucine-OH 
Tf2O (1.35 mL, 8.13 mmol) was added dropwise to a vigorously stirred 
mixture of NaN3 (2.635 g, 40.5 mmol) in H2O (6.5 mL) and CH2Cl2 (11 mL) 
at 0 oC. The resulting mixture was allowed to warm to room temperature and 
stirring was continued for 2 h. The water layer was extracted with CH2Cl2 (2 
× 4 mL) and the combined organic layers were washed with saturated 
aqueous Na2CO3 (12.5 mL). The resulting solution of TfN3 in CH2Cl2 was 
then slowly added to a solution of Nα-Boc-lysine (1.0 g, 4.06 mmol), K2CO3 
(0.84 g, 6.08 mmol), and CuSO4·5H2O (0.01 g, 0.04 mmol) in H2O (13 mL) 
and MeOH (27 mL). The mixture was stirred overnight and the reaction was 
checked by TLC (iPrOH—AcOEt—H2O 6/1/3, revealed with (a) and (b), Rf 
0.81). The organic solvents were evaporated under reduced pressure. The 
water layer was acidified to pH 6 with concd HCl, diluted with 0.25 M of 
phosphate buffer at pH 6.2 (25 mL), and extracted with CH2Cl2 (4 × 50 mL). 
The organic layers were washed with brine (25 mL), dried over Na2SO4, and 
concentrated under vacuum. The colorless oil was purified using column of 
RP-18 LiChroprep by solutions of different concentrations of H2O/CH3CN to 
afford 6-azido-Boc-L-norleucine (0.451 g, 41%).  
Cleavage of the Boc protecting group of 6-azido-Boc-L-norleucine (1.079 g, 
3.96 mmol) was achieved by treatment with an excess of concd HCl (2.5 
mL) at room temperature for 6 h. The residue was dissolved in water (5.0 
mL) and lyophilized. A solution of 2,5-dioxo-1-pyrrolidinyl 9H-fluoren-9-
ylmethyl carbonate (Fmoc-OSu; 1.469 g, 4.36 mmol) in dioxane (20 mL) 
was then added dropwise to a solution of the deprotected amino acid in 
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dioxane (30 mL). A solution of 1 M NaOH was subsequently slowly added 
to pH 8–9 and the reaction mixture was stirred at room temperature for 1 h. 
The reaction was checked by TLC (CH2Cl2—MeOH 9/2, UV, Rf 0.58). 
Water (12 mL) was added and the solution was acidified with 2 M HCl until 
pH 3. The product was extracted with CH2Cl2 (3 × 30 mL), dried with anhyd 
Na2SO4, and the solvent removed under vacuum. The crude material was 
purified by flash chromatography on silica gel (CH2Cl2 to CH2Cl2—MeOH 
10/1) to obtain the pure 6-azido-Fmoc-L-norleucine 3 (496 mg, 32%) as a 
yellow oil. RP-UPLC: Rt 1.51 min (50 to 100% of B in 3 min). IR (KBr): 
2100 cm–1 (N3). ESI-MS: m/z calcd for C21H22N4NaO4 [M + Na]+: 417.15; 
found 417.2. [α]D –2.5 (c 1.0, MeOH). 1H NMR (CDCl3, 400 MHz,): δ 7.74 
(d, 2H, J3,4 = J5,6 = 7.4 Hz, fluorenyl 4-H and 5-H), 7.54 (d, 2H, J1,2 = J7,8 = 
7.4 Hz, fluorenyl 1-H and 8-H), 7.37 (pseudo t, 2H, fluorenyl 3-H and 6-H), 
7.28 (pseudo t, 2H, fluorenyl 2-H and 7-H), 6.19 (broad s, COOH), 5.46 (m, 
1H, NH), 4.49–4.33 (m, 3H, CH2–O and α-H), 4.18 (t, 1H, J = 6.4 Hz, 
fluorenyl 9-H), 3.24–3.21 (m, 2H, ε-H2), 1.70–1.42 (m, 6H, 3 × CH2). 13C 
NMR (CDCl3, 100 MHz): δ 176.97 (COOH), 156.35 (CONH), 143.75, 
143.60, and 141.28 (fluorenyl C-4a, C-4b, C-8a, and C-9a), 127.74, 127.06, 
and 125.01 (fluorenyl C-2 to C-7), 120.00 (fluorenyl C-1 and C-8), 67.14 
(CH2–O), 53.90 (C-α), 51.02 (C-ε), 47.07(fluorenyl C-9), 31.68 (CH2), 28.31 
(CH2), 22.55 (CH2). Anal. Calcd for C21H22N4O4: C, 63.95; H, 5.62; N, 
14.20. Found: C, 64.01; H, 5.58; N, 14.23. 
 
6.1.2 Synthesis of Nα-Fmoc-δ-azido-Norvaline-OH 
Cleavage of the Boc protecting group of 5-azido-Boc-L-norvaline (prepared 
from Boc-L-Orn-OH as in 6.1.1) (1.3 g, 5.01 mmol) was achieved by 
treatment with an excess of concd HCl (6 mL) at room temperature for 6 h. 
The residue was dissolved in water and lyophilized. A solution of Fmoc-OSu 
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(1.88 g, 4.9 mmol) in dioxane (40 mL) was added dropwise to a solution of 
the deprotected amino acid in dioxane (20 mL). A solution of 1 M NaOH 
was subsequently slowly added until pH 8 and the reaction mixture stirred at 
room temperature for 3 h. The reaction was checked by TLC (CH2Cl2—
MeOH 9/2, UV, Rf 0.58). Water (30 mL) was added and the solution was 
acidified with 2 M HCl until pH 3. The product was extracted with CH2Cl2 
(3 × 50 mL), dried over Na2SO4, and the solvent removed under vacuum. 
The crude was purified by flash chromatography on silica gel (CH2Cl2 to 
CH2Cl2—MeOH 10/1) to obtain the pure 5-azido-Fmoc-L-norvaline 4 (1.3 g, 
69%) as a yellow oil. RP-UPLC: Rt 1.37 min (50 to 100% of B in 3 min). IR 
(KBr): 2100 (N3) cm–1. ESI-MS: m/z calcd for C20H20N4NaO4 [M + Na]+ 
403.14; found 403.3. [α]D –2.3 (c 1.0, MeOH). 1H NMR (CDCl3, 400 MHz,): 
δ 7.76 (d, 2H, J3,4 = J5,6 = 7.6 Hz, fluorenyl 4-H and 5-H), 7.61 (pseudo d, 
2H, J1,2 = J7,8 = 7.6 Hz, fluorenyl 1-H and 8-H), 7.40 (pseudo t, 2H, fluorenyl 
3-H and 6-H), 7.31 (pseudo t, 2H, fluorenyl 2-H and 7-H), 6.16 (broad s, 
COOH), 5.34 (m, 1H, NH), 4.45–4.40 (m, 3H, CH2–O and α-H), 4.22 (t, 1H, 
J = 6.6 Hz, fluorenyl 9-H), 3.37–3.30 (m, 2H, δ-H2), 2.01–1.46 (m, 4H, 2 × 
CH2). 13C NMR (CDCl3, 100 MHz): δ 175.72 (COOH), 156.72 (CONH), 
143.75, 143.57, and 141.33 (fluorenyl C-4a, C-4b, C-8a, and C-9a), 127.76, 
127.08, and 125.00 (fluorenyl C-2 to C-7), 120.02 (fluorenyl C-1 and C-8), 
67.12 (CH2–O), 53.16 (C-α), 50.76 (C-δ), 47.15 (fluorenyl C-9), 29.62 
(CH2), 24.81 (CH2). Anal. Calcd for C20H20N4O4: C, 63.15; H, 5.30; N, 
14.73. Found: C, 63.09; H, 5.25; N, 14.80. 
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6.1.3 Synthesis of Nα-Fmoc-γ-azido-hSerine-OH 
Cleavage of the Boc protecting group of Boc-Abu(γ-N3)-OH (obtained from 
Boc-Abu(γ-N3)-OH as in 6.1.1) (0.748 g, 2.9 mmol) was achieved by 
treatment with an excess of TFA (10 mL) at room temperature for 10 min. 
The reaction was checked by TLC (AcOEt—n-hexane 1/1; revealed with (a), 
Rf 0.10). TFA was removed by flushing with N2 and the residue dissolved in 
water and lyophilized. The methyl ester was hydrolyzed by stirring with 1 M 
NaOH (5 mL) at room temperature for 6 h. The solution was then treated 
with concd HCl to pH 7 and lyophilized to afford the free amino acid. A 
solution of Fmoc-OSu (0.843 g, 2.5 mmol) in dioxane (6 mL) was added 
dropwise to a solution of the deprotected amino acid in dioxane (10 mL). A 
solution of 1 M NaOH was subsequently slowly added until pH 8 and the 
reaction mixture stirred at room temperature for 3 h. The reaction was 
checked by TLC (CH2Cl2—MeOH 9/2, UV, Rf 0.58). Water (7.5 mL) was 
added and the solution was acidified with concd HCl until pH 3. The product 
was extracted with CH2Cl2 (3 × 20 mL), dried over Na2SO4, and the solvent 
removed under vacuum. The crude was purified by flash chromatography on 
silica gel (CH2Cl2 to CH2Cl2—MeOH 10/1) to obtain the pure Nα-Fmoc-γ-
azido-hSerine-OH 5 (124 mg, 27%) as yellow oil. RP-UPLC: Rt 1.31 min 
(50 to 100% of B in 3 min). IR: 2100 cm–1 (N3). ESI-MS: m/z calcd for 
C19H18N4NaO4 [M + Na]+ 389.12; found 389.4. [α]D –11.5 (c 1.0, MeOH). 
1H NMR (CDCl3, 400 MHz,): δ 7.75 (pseudo d, 2H, J = 7.6 Hz, fluorenyl 4-
H and 5-H), 7.54 (pseudo d, 2H, J = 7.4 Hz, fluorenyl 1-H and 8-H), 7.39 
(pseudo t, 2H, fluorenyl 3-H and 6-H), 7.31 (pseudo t, 2H, fluorenyl 2-H and 
7-H), 6.14 (broad s, COOH), 5.63 (m, 1H, NH), 4.53–4.41 (m, 3H, CH2–O 
and α-H), 4.21 (t, 1H, J = 6.8 Hz, fluorenyl 9-H), 3.42–3.39 (m, 2H, γ-H2), 
2.19–1.96 (m, 6H, 3 × CH2). 13C NMR (CDCl3, 100 MHz): δ 172.71 
(COOH), 156.26 (CONH), 143.53 and 141.29 (fluorenyl C-4a, C-4b, C-8a, 
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and C-9a), 127.76, 127.08, 125.04, 124.99 (fluorenyl C-2 to C-7), 120.00 
(fluorenyl C-1 and C-8), 67.17 (CH2-O), 51.70 (C-α), 47.68 (C-γ), 47.09 
(fluorenyl C-9), 31.21 (CH2). Anal. Calcd for C19H18N4O4: C, 62.29; H, 4.95; 
N, 15.29. Found: C, 62.36; H, 4.99; N, 15.24. 
6.2 Synthesis of Nα-Fmoc-ω-alkynyl-α-amino acids 
6.2.1 General procedure for the synthesis of p-toluenesulfonate 
derivatives  
p-Toluenesulfonyl chloride (6.49 mmol) in pyridine (10 mL) was added to a 
stirred solution of the alcohol derivative (5.9 mmol) at 0 °C. The reaction 
was stirred for 4 h at rt and checked by TLC [AcOEt—n-hexane 5/4; 
revealed with (a), (e)]. The reaction mixture was neutralized with 2 M HCl, 
the p-toluensulfonate derivative extracted with CHCl3, and the organic layer 
evaporated under vacuum to afford the product as a pale yellow oil. 
 
5-Hexyn-1-ol 1-(4-methylbenzene sulfonate).(6) Yield 96%. 1H-NMR 
(CDCl3, 200 MHz): δ 7.78 and 7.34 (AA’BB’ system, 4H, J = 8.4 Hz, 
MeC6H4), 3.57 (t, 2H, J = 6.2 Hz, 1-H2), 2.45 (s, 3H, MeC6H4), 2.13–2.09 
(m, 2H, 4-H2), 1.90 (t, 1H, 6-H), 1.93–1.72 (m, 4H, 2-H2 and 3-H2). 
 
4-Pentyn-1-ol 1-(4-methylbenzene sulfonate) (7) Yield 93%. 1H-NMR 
(CDCl3, 200MHz): δ 7.77 and 7.35 (AA’BB’ system, 4H, J = 8.4 Hz, 
MeC6H4), 4.12 (t, 2H, J = 5.8 Hz, 1-H2), 2.43 (s, 3H, MeC6H4), 2.32–2.15 
(m, 2H, 3-H2), 1.93 (t, 1H, 5-H), 1.91–1.82 (m, 2H, 2-H2). 
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6.2.2 General procedure for the synthesis of bromo derivatives 
Lithium bormide (6.67 mmol) was added in portions to a stirred solution of 
the p-toluensulfonate derivative (4.45 mmol) in acetone (10 mL) at rt. The 
reaction mixture was heated at 40 °C for 20 h. The reaction was checked by 
TLC (AcOEt—hexane 5/4; revealed with (e), Rf 0.75). The solvent was 
evaporated by flushing with N2. The residue was treated with n-hexane, 
filtration of the residue and evaporation of DCM under nitrogen flux, 
afforded the bromo derivative as a yellow oil. 
 
6-Bromohex-1-yne. (9) Yield 31%. 1H NMR (CDCl3, 200 MHz): δ 3.41 (t, 
2H, J = 7.2 Hz, 6-H2), 2.21 (dt, 2H, J = 3.0 Hz, 7.4 Hz, 4-H2), 2.02–1.91 (m, 
2H, 3-H2), 1.96 (t, 1H, J = 3.8 Hz, 1-H ), 1.71-1.60 (m, 2H, 5-H2) . 
 
5-Bromopent-1-yne (10) Yield 28%. 1H NMR (CDCl3, 200 MHz): δ 3.44 (t, 
2H, J = 6.4 Hz, 5-H2), 2.75 (dt, 2H, J = 2.6 Hz, 7.0 Hz, 3-H2), 2.02-1.95 (m, 
2H, 4-H2), 1.86 (t, 1H, J = 3.6 Hz, 1-H). 
 
6.2.3 Synthesis of the Chiral Inductor BPB 
A solution of 10 g (86,8 mmol) of (S)-proline and 18,5 g (330 mmol) of 
KOH in 70 mL of iPrOH was prepared with stirring at 40°C. As soon as the 
solution became transparent, slow addition of freshly distilled BnCl (18,30 g, 
130 mmol) was added under stirring at the same temperature for 6h. The 
reaction mixture was neutralized with concentred aqueous HCl until pH 5-6 
(indicator paper), then was added to the reaction mixture CHCl3 (30 mL) 
with stirring. The mixture was left overnight, then filtered and the precipate 
was washed with CHCl3. The CHCl3 solutions were combined and evapored, 
the residue was treated with cold acetone and the precipitate of crude BP 
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filtered and additionally washed with acetone. Some BP was also recovered 
from the acetone washings. The crude material was dried in air and then over 
P2O5 in vacuo to give 10,23 g of (S)-N-benzylproline (BP) (12) ( 57 %).  
Product 12 (3.467g, 16.9 mmol) was added at RT under N2 to a stirred 
freshly-prepared transparent solution of PCl5 (7.035g, 33.8 mmol) in anhyd 
CH2Cl2 (55 mL). After 30 min cold petroleum ether was added and the acyl 
chloride precipitated as an oil. The oil was dissolved in anhyd CH2Cl2 (60 
mL) under N2 and 2-aminobenzophenone (3.33 g, 16.9 mmol) was added in 
one portion, followed by Et3N to pH 8. The mixture was stirred for 4 h at rt, 
then washed with a saturated solution of Na2CO3 and twice with H2O. The 
organic layer was evaporated under reduced pressure. The crude BPB was 
recrystallized from EtOH. Some product was also recovered from the EtOH 
washings. The material was dried under vacuum over P2O5 to give the chiral 
inductor (S)-2-(N-Benzylprolyl)aminobenzophenone (BPB) (13) (1.873 g, 
29%). ESI-MS: m/z calcd for C25H24N2O2 [M + H]+: 385,18; found 385,2. 1H 
NMR (CDCl3, 400 MHz): δ 11.52 (s, 1H, NH), 8.56 (d, 1H, J= 8.4 Hz, Bn), 
7.79-7.36 (m, 9H, Bn), 7.15 (m, 4H, Bn), δA= 3.92, δB= 3.59 (syst AB, 2H, 
JAB= 12.8 Hz, CH2Bn), 3.32 (dd, 1H, Jα,β= 4.4 Hz, Jα,β’=10.0 Hz, Hα), 3.22 
(dd, 1H, Jδ,δ’= Jδ,γ= 6.4 Hz, Hδ), 2.41 (dd, 1H, Jβ,β’= 8.8 Hz, Jβ,γ= 16 Hz, Hβ’), 
2.26 (ddd, 1H, Jδδ’= 6.4 Hz, Jδγ=12.8 Hz, Jδγ’= 22 Hz  Hδ’), 1.96 (ddd, 1H, 
Jβ,β’= 8.8 Hz, Jβ,γ= 4.4 Hz, Jβγ’= 16.4 Hz, Hβ), 1.85-1.76 (m, 2H, H,γ,H,γ’ ). 13C 
NMR (CDCl3, 100 MHz): δ 198.03 (Ph-CO-Ph), 174.64 (COOH), 139.16, 
138.54, 138.12, 133.37, 132.55, 132.48, 130.11, 129.12, 128.30, 128.15, 
127.05, 125.32, 122.19, 121.52 (18 Ar), 68.25 (Cα), 59.82 (CH2Bn), 53.85 
(Cδ), 30.98 (Cβ), 24.14 (Cγ). 
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6.2.4 Synthesis of the [Gly-Ni-BPB] complex  
A solution of KOH 1,02 g (18,2 mmol) in 4 mL of MeOH was poured into a 
variously stirred mixture of BPB 1 g (13) (2,6 mmol), Ni(NO3)2.6H2O 1,511g 
(5,2 mmol), glycine 0,975 g (13 mmol) in 9,1 mL of MeOH under N2 at 40-
50°C. The resulting mixture was stirred at 55-65°C for 1h (a prolonged 
heating of the reaction mixture might result to a partial racemization of the 
BPB moiety), and then neutralized with 1mL of AcOH diluted in 39 mL of 
water. The separated crystalline solid was filtered and washed with water. 
The crude material was dried in air and then over P2O5 in vacuo to give 1,06 
g of product 14 ( 81 %). ESI-MS: m/z calcd for C27H25N3NiO3 [M + H]+: 
498,20 ; found 498,3. 1H-NMR (CDCl3, 200MHz): δ 8.27 (d, 1H, J= 8.8 Hz, 
Bn), 8.07 (d, 1H, J= 7.2 Hz, Bn), 7.51-7.30 (m, 6H, Bn), 7.24-6.69 (m, 6H, 
Bn), δA= 4.48, δB= 3.69 (syst AB, 2H, JAB= 6.2 Hz, CH2Bn), 3.51-3.31 (m, 
2H, Hαpro), 2.63-2.41 (m, 3H, Hδpro, Hαα’Gly), 2.13-1.91 (m, 4H, Hβ’pro, Hδ’Pro, 
HβPro, H,γPro, H,γ’Pro ). 13C-NMR (CDCl3, 50MHz): δ 181.19 (COGly), 177.18 
(CO-N-Ph), 171.49 (C=N), 134.53, 133.11, 132.16, 131.66, 129.67, 129.53, 
129.28, 129.06, 128.87, 126.19, 125.60, 125.12, 124.21, 120.82 (18 Ar), 
69.96 (CαPro), 63.23 (CH2Bn), 61.38 (CαGly), 57.60 (CδPro), 30.90 (CβPro), 23.89 
(CγPro). 
 
6.2.5 General procedure for the alkylation of the Gly-Ni-BPB 
complex with bromoalkynes 
To a stirred mixture of Gly-Ni-BPB (14) (1.99 g, 4 mmol) in anhyd CH3CN 
(17.5 mL) were added, under N2, finely powdered NaOH (0.4 g, 10 mmol) 
and bromoalkyne (6.01 mmol). After 5 h, the reaction mixture was treated 
with 0.1 M HCl (59 ml) and the red product extracted with CH2Cl2 (4 × 40 
mL), dried over MgSO4, and the solvent removed under vacuum. The crude 
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was purified by flash chromatography on silica gel (CH2Cl2—Me2CO 2/1) 
affording the product as a red amorphous solid. 
 
6.2.6 General Procedure for the hydrolysis of the alkylated 
complexes and Fmoc protection of the free amino acid.  
A solution of the alkylated complex (1.33 mmol) in MeOH (22.5 mL) was 
added to warm 2 M HCl (16 mL) and the mixture refluxed for 1 h. After 
cooling to rt, 1 M NaOH was added until pH 6 and the solvent removed 
under vacuum. The solid residue was washed with acetone, the dried solid 
product was dissolved in MeOH—H2O 15/20 (70 mL) and then gently 
swirled overnight with Chelex 100 H+ resin, converted from its Na+ form. 
The mixture was filtered and the resin washed with water, the layers of 
combined filtrates were evaporated under vacuum, and the residue 
lyophilized. 
A solution of FmocOSu (1.51 mmol) in dioxane (15 mL) was added 
dropwise to the lyophilized product (1.37 mmol) dissolved in dioxane (15 
mL) and then 1M NaOH was added until pH 8. The reaction mixture was 
stirred at RT for 4 h, after which time, water (7.5 mL) was added and the 
solution acidified with 2 M HCl to pH 3. The product was then extracted 
with CH2Cl2 (3 × 20 mL), dried over Na2SO4 and the solvent removed under 
vacuum. The crude was purified by FCC (CH2Cl2 to CH2Cl2—MeOH 10/1) 
to obtain the pure amino acid as a yellow oil. 
 
Nα-Fmoc-ε-alkynyl-Norleucine-OH (18) Yield 31%. RP-UPLC: Rt 1.49 min 
(50–100% of B in 3 min). [α]D –3.1 (c 1.0, MeOH). ESI-MS: m/z calcd for 
C23H23NNaO4 [M + Na]+ 400.15; found 400.3. 1H NMR (CDCl3, 400 MHz): 
δ 7.75 (pseudo d, 2H, J = 7.6 Hz, fluorenyl 4-H and 5-H), 7.59 (pseudo d, 
2H, J = 7.6 Hz, fluorenyl 1-H and 8-H), 7.37 (pseudo t, 2H, fluorenyl 3-H 
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and 6-H), 7.28 (pseudo t, 2H, fluorenyl 3-H and 6-H), 5.79 (broad s, COOH), 
5.48(m, 1H, NH), 4.44–4.38 (m, 3H, CH2–O and α-H), 4.21 (t, 1H, J = 6.8 
Hz, fluorenyl 9-H), 2.08–1.99 (m, 3H), 1.94 (t, 1H, J = 2.4 Hz, HC≡C), 
1.80–1.75 (m, 1H), 1.58–1.42 (m, 4H, 2 × CH2). 13C NMR (CDCl3, 100 
MHz): δ 176.63 (COOH), 156.17 (CONH), 143.83, 143.67 and 141.29 
(fluorenyl C-4a, C-4b, C-8a, and C-9a), 127.71, 127.06, 125.04 (fluorenyl C-
2 to C-7), 119.98 (fluorenyl C-1 and C-8), 83.97 (HC≡C), 68.69 (CH2-O), 
67.06 (HC≡C), 53.83 (C-α), 47.15 (fluorenyl C-9), 31.73 and 27.81 (C-β and 
δ), 24.31 (C-γ), 18.15 (C-ε). Anal. Calcd for C23H23NO4: C, 73.19; H, 6.14; 
N, 3.71. Found: C, 73.09; H, 6.19; N, 3.81. 
 
Nα-Fmoc-δ-alkynyl-Norvaline-OH (19) Yield 28%. RP-UPLC: Rt 1.49 min 
(50–100% of B in 3 min). [α]D –3.0 (c 1.0, MeOH). ESI-MS: m/z calcd for 
C22H21NNaO4 [M + Na]+ 386.14; found 386.2. 1H NMR (CDCl3, 400 MHz): 
δ 7.73 (d, 2H, J = 7.2 Hz, fluorenyl 4-H and 5-H), 7.57 (d, 2H, J = 7.4 Hz, 
fluorenyl 1-H and 8-H), 7.39 (pseudo t, 2H, fluorenyl 3-H and 6-H), 7.30 
(pseudo t, 2H, fluorenyl 2-H and 7-H), 6.60 (broad s, COOH), 5.51 (m, 1H, 
NH), 4.43–4.35 (m, 3H, CH2–O and α-H), 4.18 (t, 1H, J = 6.6 Hz, fluorenyl 
9-H), 2.08–1.99 (m, 3H), 1.94 (t, 1H, J = 2.4 Hz, HC≡C), 1.80–1.75 (m, 1H), 
1.58–1.42 (m, 2H, CH2). 13C NMR (CDCl3, 100 MHz): δ 177.06 (COOH), 
156.26 (CONH), 143.81, 143.62 and 141.27 (fluorenyl C-4a, C-4b, C-8a, and 
C-9a), 127.70, 127.06 and 125.05 (fluorenyl C-2 to C-7), 119.96 (fluorenyl 
C-1 and C-8), 83.49 (HC≡C), 69.11 (CH2-O), 67.06 (HC≡C), 53.77 (C-α), 
47.11 (fluorenyl C-9), 31.33 (C-β), 24.28 (C-γ), 18.01 (C-δ). Anal. Calcd for 
C22H21NO4: C, 72.71; H, 5.82; N, 3.85. Found: C, 72.80; H, 5.87; N, 3.80. 
 
. 
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6.3 General procedure for the synthesis of clicked peptides 
Linear eIF4E b.p peptide analogs for click chemistry, XVI-XX, were 
synthesize and purify according to the procedures described in chapter 5.6. 
The modified amino acids carrying the alkynyl and azido modifications 
where introduced on the peptide sequences by manual SPPS using a low 
excess (1.1-1.2) under high concentration of activating agents (4-5 fold) and 
long coupling time (1.5 h). 
For click cyclization the linear pure peptides (3.1 μmol), CuSO4.5H2O (43,4 
μmol), and ascorbic acid (40.3 umol) where dissolved in 4 mL of 
H2O/tBuOH 2:1. The mixture was stirred at room temperature overnight and 
the solution was concentrated and lyophilized. To remove copper derivatives 
from the crude and to purify the clicked peptides, a SPE purification was 
performed followed by semi-preparative HPLC purification to afford pure 
clicked peptide (97% purity). 
The cyclic peptides XVIc-XXc were characterization by UPLC-MS. The 
analytical data are reported in Table 3.5-6 . 
6.4 Circular dichroism spectrometry 
All CD spectra were recorded on a Jasco J-810 spectropolarimeter using cells 
of 1 mm path length. The pH of the samples was adjusted to 6.6 with 
aqueous phosphate buffer. After pH adjustment, samples were lyophilized 
and dissolved in water, or in water containing 50% (v/v) HFA to obtain a 
final peptide concentration of 0.02 mM. Spectra were the average of ten 
scans from 190 to 260 nm, recorded with a band width of 0.5 nm at scan rate 
of 5 nm/min. 
  199 
 
6.5 NMR spectrometry for conformational studies 
Samples for NMR were prepared by dissolving lactam- and 
[1,2,3]triazolylcontaining peptides in 0.5 mL of aqueous phosphate buffer 
(pH 5.5). NMR spectra were recorded on a Bruker DRX-600 spectrometer. 
One-dimensional (1D) NMR spectra were recorded in the Fourier mode with 
quadrature detection. The water signal was suppressed by a low-power 
selective irradiation in the homogenous mode. DQF-COSY,155 TOCSY,156 
and NOESY157 experiments were run in the phase sensitive mode using 
quadrature detection in ω1 by time-proportional phase increments of the 
initial pulse.308 Data block sizes comprised 2048 addresses in t2 and 512 
equidistant t1 values. Before Fourier transformation, the time domain data 
matrices were multiplied by shifted sin2 functions in both dimensions. A 
mixing time of 70 ms was used for the TOCSY experiments. NOESY 
experiments were run at 300 K with mixing times in the range of 100-250 
ms. The qualitative and quantitative analyses of DQF-COSY, TOCSY and 
NOESY spectra were obtained using the SPARKY158 interactive program 
package. 
                                                 
308 Marion, D. and Wuthrich, K. (1983) Biochem. Biophys. Res. Commun., 113, 967. 
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Characterization of AGE-modified synthetic HSA peptide fragments and study of their 
possible role in Diabetes auto-antibody recognition 
 
Synthetic strategies to Advanced Glycation End products 
peptides involved in diabetes 
S. Carganico1, M.A. Bonache1, M.C. Alcaro1, M. Chelli1, P. Rovero1, A.M. Papini1, M. Chorev2, A. Lapolla3, P. Traldi4,  
1Laboratory of Peptide & Protein Chemistry & Biology and CNR-ICCOM, Polo Scientifico e Tecnologico, Università di Firenze, Sesto 
Fiorentino (FI),  
Italy; 2Laboratory for Translational Research, Harvard Medical School, Cambridge, Massachusetts; 3Dipartimento di Scienze Mediche e 
Chirurgiche, Università di Padova, Padova, Italy; 4CNR-ISTM, Padova, Italy  
 
LC/ESI Q-TOF MS  ?
Chemoselective Synthesis of CarboxyMethylLysine 
(Cml)  protected for Fmoc/tBu Solid Phase-Peptide 
Synthesis (SPPS) 
?
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HSA(342-351) has been characterized by liquid chromatography (CapLC, 
Waters) coupled with a nano electron spray ionization Q-TOF 
mass spectrometer (Micro, Waters) 
Multiple automatic 
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Glycation and AGE products 
 
Diabetes complications seem to be related to the Maillard reaction 
occurring between a free amino group of a protein and glucose or a 
reducing sugar. Early glycation products undergo further complex reactions 
to become irreversibly crosslinked heterogeneous derivatives, usually called 
advanced glycation endproducts (AGEs) [1]. 
Some AGEs have been structurally characterized, including N-
(carboxymethyl)Lysine (Cml), which has been demonstrated to be a major 
immunological epitope among AGEs [3]. However, these structurally identified 
AGEs account for only a small percentage of AGE that occur in vivo.  
? 
 
Glycated-
peptide 
Traldi et al. reported the analysis of enzymatic digestions of 
glycated human serum albumin (HSA) by MALDI TOF mass 
spectrometry [2].  
Among the glycated peptides characterized by mass 
spectrometry, we selected 342NYAEAKDVFL351. 
? Previous results 
We selected from HSA sequence a peptide fragment known to 
be glycated at a Lysine residue [1]. 
In vitro incubation with glucose can be performed under 
physiological conditions to achieve non enzimatic 
spontaneous glycation of the peptide and successive 
AGE products formation [6]. 
 
342NYAEAKDVF351
Future goals 
Autoantibody recognition through ELISA test in 
diabetes patients’ sera using [Cml347]HSA(342-351) 
as synthetic antigenic probe 
LC-MS monitorig of HSA(342-351) spontaneous 
glycation  
Peptide selection ? 
Spontaneous glycation of the peptide ? 
? 
[4] 
[5] 
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Post translationally modified peptides for an efficient detection 
of autoantibody biomarkers of autoimmune diseases
Stefano Carganico1, Francesca Nuti1, Elisa Peroni1, Claudia Alcaro2, Mario Chelli1, Paola Migliorini3, Carlo Selmi4, Francesco Lolli5, 
Michael Chorev6, Paolo Rovero7, and Anna Maria Papini1
1PeptLab c/o Dept of Organic Chemistry, University of Firenze;  2Toscana Biomarkers S.r.l., Siena; 3Laboratory of Clinical Immunology, Dept of Internal Medicine, University 
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Our hypothesis on the molecular mechanism of antibody-mediated autoimmune diseases
Changes at the level of protein post-translational modifications (PTMs) may 
create neoantigens triggering an autoimmune response in which 
autoantibodies are biomarkers of disease activity.
Identification of disease biomarkers using a “Chemical
Reverse Approach” based on synthetic post-translational
modified peptides for fishing-out antibodies as biomarkers in 
patients’ biological fluids
Post-translationally modified synthetic 
peptides can be useful tools for mimicking 
neoantigens responsible of the autoimmune 
response.
PTM
CSF114 may be 
proposed as “Universal 
Peptide Scaffold”
because of its β -turn 
structure, exposing at 
the best the aberrant 
PTM specific for antibody 
recognition in 
autoimmune diseases
Epitope
M. C. Alcaro, et al., Chem.Today, (2007), 25, 14; Papini, A.M. J. Pep Sci (2009), in press.
Multiple Sclerosis
The CSF114(Glc)-based not competitive solid phase ELISA enabled the reproducible and effective 
detection of IgM autoantibodies to this glycopeptide in a significant population (30%) of MS patients. The 
antibodies detected in the present study were typical of Relapsing-Remitting patients (RR-MS). 
Therefore, a CSF114(Glc)-based immunoassay on sera has an important prognostic value in monitoring 
MS disease progression guiding the optimal therapeutic treatment.
Lolli et al. Proc. Natl. Acad. Sci., U.S.A., (2005), 102, 10273; A.M. Papini Nature Medicine (2005) 11(1), 13; A.M. Papini, et al. Applicant: 
University of Florence, Italy. PCT International application (2003) WO 03000733 A2.; F. Lolli, et al. The glycopeptide CSF114(Glc) 
detects serum antibodies in Multiple Sclerosis. J. Neuroimmunol. (2005) 167, 131-137.
CSF114(Glc) is a mimetic of in vivo  auto-antigens 
triggeringauto-immunoresponse
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Fmoc-L-Asn(OAc4)OH
Ipotetic structure of 
[Lys7(ALA)]CSF114
Lys7(ALA)]CSF114 exposing lipoamide residue on the tip of a β-turn 
structure is able to detect the best antibody titre in PBC patients’ sera
Long S. A., Quan C., Van de Water J., Nantz M. H., Kurth M. J., Barsky D., Colvin M E., Lam K. 
S., Coppel R. L., Ansari A., and Gershwin M. E., J. Immunol., 2001, 2956-2963.
PrimaryBiliary Cirrhosis (PBC)
More than 95% of PBC patients have detectable levels of autoantibodies to PDC-E2 [Pyruvate
Dehydrogenase Complex (PDC-E2)] and in general these react with a region of the molecule  
containing a lipoamide lysine residue [Lys(ALA)]. It has been hypothesized that the lipoamide in 
PDC-E2 serves as a xenobiotic target becoming immunogenic and initiates or perpetuates an 
antimitochondrial antibodies (AMA) response.
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Fmoc-Ser(GalBz4)-OPfp
The O-glycopeptide
[Ser7(Gal)]CSF114
recognizes antibodies 
in 30% ca of RA 
analyzed sera
Rheumatoid Arthritis is a common systemic autoimmune disease and it is characterized by 
inflammation of the synovial membrane of diarthrodial joints. Large number of activated leukocytes 
infiltrate the synovial membrane leading to progressive destruction of cartilage and bone.
[Asn7(Gal)]CSF114      N-glycopeptide
[Ser7(Gal)]CSF114      O-glycopeptide
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Papini, A.M. et al. Filing date 16/10/2007. Applicant: Toscana Biomarkers Srl. EPC Application (2007) 07118566.4
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In conclusion, modified peptides as synthetic probes characterizing families of 
antibodies in biological fluids are a suitable option for the development of 
multiple diagnostic/prognostic immunoassays, increasing sensitivity of 
diagnostics
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OUTLOOK
Type I diabetes
Glycation of proteins through non-enzymatic reactions between glucose or other reducing sugars 
and reactive amino groups represents one of the more abundant processes involved in post-
translational modification of proteins. Diabetic pastients, because of their characteristic 
iperglicemia, develop high levels of glycated proteins.
O O
O
O
O
FmocNH CO2H
N
Boc
Nα-Fmoc-Lys-Nε-(2,3;4,5-di-O-
isopropylidene-1-
deoxyfructopyranosyl,Boc)-OH
Carganico S, Rovero P, Halperin JA, Papini AM, Chorev M. J Pept Sci. (2009) 67-71 
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8 ABBREVIATIONS 
Ab: antibody 
Ac: acetyl 
Ag: antigen 
AMBER: assisted model building with energy refinement 
ATP: adenosine triphosphate 
BD: blood donors 
Boc: tert-butoxycarbonyl 
BOP : benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluoro- 
-phosphate 
BP: N-benzyl-(S)-proline 
BPB: (S)-2-(N-benzylprolyl)aminobenzophenone 
BSA: bovine serum albumin 
cAMP: cyclic adenosine monophosphate 
CD: circular dichroism  
CDMT : 2-Chloro-4,6-dimethoxy-1,3,5-triazine 
CNS: central nervous system 
DBU: 1,8-Diazabicycloundec-7-ene 
DCM: dichloromethane 
DIEA: diethylamine 
DMF: N,N-dimethylformamide 
DMTMM-BF4: 4-(4,6-dimethoxy-1,3,5-triazin-2-yl-)-4-methylmorpholinium 
tetrafluoroborate 
DNA: deoxyribonucleic acid 
DQF-COSY: double quantum filtered correlated spectroscopy 
EDT: 1,2-ethanedithiole 
ELISA: enzyme-linked immunosorbent assay 
FCC: flash column chromatography 
Fmoc: 9-H-fluoren-9-yl-methoxycarbonyl 
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Fmoc-OSu: N-(9-fluoren-9-yl-methoxycarbonyloxy)-succinimide 
GABA: γ-aminobutyric acid 
HFA: hexafluoroacetone 
HOBt: 1-hydroxybenzotriazole 
HPLC: high performance liquid chromatography 
IC50: inhibitory concentration of 50 
IP: inositol phosphate 
IP3: inositol 1,4,5-trisphosphate 
MOG: myelin oligodendrocyte glycoprotein 
MRI: magnetic resonance imaging 
mRNA: messenger ribonucleic acid 
MS: multiple sclerosis 
MSAP: multiple sclerosis antigenic probe 
NMM: N-methylmorpholine 
NMR: nuclear magnetic resonance 
NOE: nuclear Overhauser effect 
NOESY: nuclear Overhauser enhancement spectroscopy 
ON: overnight 
PBS: phosphate buffered saline 
Ph: phenyl 
PrG: propargylglycine 
PTH: parathyroid hormone 
PTH1-Rc: human PTH type 1 receptor 
PTHrP: parathyroid hormone-related protein 
PTM: post-translational modification 
RCM: ring-closing metathesis 
RP-HPLC: reverse phase-high performance liquid chromatography 
Rt: retention time 
RT: room temperature  
SPE: solid phase extraction 
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SP-ELISA: solid-phase ELISA 
SPPS: solid-phase peptide synthesis 
TBTU:2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
tBu: tert-butyl 
TFA: trifluoroacetic acid 
TFE: trifluoroethanol 
THF: tetrahydrofuran 
TLC: thin layer chromatography 
TOCSY: total correlated spectroscopy 
UPLC: ultra performance liquid chromatogra 
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